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The heart, a muscular organ roughly the size of a fist, provides the body with oxygen 
and nutrients through the circulatory system. In the normal heart the venous blood 
from the body -with low oxygen saturation and high carbon dioxide levels - enters the 
right atrium (RA) and subsequently the right ventricle (RV). The RV supports the 
pulmonary circulation in which respiratory gas exchange takes place. The left ventricle 
(LV) supports the systemic circulation and ejects the high saturated blood towards the 
systemic arteries (Figure 1). The systemic circulation provides oxygenated blood to the 
brain, organs, muscles and other tissues. Beyond infancy, the pulmonary circulation 
and the systemic circulation are closed circuits.
Congenital heart disease
In congenital heart defects (ConHD) there is a structural malformation of the heart 
and/or the intrathoracic great vessels.1, 2 ConHD occur in approximately 8 per 1000 live 
births, which makes ConHD the most common birth defect.1, 2 In the Netherlands, every 
year 1250-1400 children are born with a ConHD.1, 3, 4 
There are many different types of ConHD, ranging from small atrial septal defects 
to severe and complex univentricular heart defects.5-7 Often a division is made between 
non-cyanotic and cyanotic ConHD. In cyanotic ConHD the structural defects results in 
mixing of oxygen rich and poor oxygen blood.6, 7 In case of a right-to-left shunt, the 
blood shunts from the right side to the left side of the heart. This situation creates a 
mix of oxygen poor and oxygen rich blood, resulting in oxygen desaturation in the 
Figure 1. Normal heart. 
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systemic arteries. The degree of arterial desaturation depends on the type of intra-
cardiac mixing and the type of ConHD. Cyanosis is often a clinical sign in ConHD 
patients. Chronic cyanosis can result in vascular remodeling, erythrocytosis and 
hyperviscosity of the blood which can result in a decrease in the microcirculation.5, 6, 8 
Other symptoms of ConHD, depending on the type, are shortness of breath, excessive 
sweating, fatigue and failure to thrive.5-7
Long-term outcomes
Over the last decennia advances in diagnostics, catheter interventions, cardiothoracic 
surgery, pre- and (post)operative management and specialized care have contributed 
to a dramatic increase of survival in ConHD patients.1 In the current era around 90% 
of ConHD children survive into adulthood,9-11 which has now resulted in a population 
of adults with ConHD that is larger than the pediatric ConHD population.12 However, 
frequently residual lesions remain, even after optimal surgical or catheter interventions. 
These residual abnormalities may result in pressure and/or volume overload of the 
ventricle and can contribute to long-term problems such as fatigue, diminished exercise 
tolerance, diminished ventricular function, chronic hypoxemia, arrhythmias and cardiac 
death.13-15 Often ConHD patients require lifelong specialized medical care.9 Particularly 
patients with complex ConHD have better outcomes when cared for in a multidisciplinary 
program.9
This thesis will particularly focus on two groups of patients with cyanotic heart 
diseases: patients with an univentricular heart defect and patients with a Tetralogy of 
Fallot (TOF). TOF is the most common cyanotic heart defect.14, 16 In the Netherlands 
approximately 60 patients per year are born with TOF and require corrective surgery 
within the first few months of life.14, 16 Patients with an univentricular heart defect are 
a heterogeneous group comprising approximately 10% of ConHD,17 meaning that in 
the Netherlands approximately 125-140 patients a year are born with an univentricular 
heart defect.16 Patients with an univentricular heart defect are among ConHD patients 
with the worst prognosis. 
Etiology
In most ConHD patients the underlying cause for the ConHD is unknown and assumed 
to be multifactorial: a combination of predisposing genetic factors and environmental 
factors.18-20 In a small number of patients a cause for the ConHD is found. 
About 10% of all ConHD is explained by a chromosomal anomaly such as Down 
syndrome (Trisomy 21), Trisomy 13, Trisomy 18 or Turner syndrome (monosomy X).21 
Approximately 5% of TOF patients have Down syndrome.22 Microdeletions and 
duplication such as 22q11 deletion syndrome and TBX5 gene mutations account for 
an estimated 15% of ConHD.20, 23 22q11 deletion syndrome is relatively common in TOF 
patients, with an estimated incidence of 15%.24 The incidence of 22q11 deletion 
syndrome in patients with tricuspid atresia, an univentricular heart defect, is 
approximately 7%.25 In some ConHD patients the cause of the heart defect lies in a 
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single abnormal gene (monogenic syndrome).26 Even if no specific genetic cause for 
the ConHD is found, the recurrence risk for siblings and children of ConHD patients 
lies around 2-5%.17 This suggests that more associated genes are waiting to be 
discovered. In the last decades several hundreds of genes have been identified that 
cause or contribute to the development of ConHD.21, 23 
Some environmental factors have been linked to ConHD, explaining approximately 
2% of the ConHD.21 These include factors such as maternal exposure to lithium, folic 
acid antagonists, some selective serotonin reuptake inhibitors, maternal rubella 
infection and obesity.20, 27, 28 
Univentricular heart defects
Univentricular heart defects are a group of different lesions that have in common that 
they have a functional single ventricle which supports both the systemic and pulmonary 
circulation at birth.29 Often a relatively normal ventricle and an underdeveloped 
ventricle are present. In chapter 2 of this thesis an extensive overview is given on the 
surgical treatment options, management and outcomes of patients with an 
univentricular heart defect. 
As in all other types of ConHD, univentricular hearts are described using the system 
of sequential segmental analysis. This includes thorough description of abdominal and 
atrial situs, atrio-ventricular connections and ventriculo-arterial connections.17, 29, 30 The 
anatomy in univentricular heart defects is highly variable, ranging from tricuspid atresia 
to hypoplastic left heart syndrome (HLHS).31, 32 In addition, in a significant proportion 
of patients with univentricular heart defects, abnormalities in the systemic venous and/
or pulmonary venous connection are present, which makes the treatment of this 
patient group even more challenging.
The Fontan operation
The natural history of patients with univentricular heart defect is poor. Depending on 
the underlying cardiac condition, the reported 1-year survival lies between 0-50%.33-35 
Before 1971, the year Francis Fontan published the paper ‘Surgical repair of tricuspid 
atresia’, limited surgical options were available for univentricular heart defect patients.36 
Fontan proposed a separation of the pulmonary circulation and the systemic circulation 
by connecting the systemic venous return directly to the pulmonary arteries.36 The 
Fontan circulation therefore bypasses a sub-pulmonary ventricle (i.e the RV in normal 
hearts) and solely relies on passive flow for pulmonary perfusion. 
In the original Fontan operation the superior caval vein was connected to the right 
pulmonary artery (RPA) and the RA appendage was connected to the left pulmonary 
artery (LPA) with a valved conduit in a single procedure.36 Over time several adaptations 
have been made to the original Fontan operation. Initially the atriopulmonary 
connection (APC) was used, in which the RA was connected directly to the pulmonary 
artery (see Figure 2).37 The APC technique caused progressive dilatation of the RA and 
secondary chronic volume and pressure overload.38 This atrial dilatation is associated 
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with thrombo-embolic events, compression of the pulmonary veins and arrhythmias.38 
Later, the modern Fontan procedure or the total cavopulmonary connection (TCPC) 
was described.39 In the TCPC technique the superior caval vein is connected to the RPA 
with an end-to-side anastomosis.39 Nowadays, there are two techniques to connect 
the inferior vena cava to the pulmonary arterial system. In 1988 the intra-atrial lateral 
tunnel (ILT) technique was described. The ILT was constructed with use of the posterior 
wall of the RA and a prosthetic patch to channel the inferior vena cava to the enlarged 
orifice of the transected superior vena cava that is anastomosed to the main pulmonary 
artery.39 A couple years later the extracardiac conduit (ECC) technique was developed.40 
In the ECC technique the inferior vena cava is connected to the pulmonary arteries by 
using a Gore-Tex conduit (Figure 2).40 
Originally the Fontan circuit was created in a single operation, resulting in a relatively 
high post-operative mortality.13 Nowadays a staged TCPC procedure is clinical practice, 
in which a series of operations, in the course of a few years, creates the Fontan circuit.13, 
41 The type of first intervention depends on the underlying univentricular heart defect.13 
E.g. in case of a HLHS the single ventricle has to be connected to the aorta with the 
Norwood procedure.13, 42 At approximately 3-6 months of age, the vena cava superior 
is connected to the pulmonary arteries creating a partial cavopulmonary connection 
(PCPC).17 The TCPC is completed sometime between 18 months and 4 years of age, 
with an ECC or an ILT.17, 43 When the Fontan circulation is completed a highly abnormal 
circulation is created in which a subpulmonary ventricle is lacking.44, 45 This abnormal 
physiological state is characterized by an elevated systemic venous pressure and a 
decreased cardiac output.44, 45
Figure 2. Atrio-pulmonary Fontan, intra atrial lateral tunnel and extra cardiac conduit.
Adapted from Khairy et al.17 
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Long-term outcome
Since the development of the Fontan procedure, the long-time survival of Fontan 
patients increased from 69% 10-year survival in the cohort operated before 1990, to 
95% 10-year survival in the patients receiving a Fontan after 2001.46 Some researchers 
expect that the population of Fontan patients will double within 2 decades.47 
Like mortality, the morbidity of the Fontan operation has declined over the last 
decades. However, long-term complications including circulatory failure, 
thromboembolic events, protein losing enteropathy (PLE), liver fibrosis and severe 
arrhythmias are common. These problems all relate to the highly abnormal physiological 
state in the Fontan circulation and/or to myocardial scars after extensive surgical 
procedures.10, 43, 48, 49 
In ConHD patients, hospital admission for heart failure is an ominous sign with an 
one-year mortality of 24%.50 In Fontan patients circulatory failure is relatively common 
during long-term follow-up.45 The morphological abnormal functional single ventricle 
has been stressed for years through abnormal hemodynamic conditions, which 
potentially lead to diastolic and systolic dysfunction.45 Only 56% of APC patients were 
free of Fontan-failure after 25 years of follow-up.13, 49 It is expected that in contemporary 
Fontan patients the incidences of heart failure and circulatory failure will be lower, 
however the exact numbers are generally lacking.
Studies in older APC Fontan patients show that 15-year freedom from supraventricular 
tachycardia ranges between 46-49%.51 Since the introduction of the TCPC Fontan the 
incidence of arrhythmias has decreased.51, 52 However after TCPC arrhythmias still 
remain prevalent, with freedom from tachyarrhythmias ranging between 81-94% 15 
years after TCPC.51 Studies have shown that ECC patients often experience less 
arrhythmic events, most likely explained by less atrial scarring when using this surgical 
technique.49, 53, 54 However, follow-up duration often differs in studies comparing 
outcomes in patients with ILT versus ECC, complicating the comparison between the 
two techniques.55, 56 
After the Fontan operation cardiac reinterventions, both surgical and by catheter, 
are relatively common.13, 57 Like arrhythmias, cardiac reinterventions are more prevalent 
in the older Fontan cohorts compared to the younger cohorts operated with more 
contemporary techniques.13, 58 Another complication in Fontan patients is PLE, with an 
incidence of 1.5-11%.55 The cause of PLE is incompletely understood. Some studies 
suggest that elevated systemic venous pressure is related to the pathophysiology, 
although not all patients with PLE experience this. This suggests that more mechanisms 
are involved in the development of PLE.55
In conclusion, despite improvements in survival, adverse events occur frequently in 
Fontan patients during long-term follow-up. Fifteen years after contemporary Fontan 
completion the overall event-free survival ranges between 39-59%.49, 59 This emphasizes 
the need for lifelong close follow-up in a specialized facility for these patients.9 Research 
is necessary to determine the optimal TCPC technique in Fontan patients and to 
determine which other factors affect and/or predict long-term outcome and morbidity. 
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Tetralogy of Fallot
TOF is the most prevalent cyanotic ConHD, with a reported incidence of 0.34 per 1000 
live births.1 In the Netherlands, yearly approximately 60 babies with TOF are born.4, 16 
The tetrad was first described in 1673 by Nicolaus Steno, but was more extensively 
described by the French physician Etienne Fallot in 1888.14, 60 TOF consist of four cardiac 
anomalies: a ventricular septal defect (VSD), a (sub) pulmonary stenosis (PS), an 
overriding of the aorta across the VSD and RV hypertrophy (Figure 3).14, 60
In chapter 6 of this thesis an extensive overview is given on the surgical treatment 
options and outcomes of TOF patients. 
Tetralogy of Fallot repair
Before the surgical era, approximately 50% of TOF patients died within the first year 
of life.61 In 1944 the first palliative procedure was performed by Helen Taussig, Alfred 
Blalock and Vivien Thomas. A connection was created between the subclavian artery 
and pulmonary artery to guarantee adequate pulmonary blood flow.62 A decade later 
in 1954 the first intracardiac TOF repair was performed by Walter Lillehei.63 Via a large 
right ventriculotomy the VSD wat closed and a large transannular patch (TP) was 
created to relieve the right ventricular outflow tract (RVOT) obstruction and PS.63 In the 
first reported series, early mortality was as high as 40%,63 but this decreased in the 
following decades with advances in surgical techniques and postoperative 
management.14, 60
Figure 3. Tetralogy of Fallot
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Nowadays, TOF is often diagnosed prenatally or soon after birth.14 Patients will be 
usually operated on between 3-6 months of age and surgery is performed using a 
transatrial-transpulmonary approach, avoiding a right ventriculotomy which is 
associated with RV scarring, arrhythmias and RV dysfunction.61 Despite a successful 
TOF-repair the surgical relief of the PS often creates an incompetent pulmonary valve 
which causes pulmonary regurgitation (PR).14 
Long-term outcome
Nowadays the reported early mortality is 1.1%, and 25-year survival rates between 
93-97% have been described.64-66 However, despite relatively good long-term survival, 
morbidity after contemporary TOF-repair remains high. Patients suffer from PR, RV 
dilatation, impaired RV and LV function, residual RVOT obstruction, arrhythmias and 
even sudden cardiac death.61, 67, 68 PR is a key factor in the development of these 
problems and severe PR is often treated with a pulmonary valve replacement (PVR), 
although survival benefit of PVR has not been demonstrated.9, 68-71
Adverse events are common during follow-up in TOF patients. In an older surgical 
cohort the overall event-free survival was 25% after 40 years of follow-up, the freedom 
from reinterventions was 56% after 35 year follow-up.72 In a contemporary cohort of 
patients with trans-atrial transpulmonary TOF-repair, 25-year freedom from reoperation 
was 75%.64 The known predictors for adverse outcome in TOF patients have often been 
assessed in older surgical cohorts from a different surgical era.67, 72, 73 As mentioned, 
many factors in surgical and postoperative management have changed over time, 
possibly influencing long-term outcome. It is therefore important to continuously follow 
contemporary TOF patients and to describe their long-term follow-up and assess 
factors associated with their long-term outcome. 
In clinical practice, parameters are needed to identify ConHD patients at risk for 
future cardiac events or deterioration of cardiac function. Modalities to assess clinical 
condition in ConHD patients are echocardiography, cardiovascular magnetic resonance 
imaging (CMR), cardiopulmonary exercise test (CPET) and blood marker assessment. 
These modalities will be discussed in the remainder of this introduction.
Echocardiography
In clinical practice, echocardiography is widely used to assess cardiac function in ConHD 
patients.74 Echocardiography is widely available, portable and relatively cheap.75 
However, imaging patients with a higher body mass or imaging the RV can be 
challenging due to a limited echo window. 
In addition, the complex anatomy of univentricular hearts and multiple thoracotomies, 
which affects echocardiographic windows and image quality, potentially limits the use 
of echocardiography in a substantial proportion of patients.
Speckle tracking echocardiography (STE) is a technique which received increasing 
attention in the last two decades. STE is based on B-mode frame-by-frame tracking of 
acoustic markers (or speckles) throughout the cardiac cycle.76, 77 This allows to assess 
General introduction and outline of this thesis
17
1
the degree and speed of cardiac deformation throughout the cardiac cycle (e.g. strain 
and strain rate).77 In TOF patients a diminished LV global longitudinal strain is associated 
with cardiac death and severe arrhythmias.78 In Fontan patients diminished global 
circumferential strain, measured by echocardiography, has been related to death or 
cardiac transplant during follow-up.79 However echocardiographic longitudinal strain 
did not predict the presence of a low ejection fraction (EF) by CMR.80
Cardiovascular magnetic resonance imaging 
Another imaging technique is CMR. CMR provides information on cardiac and 
extracardiac anatomy, valvular function and ventricular size, all without ionizing 
radiation.81 CMR is the golden standard for measuring ventricular size and global 
function.75, 82, 83 Subsequently CMR has an important place in the clinical follow-up and 
decision making in ConHD patients including TOF and Fontan patients.9, 81 CMR has 
some limitations including relatively high costs, long scanning time, the need for 
anesthesia in younger patients and it is not always feasible in patients with cardiac 
devices or claustrophobia.75 
In addition to assessing ventricular size and function, CMR techniques such as late 
gadolinium enhancement and T1 mapping are useful to detect fibrosis in the 
myocardium.84 Myocardial fibrosis has been associated with arrhythmias, morbidity 
and mortality.85 A relatively new and promising CMR technique is four dimensional (4D) 
flow. This technique visualizes blood flow and energy distribution in the heart and the 
great vessels.86 The potential value of this technique in clinical practice has to be 
determined, but 4D flow derived energy loss and vorticity have been related to VO2 
max in Fontan patients.87 CMR derived parameters such as end diastolic volume (EDV), 
cardiac mass and EF have been associated with long-term outcomes in some ConHD.78, 
88-90 However serial longitudinal CMR studies have been generally lacking as have CMR 
studies with longitudinal follow-up in more contemporary TOF and Fontan cohorts.
Stress CMR
Another potential clinically valuable CMR technique is stress CMR. This technique 
combines the gold standard for volumetric analysis with functional information during 
stress, providing potential information regarding early dysfunction.91 
A stress CMR can be performed with physical stress and pharmacological stress.92 
In case of a physical stress CMR, a CMR compatible ergometer has to be used.92 Physical 
stress creates activation of the cardiac, vascular and muscular system.91 However 
several difficulties arise with physical stress; increased respiratory rate complicates 
breath-holding during the image acquisition and the maximal exercise is dependent 
on the patients motivation.92 These practical issues have limited the use of physical 
stress imaging in clinical practice.92 Pharmacological stress is more widely used. The 
most commonly used form of pharmacologic stress is intravenous dobutamine 
administration, a synthetic catecholamine that has a positive inotropic effect.93 It 
increases the myocardial demand for oxygen in a comparable manner as physical 
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exercise. In children with heart diseases good clinical tolerance for low-dose 
dobutamine (7.5 µg/kg/min) stress imaging has been reported.94 
In healthy volunteers a similar response to physical stress and dobutamine stress 
has been observed,95 this response consists of a decrease in end systolic volume (ESV) 
and a subsequent increase of EF, while EDV does not change. In ConHD patients the 
ventricular response to stress is often abnormal: patients display an impaired increase 
in EF, and impaired decrease of ESV and an abnormal decrease in EDV.96-100 In systemic 
RV patients with a biventricular circulation, an abnormal stress response was predictive 
for cardiac events during follow-up.101 In Fontan and TOF patients, the relationship 
between abnormal stress response and subsequent outcome remains the subject of 
study.102 
Cardiopulmonary exercise testing
Like cardiac imaging, a CPET is a recommended instrument in the follow-up of ConHD 
patients.9 Patients with ConHD can experience a diminished exercise capacity and are 
often less active and exercise less vigorously than their healthy peers.103-106 
A CPET is used to objectify exercise capacity.9 During the CPET the patient wears a 
mask to measure the air volumes passing through the mask and to measure the inhaled 
oxygen and exhaled carbon dioxide.107 These measurements allow to assess several 
CPET parameters such as oxygen consumption (VO2), carbon dioxide production (VCO2) 
and the respiratory exchange ratio (RER).107 During the CPET also heartrate, peak 
workload, blood pressure and saturation are measured. The peak VO2 (maximal 
reached VO2) is the primary outcome of the CPET. Peak VO2 is corrected for the weight 
of the patient and is also calculated as percent of predicted peak VO2, using reference 
data of healthy volunteers.
Like other ConHD patients, Fontan and TOF patients often experience diminished 
exercise capacity and a reduced peak VO2.
108 106, 109 Several clinical parameters have 
been associated with CPET parameters.108-113 Fontan patients operated on with older 
surgical techniques experience a lower peak VO2 compared to patients operated on 
with contemporary TCPC techniques.109 Furthermore, patients with a RV morphology 
display a more rapid decline in exercise capacity over time.110 A poor clinical outcome 
has been associated with exercise capacity in both Fontan and TOF patients.106, 109, 114-117 
In TOF patients a peak VO2 of ≤15.5 ml/kg/min or a peak VO2 ≤65% of predicted are 
associated with hospitalization for sustained ventricular tachycardia and death during 
subsequent follow-up.115, 118 Likewise, a study in Fontan patients observed that a peak 
VO2 of ≤16.6 ml/kg/min was associated with new morbidity and death.
117
Serum biomarkers
In ConHD patients pathways related to inflammation, hypertrophy, remodelling and 
fibrosis are most likely involved in the development of heart failure and decline in 
cardiac function.119 These pathways have been the subject of extensive research in 
acquired heart disease, but remain less well understood in ConHD.85, 119 However the 
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search continues to unravel these mechanisms and to search for biomarkers of these 
processes. A biomarker is “any substance, structure, or process that can be measured in 
the body or its products and influence or predict the incidence of outcome or disease”.120 
Potentially, assessment of blood biomarker levels is a relatively non-invasive method 
to monitor the clinical condition of ConHD patients and to identify those patients at 
risk for clinical deterioration or adverse events. 
In the last decades neurohormones such as brain natriuretic peptide (BNP) and 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) have received much attention.121 
The ventricular myocyte releases NT-proBNP as a response to stretch and in acquired 
heart failure patients NT-proBNP levels have an important role in the clinical follow-
up.122, 123 In TOF and Fontan patients (NT-pro)BNP levels have been related to the clinical 
condition.88, 98, 124, 125 Although NT-proBNP levels are often within normal range in Fontan 
patients,126 Fontan patients with heart failure, Fontan patients operated on using older 
techniques and Fontan patients with morphological RV’s have higher NT-proBNP 
levels.124, 127-129 The role of NT-pro BNP in clinical practice in cyanotic heart disease has 
been fully established.
In the recent years several other serum biomarkers have been identified in ConHD 
patients such as galectin-3, suppression of tumorigenicity 2 (ST2) and growth 
differentiation factor 15 (GDF-15). Galectin-3 is involved in several biological processes 
including fibrosis and inflammation.130, 131 In a large adult ConHD cohort an increased 
galactin-3 was observed in 7% of the patients and a higher galactin-3 was associated 
with adverse cardiovascular events.132 In adult Fontan patients, elevated galectin-3 is 
associated with adverse outcome.133 In a pediatric cohort undergoing ConHD surgery, 
elevated galectin-3 levels were associated with an increased risk of mortality and 
readmissions, as did ST2.134, 135
ST2 is a protein which can be expressed in a soluble form (sST2) and a transmembrane 
form (ST2 ligand), it is it marker for fibrosis and myocardial apoptosis.136 ConHD patients 
display higher levels of sST2 compared to healthy volunteers, also different sST2 levels 
are observed between different ConHD types.136 In adult complex ConHD sST2 is a 
predictor for all-cause mortality and adverse events.136 137 Also in children with ConHD 
and heart failure, sST2 was significantly correlated with fractional shortening and left 
ventricular end systolic and end diastolic dimensions.138
Like sST2, GDF-15 is a marker of abnormal function, in pediatric Fontan patients 
higher GDF-15 levels are related to impaired echocardiographic singe ventricle EF.139 
GDF-15 is a member of the transforming growth factor beta (TGFβ) family and is a 
marker of oxidative stress.140-143 In adult ConHD patients, higher GDF-15 levels correlate 
with poorer functional status, cardiac dysfunction and adverse outcome.141, 142, 144 
Specifically in Fontan patients higher GDF-15 levels are associated with impaired systolic 
function.139
Additional studies are necessary to unravel the biochemical mechanisms of heart 
failure in ConHD patients and to find new biomarkers and potentially find targets for 
therapy. 
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Aims and outline of this thesis
The studies in this thesis are part of the multicenter prospective study entitled: ‘COBRA3: 
Congenital heart defects: Bridging the gap between Growth, Maturation, Regeneration, 
Adaptation, late Attrition and Ageing’. The multicenter prospective COBRA3 study has 
several objectives: 
1. To assess factors during mid-term to long-term follow-up which are related to the 
achievement of myocardial homeostasis or are related to deterioration of clinical 
state and impending failure. 
2. To assess the impact of ConHD on the growth, homeostasis and premature ageing 
of the heart, particularly for the RV. 
3. To carry out prospective and cross-sectional assessment of parameters of cardiac 
function and maintenance of myocardial homeostasis in ConHD patients.
This thesis focuses on describing the mid- to long-term outcomes of Fontan and TOF 
patients and to assess parameters which correlate with endpoints or adverse outcome. 
Part I – Fontan circulation
Part I of this thesis focuses on the Fontan circulation. In chapter 2 an overview is given 
on the surgical treatment options, management and outcomes of the Fontan circulation. 
In chapter 3 we investigate in a retrospective follow-up study, whether differences 
exist in long-term outcomes in TCPC patients operated on with the ILT vs the ECC 
technique and current modifications of these techniques. In chapter 4 we look into 
the ventricular response to dobutamine stress CMR of Fontan patients and if this is 
related to outcomes during follow-up. In chapter 5 biomarkers, CMRs and CPET’s were 
assessed in a multicenter prospective study to evaluate if these factors are associated 
with outcome in a young and contemporary Fontan cohort. 
Part II – Tetralogy of Fallot
The second part of this thesis focus on TOF patients. Chapter 6 starts with a review 
on the current treatment strategies, the management and long-term outcomes of TOF 
patients. Chapter 7 and 8 describe a retrospective follow-up study in transatrial 
transpulmonary operated TOF patients. These studies research surgical determinants 
of long-term outcome and whether there is an optimal timing for primary TOF repair. 
Chapter 9 assesses whether the ventricular response to dobutamine stress CMR is 
related to outcome in TOF patients. In chapter 10 we assess the research question of 
biomarkers, CMR and CPET’s are associated with cardiac function and long-term 
outcome in young Fontan patients. We will discuss the findings of all the studies in 
chapter 11, the General Discussion of this thesis. 
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Abstract
In patients with a functionally univentricular heart the Fontan strategy achieves 
separation of the systemic and pulmonary circulation and reduction of ventricular 
volume overload. Contemporary modifications of surgical techniques have significantly 
improved survival. However, the resulting Fontan physiology is associated with high 
morbidity. 
In this review we discuss the state of the art of the Fontan strategy by assessing 
survival and risk factors for mortality. Complications of the Fontan circulation, such as 
cardiac arrhythmia, thrombo-embolism and protein-losing enteropathy are discussed. 
Common surgical and catheter-based interventions following Fontan completion are 
outlined. We describe functional status measurements such as quality of life and 
developmental outcomes in the contemporary Fontan patient. The current role of drug 
therapy in the Fontan patient is explored. Furthermore, we assess the current use and 
outcomes of mechanical circulatory support in the Fontan circulation and novel surgical 
innovations. 
Despite large improvements in outcomes for contemporary Fontan patients, a large 
burden of disease exists in this patient population. Continued efforts to improve 
outcomes are warranted. Several remaining challenges in the Fontan field are outlined.
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Introduction
Functionally univentricular congenital heart disease (CHD), in which only one ventricle 
is fully developed, poses a complex clinical problem. Estimates of the incidence of this 
disease entity range from 0.08 to 0.4 per 1000 births.1-3 Functionally univentricular CHD 
entails different morphological diagnoses, the most common of which are: hypoplastic 
left heart syndrome (HLHS) (25% to 67% of functionally univentricular hearts), tricuspid 
atresia (15% to 24%), and double inlet left ventricle (14% to 18%).1, 3-5 It is estimated 
that currently there are about 22.000 patients in Europe and approximately 50.000 in 
the United States.6 Recent advancements in prenatal screening have increased the 
rates of prenatal diagnosis and possibly termination of pregnancy in patients with 
univentricular hearts.1, 7 Despite the low incidence, improvements in treatment have 
reduced the mortality to the point where a large number of patients survives into 
adulthood. 
Palliation can be achieved with the Fontan strategy. A series of operations is 
performed to palliate the adverse effects of a univentricular heart. The Fontan strategy 
refers to the landmark surgery for tricuspid atresia by Fontan et al.8 In the ‘early days’ 
of these procedure it was attempted to replace the function of the right ventricle with 
the right atrium by connecting the right atrium to the pulmonary artery. Although 
short-term results were unprecedented, this strategy caused dilation of the right 
atrium, resulting in arrhythmia and thrombo-embolism due to sluggish blood flow.9 
Modifications of this surgery are referred to as atrio-pulmonary connections (APC). In 
a later era, de Leval et al. found atrial contractions did not contribute significant power 
to the APC circuit, and proposed the intra-atrial lateral tunnel (ILT), a trans-atrial 
connection using an intra-atrial baffle connecting the inferior caval vein to the 
pulmonary artery in a more energetically favorable manner. Currently, most centers 
employ an extra-cardiac conduit (ECC), a prosthetic conduit that bypasses the atrium 
completely. Both ILT and ECC are referred to as total cavo-pulmonary connection (TCPC) 
Fontan modifications. 
A Fontan circuit was originally created in a single surgical setting. This resulted in 
relatively high mortality. A staged TCPC, in which a series of operations is performed 
at different ages, is the current standard of care. These operations are tailored to the 
individual anatomy of the patient. First, the single ventricle (SV) needs to be connected 
to the aorta, which may require extensive surgery, such as the Norwood procedure 
for HLHS. At approximately 3 to 6 months of age, a partial cavo-pulmonary connection 
(PCPC), connecting the superior caval vein to the pulmonary artery, i.e. bidirectional 
Glenn procedure, is performed. Completion of the TCPC is usually performed between 
18 months and 4 years of age.4 The connections and circulatory pattern after these 
operations are illustrated in Figure 1.
These patients require a lifetime of highly specialized care and significant healthcare 
resources. In Oceania, the mean hospital costs across all stages of palliation are 
approximately $200.000 per patient.10 Following Fontan palliation, hospital admission 
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rates for patients are 8 times higher than the general population11 and both length of 
stay and hospital costs are higher compared to other CHD diagnoses, including e.g. 
Tetralogy of Fallot.12-14
Physiology
In unpalliated univentricular CHD cyanosis occurs due to mixing of saturated and 
unsaturated blood in the heart. The SV is also exposed to volume overload as it drains 
both systemic and pulmonary venous return at the same time. The Fontan strategy 
reduces volume overload and restores normoxaemia. Following PCPC surgery some 
volume unloading of the single ventricle is achieved. Following TCPC the volume load 
of the SV is further reduced.15 Furthermore, after TCPC the systemic and pulmonary 
blood flows are connected in series, rather than parallel as before this strategy has 
been deployed. This comes at the expense of the lack of a ventricle supplying energy 
to the pulmonary circulation. This is illustrated in Figure 2. The single ventricle provides 
the energy needed to attain blood flow through the systemic as well as the pulmonary 
vascular bed and is subjected to increased afterload. After TCPC central venous 
pressures are higher than normal. Pulsatility in the pulmonary artery is mostly lost and 
there is preload insufficiency of the single ventricle. This highly abnormal circulation 
is called the Fontan circulation. The resulting physiology has been referred to as a 
This figure has been reproduced from Kerlo et al. with permission of the author.157 
Abbreviations: IVC: Inferior vena cava; SVC: superior vena cava; PA: pulmonary artery; SV: Single ventricle.
Figure 1. Illustration of the anatomic relations following PCPC (A) and TCPC (B) palliation. 
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“Fontan paradox”, where systemic venous pressure is high in the presence of relative 
pulmonary artery hypotension.16 This might augment lymphatic outflow, and impede 
lymphatic inflow from the thoracic duct. Several complications of the Fontan strategy 
have been linked to abnormalities in lymphatic drainage. Because of the multiple 
inherent hemodynamic challenges of the Fontan circulation, it is generally considered 
a palliative procedure.17 
The aim of this paper is to provide an overview of current outcomes, treatment 
options and remaining challenges to improve outlook for patients with univentricular 
heart disease. 
State of the Art
Overall survival
Survival following the Fontan procedure has increased dramatically in the past decades. 
We will discuss data from recently published reports of large cohorts with long follow-
up intervals. An overview of studies assessing survival is presented in Figure 3, obtained 
from Kverneland et al.18
This figure has been reproduced from Gewillig et al. with permission of the author.158
This scheme illustrates the effects of the lack of a prepulmonary pump in the Fontan physiology. Red 
represents oxygenated blood where blue represents deoxygenated blood. 
Abbreviations: LV: Left ventricle; Ao: aorta; S: systemic circulation; RA: Right atrium; RV: Right ventricle; PA: 
Pulmonary artery; P: Pulmonary circulation; LA: Left atrium; V: Single ventricle; CV: Caval veins. 
Figure 2. Scheme of pressures in the normal circulation (A) and the Fontan circulation (B). 
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In a recent study from Oceania perioperative mortality decreased from 8% between 
1975 and 1990 to 1% in 2001-2010. 19 In this cohort early Fontan takedown occurred 
in 2% of patients. 10-Year survival among patients discharged with a Fontan circulation 
was 89% following APC and 97% for both ECC and ILT.20 Survival at 25 years was 76%. 
This group was comprised only of APC patients.
In a retrospective study from the Mayo clinic of 40 years and 1052 Fontan patients, 
overall survival was 74% at 10 years, 61% at 20 years and 43% at 30 years.21 Survival 
was significantly higher in later surgical eras, with a 10-year survival of 95% for patients 
operated after 2001. Interestingly, patients operated with the ECC technique showed 
better overall survival over ILT. It should be taken into account that ILT patients suffered 
from diagnoses with worse prognosis. 
A Danish national registry described outcomes for SV patients from 1977 to 2009.1 
50% of patients died before Fontan completion. Overall survival improved in later birth 
eras. Five-year survival for any univentricular CHD increased from 22% in 1977-1989 
to 51% in 2000-2009.
One should note that follow-up studies after Fontan procedures reflect results of an 
earlier surgical era and do not necessarily represent the outlook of patients treated 
according to the current standard of care.
This figure has been reproduced from Kverneland et al. with permission of the author.18
Each line represents a study assessing survival at multiple time points and is colored by surgical era. Dots 
represent Kaplan-Meier survival estimates. Studies marked * show survival curves for death, transplant or 
Fontan revision, others show survival curves for only death. 
Figure 3. Survival following Fontan completion. 
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Determinants of survival
Several factors have been associated with survival after the Fontan procedure. Of pre-
operative factors, male gender20 and specific CHD diagnosis, most strikingly for 
hypoplastic left heart syndrome (HLHS)22, have been associated with worse long-term 
survival. Perioperative risk factors for mortality include APC type procedure, earlier 
surgical era, older age at procedure, concomitant valve replacement and prolonged 
post-operative pleural effusion.22 Postoperative factors that affect survival include: 
elevated central venous pressure and lower arterial saturation23; imaging derived 
parameters such as lower global longitudinal strain on echocardiography and higher 
end-diastolic volume measured by magnetic resonance imaging (MRI)22; peak heart 
rate and peak oxygen uptake during cardiopulmonary exercise testing22, 24, 25; serum 
levels of sodium, creatinine, and brain natriuretic peptide.22, 26, 27
Cardiac complications
Although survival following Fontan completion has increased over time, the Fontan 
strategy has been associated with important morbidity, most likely related to extensive 
surgical procedures and the highly abnormal circulatory state after these procedures. 
In recent cohorts event-free survival has ranged from 59% to 81 % at 15 years.20, 28 
The most commonly reported event is cardiac arrhythmia. Supraventricular 
tachycardia (SVT) contributes significantly to late mortality in Fontan patients.29 SVT 
has been associated with Fontan type, with highest risk for APC type, followed by ILT 
and lowest for ECC.20, 30 Results may have improved for the ILT technique after 
introduction of the prosthetic modification.31 The incidence of SVT increases during 
follow-up and after 20 years of follow-up 10% to 60% of patients has experienced some 
form of SVT.31, 32 
Failure of the Fontan circulation can occur even in longstanding uncomplicated 
Fontan circulations. The definition of Fontan failure varies but generally includes either 
excessive constitutional limitations of the Fontan physiology, abnormal parameters of 
hemodynamic function, poor functional status or the presence of Fontan sequelae.33 
Fontan failure occurs in 2-13% of patients, depending on definitions and follow-up 
period.33 A 56% 25-year freedom of Fontan failure for APC connections has been 
reported.20 
Extracardiac complications
Abnormalities of Coagulation. Blood flow can be slow in the Fontan circuit due to the 
absence of a prepulmonary pump. This promotes coagulation. Furthermore, 
coagulation factor abnormalities have been described in the SV patient, even before 
PCPC palliation.34 Thrombo-embolic events are more common following APC surgery 
than TCPC.34 The prevalence of thrombi is particularly high in those that develop atrial 
arrhythmias.35 Up to 65% of thrombi are detected within the first year following TCPC 
(early thrombo-embolic events).36 Early thrombo-embolic events probably relate to 
perioperative factors, such as ECMO use and altered hemodynamics. Beyond 10 years 
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after Fontan completion incidence of late thrombo-embolism steadily increases.36 
Reports of the incidence of thrombo-embolism are complicated by different definitions 
and methods of detection. Studies report incidences of late thrombo-embolism 
between 1% and 25%.28, 37 Silent thrombi are detected with transesophageal 
echocardiography in up to 33% of patients.38 Thrombo-embolic events have been 
reported to account for 8% of Fontan deaths.39 
Liver function abnormalities, cirrhosis and even hepatocellular carcinoma have been 
reported following Fontan surgery.40 The elevated systemic venous pressures 
encountered in the Fontan circulation leads to chronic venous congestion in the liver. 
However, the exact mechanism for Fontan-associated liver disease remains unknown, 
as does how best to monitor progression.41, 42 The American College of Cardiology have 
recently provided a position statement on the subject, advising laboratory and imaging 
screening at least every 3-5 years in children and at least every 1-3 years in adult Fontan 
patients.43 Preventive strategies need to be developed.
Protein-losing enteropathy (PLE) is a devastating complication of the Fontan 
circulation where loss of protein in the gastro-intestinal tract occurs, leading to low 
albumin levels, edema, pleural effusions and ascites. Incidences have been reported 
between 3% and 29%.21, 28, 32, 44 It is thought to be caused, in part, by impairments in the 
lymphatic drainage. Hepatoduodenal lymphatic connections exist in some patients as 
a normal anatomic variant, which might induce competition in lymphatic flow in the 
presence of elevated venous pressure, diverting lymphatic flow to the gastro-intestinal 
tract.
Plastic bronchitis is a serious pulmonary complication of the Fontan circulation, in 
which large gelatinous casts are formed in the airways. It is thought to be related to 
abnormal lymphatic drainage directly into the airways, resulting in cast formation. 
Reported incidences range from 0.5% to 4%.45-47
Chronic kidney disease is estimated to be present in up to 50% of adult Fontan 
patients and is associated with adverse outcomes.27, 48 With the increasing availability 
of cystatin C determined GFR, a muscle mass independent estimate, the prevalence 
of clinically significant renal dysfunction appears to be lower.49 GFR estimates based 
on serum creatinine concentrations probably overestimate renal function in Fontan 
patients.48 
Psychological, psychiatric and cognitive defects have been described in Fontan 
patients. Cerebral MRI has shown morphological differences in some cerebral 
structures of Fontan patients compared with healthy controls.50, 51 Interestingly, the 
pituitary gland, supplied by a portal venous system similar to the liver, appears to be 
enlarged following Fontan surgery.52 The relevance of this possible congestion on the 
endocrine system remains unclear.
Re-interventions
Many patients require additional surgical and catheter-based interventions following 
Fontan completion. 20 year freedom of re-operation following TCPC procedures in 
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recent eras ranges from 86% to 92%.53 In older cohorts higher re-operation rates have 
been reported.21, 54, 55 The most common surgical re-intervention procedures, in order 
of incidence, are pacemaker implantation in 9% to 23% of patients,20, 21 Fontan revision 
or conversion in 3% to 18% of patients9, 21, 56 and atrioventricular (AV) valve repair in 1% 
to 14% of patients.21, 56, 57
Fontan conversion, from APC to TCPC, can improve functional status and exercise 
tolerance in the failing Fontan circulation.58 AV valve repair after Fontan completion is 
considered in patients with moderate to severe regurgitation, but survival following 
successful repair remains inferior to that of patients without prior AV-regurgitation.59, 
60
For several reasons re-interventions by catheter may be required. A fenestration in 
the atrial tunnel, inducing a right-to-left atrial shunt, can be created during surgery to 
decrease systemic venous pressure, increase ventricular preload, and improve cardiac 
output at the cost of lower arterial saturation. This fenestration sometimes closes 
spontaneously or can be closed via catheter at a later time.61
Hemodynamically significant obstruction in the Fontan pathway may occur, most 
commonly in the left pulmonary artery.54, 62 In the absence of a pre-pulmonary pump, 
this can severely affect the Fontan circulation, and obstructions are routinely dilated 
or stented. Systemic to pulmonary venous collaterals can produce a right-to-left 
shunting which often worsens in time. Coiling of these collaterals is routinely performed 
in some centers, although no survival benefit has been demonstrated.63 
Aorto-pulmonary collaterals are common in the Fontan circulation. They increase 
pulmonary blood flow but induce a volume overload on the single ventricle and might 
increase pulmonary artery pressure, limiting flow from the caval veins.62 During 
exercise, aortopulmonary flow increases, possibly augmenting loading conditions of 
the ventricle.64 A large aorto-pulmonary collateral burden has been associated with 
worse short-term outcomes.65 No clear consensus regarding the long-term effects and 
management of these collaterals exist.62
Catheter ablation of an arrhythmogenic substrate is common. Long term success 
rates vary between 15% and 72%.66, 67 The reported incidence of catheter-based 
interventions, i.e. excluding diagnostic cardiac catheterization without intervention, 
varies heavily with 3% to 65% of patients requiring at least one additional catheter 
intervention following Fontan completion.28, 53, 54, 56, 68 The most common catheter 
interventions are fenestration closure (10% to 64% of patients with a fenestration 
require catheter-based fenestration closing53, 54, 56, 69), occlusion of veno-venous or aorto-
pulmonary collaterals (incidence 10% to 20%)54, 56 and stenting and dilation of (all types 
of) obstructions in the Fontan pathway (incidence 6% to 19%).54, 56, 70
Other outcomes and functional status
Most studies report a diminished quality of life in Fontan patients compared to healthy 
controls.71-75 Physical and emotional functioning are the most severely affected 
domains.71, 76 Low perceived health status can lead to unnecessary restrictions in daily 
Part I  |  Chapter 2
40
life. Furthermore, increased rates of developmental disorders and lower intelligence 
scores have been reported in the Fontan population.50, 73 
Fontan patients have a moderately decreased exercise capacity compared to healthy 
controls.77 Mean peak oxygen uptake ranges from 61% to 74% of predicted values.77-79 
A small fraction of Fontan patients have normal exercise capacity.80 Exercise capacity 
in the Fontan patient has been shown to decrease over time.78, 79 Exercise capacity is 
predictive of hospital admissions, quality of life and late mortality.22, 25, 76, 79 Exercise 
training can be done successfully in Fontan patients and can improve quality of life, 
functional class and health perception in a short-term follow-up.81-84 Whether exercise 
training has a role in optimizing long-term outcome is currently not clear.81, 83-86 
Resistance training can be used to increase muscle mass. In the Fontan patient this 
could augment peripheral venous return, augment ventricular preload and improve 
cardiac output.87 Similarly, a benefit of inspiratory muscle training has been 
demonstrated.88
Despite high morbidity and suboptimal outcomes, most patients with a well-
functioning Fontan circulation manage to lead fulfilling lives, are employed, may attain 
academic achievements, can participate in sports and are able to successfully carry 
pregnancy to term.89-91
Assessment techniques
Fontan patients are routinely assessed for health and functional status. Diagnostic 
cardiac catheterization has been standard practice in the pre-TCPC evaluation as it 
provides excellent anatomic and necessary hemodynamic information regarding the 
pulmonary artery pressure, pulmonary vascular resistance, and end-diastolic single 
ventricle pressure.92 There is recent interest in omitting cardiac catheterization in the 
pre-TCPC assessment for low risk SV patients.92-94 No consensus regarding this policy 
has been reached, as long-term outcomes are currently unavailable. Catheter-based 
interventions are discussed above.
Cardiac magnetic resonance imaging (CMR) is routinely performed during follow-up 
after TCPC, particularly to assess ventricular size and function and to quantify large 
vessel flow including the amount of collateral flow.95-99 Death and (being listed for) heart 
transplantation have been associated with higher indexed end diastolic volume (>125 
ml/m2) as assessed with CMR in adolescents with a Fontan circulation.100, 101 Combined 
with a computational fluid dynamics approach, CMR might provide very useful 
information on the Fontan circulation and can aid in the evaluation of modifications 
in treatment strategies.102
Echocardiographic strain measurements have been shown to predict survival in the 
Fontan population and predict length of hospital stay following TCPC.101, 103 Assessment 
of VA coupling may be another important parameter as it is independent of the, often 
impaired, ventricular load. VA coupling has been shown to be suboptimal in some 
Fontan populations.104 Currently, VA coupling has not been associated with long-term 
outcomes in the Fontan population.
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Lymphangiography could play an important role in the management of Fontan 
complications with a suspected lymphatic pathogenesis, such as PLE and plastic 
bronchitis. In patients suffering from PLE or plastic bronchitis increased diameters of 
major lymphatic vessels have been noted.105 Abnormal lymphatic depositions in the 
lungs and liver have been visualized in patients suffering from plastic bronchitis and 
PLE, respectively.106, 107 
Medical therapy
Anticoagulation, in the form of anti-platelet drugs or vitamin K antagonists (VKA), is 
commonly indicated considering the increases risk for thrombo-embolic events, as 
discussed above in the ‘extracardiac complications’ section.108 A meta-analysis by Alsaied 
et al. showed both acetylsalicylic acid and VKA were equally effective in preventing 
thrombo-embolic complications.109 However, if INR is not properly controlled outcomes 
on VKA are worse compared to acetylsalicylic acid.110 Novel oral anticoagulants (NOACs) 
do not require frequent monitoring and have mostly outperformed VKA in the adult 
population. Thirty day outcomes following NOAC initiation show no major adverse 
events in the adult CHD population.111 However, no NOAC agent currently has FDA 
approval for use in children.
Medical prevention of circulatory failure in the Fontan circulation
Various medications have been assessed in the management of Fontan failure. 
No studies have shown benefit of ACE inhibitor therapy on survival, ventricular function 
or cardiopulmonary exercise outcomes.112, 113
Vasodilator drugs have been used to lower pulmonary vascular resistance.114, 115 
Sildenafil has increased ventricular function, exercise capacity and NYHA status after 
6 weeks of follow-up.116, 117 The effects of bosentan, an endothelin antagonist, in the 
Fontan population have varied.118-123 No long-term survival benefit of vasodilator 
therapy has yet been demonstrated.116
Mechanical circulatory support for the failing Fontan circulation 
The failing Fontan circulation can be supported by mechanical assist devices. Despite 
increasing use and the development of novel devices specifically for the pediatric and 
CHD population, experience in this population is still limited.124 Mechanical support 
devices are mostly used as a bridge to transplant in the failing Fontan.125 Recent reports 
showed a 60% 12-month survival in 48 Fontan patients with a ventricular assist device, 
proving viability of longer mechanical circulatory support.126, 127 A total biventricular 
artificial heart, the SynCardia, has been used to bridge a failing Fontan patient to 
transplant.128 A registry of mechanical circulatory support specifically for SV patients 
has been initiated.129 Currently, mechanical circulatory support in Fontan patients is 
associated with worse survival compared to mechanical circulatory support patients 
with a biventricular circulation.130-132 
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Cardiac transplantation
Cardiac transplantation is the only treatment that truly corrects Fontan physiology, 
and it is employed in the failing Fontan circulation. In large cohorts 1.6% to 3.6% of 
patients ultimately underwent cardiac transplant.20, 21 Survival following cardiac 
transplantation in Fontan patients is generally worse compared to other types of 
CHD.133, 134 Five-year survival ranges from 60% to 67%.133-135
Surgical innovations
Continuous efforts are made to improve the surgical techniques used in Fontan surgery. 
Recently, a Y-shaped graft has been proposed for the connection of the inferior vena 
cava to the left and right pulmonary artery.136 Theoretically, this graft is more 
energetically favorable and provides better distribution of hepatic blood flow between 
the left and right pulmonary artery, distributing ‘hepatic factors’ that may prevent 
formation of intrapulmonary collaterals, more equally. Worse energetic performance 
and pulmonary flow distributions in comparison to ECC connections have been noticed 
in practice.137, 138
Fontan completion without cardiopulmonary bypass, particularly with the ECC 
technique, is an attractive option. However, experience is still limited and reported 
rates of conduit replacement and outcomes following off-pump procedures differ 
across centers.139-142
Less invasive surgical approaches such as lateral thoracotomy have been described 
in this population.143 Hybrid procedures, which combine trans-catheter and surgical 
approaches, have been implemented in the initial management of HLHS.144 Long term 
outcomes are favorable and some centers have adopted this hybrid approach as the 
standard for selected patient populations.145
Remaining challenges 
A contemporary Fontan strategy uses either the ILT or ECC modification. Two large 
meta-analyses have recently compared surgical strategies and found no differences 
in early or late mortality and Fontan takedown between ECC and ILT.30, 146 Theoretical 
advantages of both techniques have been discussed extensively in literature.147, 148 
Further research should assess contemporary differences in outcomes between 
modifications and help guide the preferred procedure for future Fontan patients. This 
may include alternative concepts, like the Y-graft or combinations with external energy 
supply (pumps).
Remodeling of the SV, which is exposed to volume overload at birth and is volume 
deprived following TCPC procedure, is not understood very well. A better understanding 
of mechanisms of remodeling during these stages and the interaction of ventricular 
size and function with the Fontan baffle function, pulmonary circulation, atrial function 
and ventriculo-arterial (VA) interaction is required to find better means to preserve 
cardiac function. The search for new targets for drugs that may help to preserve cardiac 
and circulatory function continues. 
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Some controversy regarding the timing of TCPC surgery exists. Proponents of early 
TCPC argue a prolonged period of volume overload leads to adverse cardiac remodeling 
and reduced cardiac function.149 Others argue the Fontan circulation inherently leads 
to complications, and surgery should be delayed to reduce the amount of time in 
Fontan physiology.150 Other factors to be considered are the technique used, with ILT 
allowing TCPC at lower body weight than ECC, since small sized conduits (< 18 mm) 
need to be avoided.148, 151 Studies assessing the optimal timing of ECC procedures are 
currently being performed. 
The effect of systemic to pulmonary venous and aorto-pulmonary collaterals on the 
Fontan circulation remains poorly understood. These collaterals could provide some 
benefit in patients with a suboptimal Fontan circuit. How these collaterals develop and 
why some patients seem more prone to this development remains to be determined. 
Increasing our understanding of the role of collaterals could help guide selection of 
patients who will benefit from intervention. This requires well-designed (multicenter) 
studies. Several treatment modalities of PLE have been described in small series, 
including catheter-based strategies of both blood and lymphatic vessels and surgical 
re-implantation of the innominate vein into the common atrium.152-156 More 
comprehensive analysis is needed to determine the efficacy and safety of these 
procedures.
Drug therapy has been shown to be able to decrease pulmonary vascular resistance 
in the short-term, making this a promising therapy for the Fontan patient. However, 
currently no long-term benefit has been demonstrated. The role of drug therapy in the 
Fontan circulation needs to be studied more extensively. 
These questions require answers to make better informed decisions in the 
management of these challenging patients, suffering from some of the most severe 
kinds of CHD. We have an opportunity to help this growing patient population not just 
to survive, but thrive and live full, satisfying lives. 
Conclusion
The modern Fontan strategy has significantly transformed outcomes for patients with 
univentricular CHD. This has led to a large and growing population of Fontan patients 
surviving into adulthood. However, morbidity remains high and increases as this 
population ages and grows in proportion. Efforts to reduce morbidity and improve 
quality of life in these patients are ongoing. These efforts are focused on improving 
surgical techniques, developing novel diagnostic and therapeutic tools and increasing 
our understanding of the highly abnormal Fontan physiology. 
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Abstract 
Objectives
To compare the outcome of the intra-atrial lateral tunnel (ILT) and the extracardiac 
conduit (ECC) techniques for staged total cavopulmonary connection (TCPC). To 
compare the current modifications of the TCPC technique, the prosthetic ILT technique 
with the current ECC technique with a ≥ 18-mm conduit.
Methods
We included patients that had undergone staged TCPC between 1988 and 2008. 
Records were reviewed for patient demographics, operative details and events during 
follow-up (death, surgical and catheter-based reinterventions and arrhythmias). 
Results
Of the 208 patients included, 103 were ILT (51 baffle, 52 prosthetic) and 105 were ECC 
patients. Median follow-up duration was 13.2 years (interquartile range 9.5-16.3). At 
15 years after TCPC, overall survival was comparable (81% ILT vs 89% ECC, p=0.122). 
Freedom from late surgical and catheter-based reintervention was higher for ILT than 
for ECC (63% vs 44%, p=0.016). However, freedom from late arrhythmia was lower for 
ILT than for ECC (71% vs 85%, p=0.034). In a subgroup of patients with an current TCPC 
technique, we compared use of prosthetic ILT with ≥ 18-mm ECC, we found no 
differences in freedom from late arrhythmias (82% vs 86%, p=0.64) and freedom from 
late reinterventions (70% vs 52%, p=0.14). 
Conclusions
A comparison between the updated prosthetic ILT and current ≥ 18-mm ECC techniques 
revealed no differences in late-arrhythmia-free survival or late reintervention-free 
survival. Overall, outcomes after staged TCPC are relatively good and reinterventions 
occurred more frequently in the ECC group, while late arrhythmias were more common 
in the ILT group. 
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Introduction
The Fontan operation is the procedure of choice in patients in whom biventricular 
repair is not feasible.1, 2 Over the past 30 years, two main Fontan techniques have been 
developed. The intra-atrial lateral tunnel (ILT) technique, originally used the right atrial 
wall (all or part of it) to create a baffle to tunnel the blood from the inferior vena cava 
directly to the pulmonary arteries.3-5 When combined with a connection of the superior 
vena cava to the pulmonary arteries, this resulted in the total cavopulmonary 
connection (TCPC).1 Subsequently, the extracardiac conduit (ECC) technique was 
described, which uses a conduit from the inferior vena cava to the pulmonary arteries.6 
Over time, the atrial baffle ILT technique has evolved into the prosthetic ILT, in which 
the intra-atrial tunnel is created using part of a prosthetic tube rather than part of the 
atrial wall.7
Because of haemodynamic advantages and a significant improvement in operative 
outcomes, the single-stage TCPC has been replaced by a staged approach,8 which has 
resulted in relatively low late mortality rates.9, 10 However, a direct comparison of the 
long-term outcomes of the two TCPC techniques remains difficult due to the limited 
number of patient-years and due to differences between duration of follow-up after 
the two TCPC techniques. Furthermore, the ILT and ECC techniques have been updated 
over time, which further limits up-to-date information on the outcomes of current 
approaches.11 
Remarkably, a serial follow-up of TCPC patients has hardly been done. Without this 
data, and without data on outcome and survival after application of the updated 
current TCPC techniques, surgeons lack confirmation that these techniques continue 
to be equally effective in terms of outcome and survival. To address this lack of data, 
we made use of a previously described cohort of staged ILT or ECC patients in the 
Netherlands.12 The updated serial analysis of this cohort had two objectives: first, to 
compare the staged ILT and ECC techniques in terms of outcome and event-free 
survival after a longer follow-up period and second, to compare outcome in patients 
who have undergone TCPC procedures that use the updated ILT or ECC techniques, 
i.e. to compare the current prosthetic ILT with the current ECC using a large-diameter 
conduit.
Methods
Patients
We included all patients who were part of the previously published analysis and who 
had therefore undergone completion of a staged TCPC with the ILT or ECC technique 
between January 1988 and January 2008. The inclusion and exclusion criteria were 
published previously.12 The study complies with the regulations of institutional review 
boards with regard to retrospective data collection. The local ethics committees 
approved the retrospective study and waived informed consent. 
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Definitions
The medical records of all patients were reviewed up until September 2017. We 
recorded all cardiac events during follow-up until the patient’s last visit to the outpatient 
clinic. The primary endpoint was death; secondary endpoints were defined as 
thromboembolism (TE) that required intervention and/or hospitalization, protein-losing 
enteropathy (PLE), plastic bronchitis, arrhythmias, late reoperations or reinterventions. 
Arrhythmias were defined as documented bradyarrhythmias or tachyarrhythmias that 
required intervention and/or hospitalization.
Early complications and mortality were defined as occurring within 30 days after 
TCPC or before hospital discharge, all other sequelae were considered late. We note 
that in the previous analysis we used a different definition of early mortality; the current 
definition is that of the Society of Thoracic Surgeons Congenital Heart Surgery 
Database.12, 13
Statistical analysis 
Continuous variables with a normal distribution (according to the Shapiro-Wilk test) 
were expressed as mean and standard deviation (SD). Variables with a non-normal 
distribution were presented as median and interquartile range (IQR). Differences 
between groups were analysed by Student’s t-tests or with Mann-Whitney U tests. 
Categorical variables were presented as numbers and percentages and were evaluated 
by Chi-square test or the Fisher’s exact test. 
The incidences of the primary and secondary endpoints over time were evaluated 
with the Kaplan-Meier method. Differences in the incidence of endpoints between the 
TCPC types were evaluated using the Log-Rank test. Cox proportional hazard analysis 
was used to determine whether parameters had an influence on the probability of the 
event. We found no deviations of the proportional hazards assumption by inspecting 
the plots of log minus log survival functions. A p-value <0.05 was required for a 
parameter to remain in the multivariable model. All analyses were performed using 
the SPSS statistical software package version 24.0 (IBM Corp. in Armonk, NY, USA). 
Two-sided p-values <0.05 were considered statistically significant.
Results
A total of 208 patients were included. Patient and surgical characteristics are shown 
in Table 1. Hypoplastic left heart syndrome (HLHS) was more common in the ECC group 
and there was a trend towards more heterotaxy syndrome patients in the ILT group 
(Table 1). Further details regarding the patient characteristics have been published 
previously.12
In this cohort, the first staged ILT was performed in 1990, and the first staged ECC 
was performed in 1996. In the patients who underwent ILT, a baffle ILT was used in 51 
patients and a prosthetic ILT in 52 patients. In the patients who underwent ECC, the 
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size of the conduit diameter varied, as did the graft material. One patient received 
a 16-mm Gore-Tex conduit and 17 patients received a 16-mm Vascutek conduit, 
33 patients received an 18-mm Gore-Tex conduit and 56 patients received a Gore-Tex 
conduit with a diameter that was at least 20 mm. Figure 1 shows the change over time 
in the surgeons’ preferences for the different staged TCPC techniques. 
The total analysis consisted of 2467 patient-years (1315 ILT, 1152 ECC). The median 
follow-up duration since TCPC was 13.2 (9.5–16.3) years. The median follow-up 
Table 1. Patient and surgical characteristics
ILT (n=103) ECC (n=105) P-value
Males (n, %) 63 (61) 55 (52) 0.20
Ventricular morphology
   Left (n, %) 53 (52) 61 (41) 0.56
   Right (n, %) 48 (47) 43 (41)
   Tricuspid atresia (n, %) 16 (16) 38 (36) 0.001
   HLHS (n, %) 15 (15) 29 (28) 0.021
   Heterotaxy syndrome (n, %) 13 (13) 6 (6) 0.084
Pre-Fontan procedures 231 267
   Modified BT shunt (n, %) 34  (33) 18 (17) 0.008
   Central shunt (n, %) 6 (6) 17 (16) 0.017
   Pulmonary banding (n, %) 26 (25) 23 (22) 0.57
   Atrioseptectomy (n, %) 12 (12) 5 (5) 0.070
   Norwood (BT-shunt/ RV-PA conduit) (n, %) 15 (11/4) (15) 32 (25/7) (30) 0.006
   Systemic AVV repair (n, %) 2 (2) 3 (3) 1.00
   Branch pulmonary artery repair (n, %) 19 (18) 25 (24) 0.34
   CoA repair (n, %) 13 (13) 30 (29) 0.005
Age at BDG (years) 0.9 (0.6–1.6) 0.7 (0.5–1.3) 0.002
Interval between BDG and TCPC (years) 1.8 (1.3–2.4) 2.2 (1.7–3.0) <0.001
Age at TCPC (years) 3.0 (2.4–3.8) 3.2 (2.5–4.2) 0.35
   Weight at TCPC (kg) 14.0 (12.1–15.9) 14.0 (12.2–15.9) 0.99
   CPB time (minutes) 105 (90–105) 141 (96–202) 0.001
   Minimal temperature (ºC) 28 (26–29) 30 (28–32) <0.001
   ICU stay (days) 6 (3–12) 4 (2–7) <0.001
Fenestration 19 (18.4) 14 (13.3) 0.31
Results are given as median (IQR) or counts (percentages).
Abbreviations: AOV: aortic valve, AVV: atrioventricular valve, BDG: bidirectional Glenn anastomosis, BT: Blalock-
Taussig, CoA: aortic coarctation, CPB: cardiopulmonary bypass, ECC: extracardiac conduit, HLHS: hypoplastic 
left heart syndrome, ICU: intensive care unit, ILT: intra-atrial lateral tunnel, PA: pulmonary artery, PM: pacemaker, 
RV: right ventricle, TCPC: total cavopulmonary connection.
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durations of the ILT and ECC patients were 15.3 (10.2–18.7) and 12.0 (9.3–14.5) years, 
p<0.001. A total of nine patients were lost to follow-up; we verified that seven of these 
patients were still alive at the end of the follow-up and included them in the analysis 
for mortality. For the remainder of the analyses, these nine patients were censored at 
the time of their last outpatient clinic visit. 
Mortality
Overall mortality was 14% (19 ILT, 11 ECC). Kaplan-Meier estimates for overall survival 
after ILT were 82% at 10 years (standard error (SE) 4%), and 81% 15 years (SE 4%); after 
ECC they were 91% at 10 years (SE 3%), and 89% at 15 years (SE 3%) (p=0.12) (Figure 
2). For the entire cohort, overall survival at 15 years was 85% (SE 3%). Multivariable 
analysis revealed the following independent predictors for overall mortality: 
cardiopulmonary bypass time (CPB), right ventricle (RV) morphology and the duration 
of intensive care unit (ICU) stay after TCPC (Table 2). 
Late mortality occurred in 10 ILT and 4 ECC patients, after a median of 38.3 (4.5–91.4) 
months after TCPC. Causes for late death were Fontan failure in five, sudden cardiac 
death in three, sepsis and multiple organ failure in one, ventricular fibrillation in one, 
thrombus in the systemic RV in one, bradycardia during surgical closure of the 
fenestration in one, and endocarditis in one patient; in one patient the cause of death 
was unknown. Kaplan-Meier estimates for late survival after ILT were 90% at 10 years 
Figure 1. Staged TCPC over time 
Abbreviations: ECC: extracardiac conduit, ILT: intra-atrial lateral tunnel, TCPC: total cavopulmonary connection.
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(SE 3%), and 89% at 15 years (SE 3%); after ECC they were 97% at 10 years (SE 2%), and 
96% 15 years (SE 2%) (p=0.10) (Figure 2). Dominant RV was the only predictor in 
univariable analysis for late mortality (HR: 3.61; 95% CI 1.13–11.53, p=0.030).
Although no patients underwent Fontan takedown or heart transplantation, one 
patient was listed for heart transplantation. 
Late reinterventions
After TCPC, 140 late reinterventions (surgical and catheter-based) were performed in 
84 patients. Late surgical reinterventions accounted for 53 (38%) of all late 
reinterventions, with 35 patients needing two or more late reinterventions. Table 3 
shows the types of reinterventions performed after TCPC. In ten patients, the ECC 
conduit was replaced. All of these patients had originally received a 16-mm conduit: 
one was a Gore-Tex conduit and the other nine were Vascutek conduits which are no 
longer in use.14
ILT patients had better Kaplan-Meier estimates for late reintervention-free survival 
(Figure 3): 75% at 10 years (SE 5%), and 63% at 15 years (SE 6%); for ECC, estimates 
were 54% at 10 years (SE 5%), and 44% at 15 years (SE 6%) (p=0.016). Univariable 
analysis showed that patients were significantly more likely to require late 
reinterventions if they had an ECC (HR: 1.73; 95% CI 1.10–2.71, p=0.021) or HLHS (HR: 
2.06; 95% CI 1.25–3.39, p=0.005). In multivariable analysis, both the ECC technique and 
HLHS remained independent predictors for late reinterventions during follow-up (HR: 
1.64; 95% CI 1.04–2.58, p=0.032 and HR: 1.93; 95% CI 1.17–3.20, p=0.010).
Figure 2. (A) Overall and (B) late survival after TCPC
Abbreviations: ECC: extracardiac conduit, ILT: intra-atrial lateral tunnel, TCPC: total cavopulmonary connection.
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Late arrhythmias 
Late arrhythmias occurred in 41 patients (20%) after a median period of 9.9 (5.6–12.4) 
years after TCPC. Bradyarrhythmia was present in 15 patients, and tachyarrhythmia 
occurred in 22 patients, one of whom died of ventricular fibrillation. Four patients 
Table 2. Predictors for overall mortality and late arrhythmias
Hazard ratio 95% CI P-value
Overall mortality: univariable 
Males 1.81 0.83–4.00 0.14
ILT Fontan 1.78 0.85–3.75 0.13
Age at Fontan (years) 0.92 0.76–1.12 0.41
RV morphology 3.16 1.45–6.90 0.004
HLHS 1.67 0.76–3.65 0.20
Heterotaxy syndrome 2.11 0.81–5.50 0.13
Pre-Fontan AVV regurgitation 1.30 0.62–2.72 0.50
CPB time (minutes) 1.01 1.00–1.01 0.002
ICU stay after TCPC (days) 1.04 1.02–1.06 <0.001
Overall mortality: multivariable
RV morphology 2.31 1.02–5.22 0.044
CPB time 1.004 1.00–1.01 0.012
ICU stay after TCPC (days) 1.03 1.02–1.06 <0.001
Hazard ratio 95% CI P-value
Late arrhythmias: univariable 
Males 1.18 0.63–2.21 0.63
Baffle ILT 2.65 1.41–4.99 0.003
Age at TCPC (years) 1.00 0.90–1.11 0.97
RV morphology 1.64 0.86–3.11 0.13
HLHS 1.27 0.55–2.90 0.58
Heterotaxy syndrome 0.75 0.23–2.43 0.63
Number of post-TCPC procedures* 1.59 1.18–2.12 0.002
Pre-Fontan AVV regurgitation 1.01 0.54–1.89 0.99
CPB time (minutes) 1.00 0.99–1.00 0.97
ICU stay after TCPC (days) 1.02 1.00–1.05 0.055
Late arrhythmias: multivariable
Baffle ILT 2.65 1.41 - 4.99 0.003
Number of post-TCPC procedures* 1.60 1.18 - 2.17 0.003
*Excluding pacemaker procedures
Abbreviations: AVV: atrioventricular valve, CPB: cardiopulmonary bypass, ECC: extracardiac conduit, HLHS: 
hypoplastic left heart syndrome, ICU: intensive care unit, ILT: intra-atrial lateral tunnel, RV: right ventricle, TCPC: 
total cavopulmonary connection.
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suffered an out-of-hospital cardiac arrest (three deaths, one survivor with subsequent 
ICD for secondary prevention) and were suspected of ventricular tachyarrhythmia (no 
documentation of heart rhythm related to cardiac arrest was available). 
Freedom from late arrhythmias was better in ECC patients than in ILT patients 
(p=0.034, see Figure 3). Univariable analysis showed that patients were significantly 
more likely to experience arrhythmia if they had undergone the baffle ILT technique 
(HR: 2.65; 95% CI 1.41–4.97, p=0.003) or if they had a higher number of post-TCPC 
procedures (excluding pacemaker procedures; HR: 1.57; 95% CI 1.17–2.11, p=0.003. In 
multivariable analysis, the baffle ILT technique and the number of post-TCPC 
interventions remained independent predictors for late arrhythmias during follow-up 
(Table 2). 
Other events
Other complications were relatively rare: PLE occurred in a total of nine patients, two 
in the ILT group and seven in the ECC group, after a median period of 6.6 (2.8–9.4) 
years after TCPC; plastic bronchitis was identified in four patients, two ILT and two ECC.
Thromboembolic events (TEs) occurred in 13 patients (6 ECC and 7 ILT): two patients 
had deep venous thrombosis; two patients had a thrombus in the left pulmonary artery; 
one patient had a pulmonary embolism; one patient had a transient ischemic attack; 
one patient had a thrombus in the systemic RV; one patient developed a thrombus on 
a mechanical aortic valve while not taking anticoagulation; two patients had chest pain 
with focal delayed enhancement on MRI; and two patients had a cerebral infarction.
Table 3. Late reinterventions after TCPC
ILT (n= 94) ECC (n= 98) P-value
Patients with reinterventions (n, %) 37 (39) 47 (48) 0.23
Time between TCPC and first reintervention (years) 7.2 (3.3–12.1) 4.7 (2.5–8.7) 0.079
    Number of surgical reinterventions (n, %)     26 (28)     27 (28) 0.99
    Number of percutaneous reinterventions (n, %)     22 (23)     31 (32) 0.20
Fenestration closure (n, %) 9 (10) 6 (6) 0.37
Pulmonary artery intervention (n, %) 3 (3) 13 (13) 0.017
Coiling collaterals (n, %) 10 (11) 17 (17) 0.18
PM implantation (n, %) 15 (16) 5 (5) 0.017
PM battery replacement (n, %) 3 (3) 4 (4) 1.00
AVV repair (n, %) 1 (1) 4 (4) 0.37
AOV repair/mechanical AOV implantation (n, %) 7 (7) 7 (7) 0.94
ECC replacement (n, %) 10 (10)
Other (n, %) 12 (13) 7 (7) 0.19
Results are given as median (IQR or counts (percentage
Abbreviations: AOV: aortic valve, AVV: atrioventricular valve, CPB: cardiopulmonary bypass, ECC: extracardiac 
conduit, ILT: intra-atrial lateral tunnel, PM: pacemaker, TCPC: total cavopulmonary connection.
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No difference in event-free survival between the ILT and ECC groups were found 
(p=0.35). At 10-year follow-up, the freedom from any event for all patients was 53% 
(SE 4%); for ILT this was 59% (SE 5%) and for ECC 46% (SE 5%). At 15 years, freedom 
from any event for all patients was 39% (SE 4%).
Current TCPC techniques
Since their introduction, both TPCP techniques have been adapted and updated, and 
this was reflected in the patients in our study: 52 ILT patients had received a prosthetic 
ILT, and 89 ECC patients had received a conduit with a diameter ≥18 mm. We considered 
these two subgroups of patients as having being treated with “current TCPC” techniques. 
The median follow-up duration of the prosthetic ILT and ≥18-mm ECC patients was 
similar (12.5 (9.4–15.9) years vs 11.0 (9.3–14.5) years, p=0.12). For all patients treated 
with current TCPC techniques, the median follow-up duration post TCPC was 11.6 
(9.3–14.9) years.
The occurrence of late arrhythmias was more frequent in the older baffle ILT group 
than in the prosthetic ILT group (21 (72%) vs 8 (28%), p=0.004). Late arrhythmia-free 
survival did not differ between the prosthetic ILT and ≥18-mm ECC group (p=0.64, see 
Figure 4). There were also no differences in late reintervention-free survival between 
the prosthetic ILT and ≥18-mm ECC groups (p=0.14, see Figure 4). Neither were 
differences observed in overall survival (p=0.36) or event-free survival (p=0.58) between 
the prosthetic ILT and ≥18-mm ECC groups. 
Figure 3. (A) Late reintervention-free survival and (B) late arrhythmia-free survival after TCPC
Abbreviations: ECC: extracardiac conduit, ILT: intra-atrial lateral tunnel, TCPC: total cavopulmonary connection.
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Discussion
The results of this study indicate that for the prosthetic ILT technique and the ≥18-mm 
ECC technique currently in use, patients experience no differences in late arrhythmia-
free survival and late reintervention-free survival. The two groups of patients in this 
study had a comparable median follow-up duration of approximately 12 years. 
The long-term follow-up of Fontan patients has been studied extensively. However, 
many previous studies have included not only TCPC but also older Fontan techniques.9, 
15 In studies that have included TCPC techniques only, a direct comparison of long-term 
outcomes after the different TCPC procedures is limited by the differences in the 
duration of follow-up between the ILT and ECC techniques. This difference has been 
caused by the shift over time towards a preference for the ECC procedure, resulting 
in relatively higher numbers of older ILT patients.11 
Survival
Late survival after TCPC was 94% at 10 and 92% at 15 years. Our figures for late 
mortality are somewhat lower than the 97% late survival at 10 years post TCPC in a 
recently published large cohort.9 An explanation for this difference could be that their 
patients were relatively older at TPCP, namely 3.8 years for ILT and 4.8 years for ECC, 
which may point towards different selection criteria for eligibility for TCPC than those 
used in our cohort. In a recent study by Downing et al.10 the median age at TCPC was 
lower, namely 2.3 years, with an overall survival of 92% at 10 years and 88% at 15 years 
post TCPC. For patients who survived the first year after TCPC, their survival was similar 
to that reported here. 
Figure 4. (A) Reintervention-free survival and (B) arrhythmia-free survival late after current TCPC
Abbreviations: ILT: intra-atrial lateral tunnel, ECC: extracardiac conduit, TCPC: total cavopulmonary connection.
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We observed a trend towards better survival for ECC patients. Two recent meta-
analyses have shown a similar trend.11, 16 However, such a trend was not apparent in 
the current TCPC modifications in our cohort: patients with a prosthetic ILT and ECC 
patients with a conduit ≥18 mm. 
A potential benefit of the ECC is that it gives surgeons the option of performing the 
TCPC with a shorter CPB time, or even off-pump.16, 17 However, in our study, ILT patients 
had a significantly shorter median CPB time. In our study, both the ILT technique and 
the surgical centre were associated with CPB time. Our multivariable models for overall 
mortality identified CPB time, duration of ICU stay and RV morphology, as independent 
predictors.
Late reinterventions
Despite relatively good survival, morbidity remains high in Fontan patients.9, 18, 19 In our 
cohort, ILT patients had a better freedom from late reinterventions, which was mainly 
caused by the ECC patients who required replacement of a 16-mm Vascutek conduit. 
These conduits are no longer in use.14 Pulmonary artery reinterventions were also 
more common in the ECC group. 
Importantly, comparison of the currently used ECC technique (excluding 16-mm 
conduits) and the currently used prosthetic ILT technique showed no difference in 
reintervention-free survival after a medium-term follow-up of similar duration. 
Internationally available guidelines indicate that reintervention can be considered in 
selected patients in case of obstruction of systemic or pulmonary venous return, 
exercise limitation, or unexplained exercise deterioration and fatigue. However, such 
guidelines rarely provide quantitative limits.20, 21 As a result, different centres may have 
different thresholds for reinterventions, and this could have influenced our 
observations. 
Late arrhythmias 
Compared with older Fontan cohorts, the burden of arrhythmias is relatively low in 
our contemporary TCPC population.19 It has been suggested that ECC is the preferred 
technique because, theoretically, it minimizes factors that may lead to arrhythmias.17 
In a recent large Fontan study, the incidence of late atrial tachycardia was 7% for ILT 
and 2% for ECC patients (p<0.001). However, follow-up duration differed between both 
techniques, 9.2 years for ILT and 4.7 years for ECC, p<0.001).22 In our analysis, we found 
that late arrhythmia-free survival was better in prosthetic ILT patients than in baffle 
ILT patients. This was also observed in a recent cross-sectional prospective study 
conducted by our group.7 A key finding of our study is that we observed no differences 
in late arrhythmia-free survival after TCPC between patients who had undergone the 
current prosthetic ILT technique and those who had undergone the current ECC 
technique, in a cohort in which the two groups had a similar duration of medium-term 
follow-up.
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Other late events
Despite relatively low late mortality, we observed a high number of events, particularly 
surgical and catheter-based reinterventions. Fifteen-year event-free survival was 39%, 
with no difference between the entire cohort of ILT and ECC patients. In the Australian-
New Zealand cohort that included both TCPC and APC patients, freedom from adverse 
events at 15 years was 59%.9 This is somewhat better than the percentage found here 
and is most likely explained by the use of different definitions for adverse events and 
event-free survival. Clearly not all events have the same impact, demonstrating that 
improved consensus on outcome measures is required.23 
Theoretically, ECC patients are more prone to develop thromboembolism.1 Most of 
our patients were on platelet-aggregation inhibitors or vitamin K antagonists. We 
observed no differences in the rate of thromboembolism between ILT and ECC patients. 
However, the most severe cases – a thrombus in the systemic chamber, and a sub-total 
and total occlusion of the left pulmonary artery, conduit and chamber – occurred in 
ECC patients. 
Several other studies have also reported finding no differences in incidence of 
thromboembolism between ILT and ECC patients.24, 25 The incidence of 
thromboembolism in our cohort was lower than that reported in most other studies 
and this might be explained by differences in the methods used to identify 
thromboembolism.26
Study limitations
This is a retrospective study, although the number of patient-years is comparable there 
are more older ILT patients. Another limitation is that our data only cover a follow-up 
period of 15 years. Future research is therefore required to determine whether the 
slight outcome differences between the ILT and ECC at the current follow-up duration 
are still present after a longer duration of follow-up. 
Conclusions
Key findings were the similar rates of late arrhythmia-free survival and late 
reintervention-free survival in patients undergoing TCPC using the current prosthetic 
ILT modification and the current ECC technique that uses conduits with a diameter of 
at least 18 mm. In the entire cohort, no differences were observed in overall or late 
mortality between the ILT and ECC groups. Although survival is relatively good after 
staged TCPC, overall event-free survival at 15 years was 39%. 
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Abstract 
Objectives
To evaluate the prognostic value of dobutamine stress CMR in Fontan patients.
Background
The Fontan circulation has serious long-term complications. Evaluation of ventricular 
function using exercise or pharmacological stress cardiac magnetic resonance imaging 
(CMR) has been advocated as tool to reveal impending Fontan dysfunction. Several 
studies have shown that patients with a Fontan circulation have an abnormal 
(dobutamine) stress response.
Methods
Fontan patients who received low dose dobutamine stress CMR were followed 
prospectively. Cardiac events were recorded, time-to-event analyses (Kaplan-Meier 
method) and Cox proportional hazard regression analyses were performed to 
determine the predictive value of dobutamine stress CMR for the composite study 
endpoint including cardiac death, cardiac reintervention, hospitalization or 
cardioversion/ablation for arrhythmias.
Results 
92 patients, median age 11.5 (9.8 – 15.3) years, median time after Fontan completion 
8.0 (6.9 – 11.3) years underwent a baseline stress CMR. Overall indexed end systolic 
volume (39 ± 16 vs 26 ± 13 ml/m2, p<0.001) and indexed end diastolic volume (85 ± 21 
vs 73 ± 21 ml/m2, p<0.001) decreased during stress. Ejection fraction (EF) increased 
during stress CMR (55 ± 10 vs 65 ± 10%, p<0.001). 23 patients reached the study 
endpoint, 3.1 (1.5 – 5.7) years after baseline CMR. They had a lower increase in EF 
during stress (functional reserve (FR)) compared to the non-event-group (6 ± 7 vs 11 ± 
6 %, p=0.002). Patients with a FR of ≥ 14% (highest quartile) had significantly less events 
during follow-up. Patient who reached the study endpoint also had a higher ventricular 
mass; 73 ± 23 vs 57 ± 16 gram/m2, p<0.001. Multivariable analyses identified FR (HR 
0.86/%; 95% CI 0.79 – 0.93; p<0.001) and indexed ventricular mass (HR 1.04/gram/m2; 
95% CI 1.02 – 1.07; p=0.001) as predictors of the study endpoint.
Conclusion
Ventricular response to dobutamine stress is a predictor for events in young patients 
with a Fontan circulation. 
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Introduction
The Fontan has evolved over the years into the treatment of choice in most patients 
with a functional univentricular heart.1 Univentricular hearts account for approximately 
9% of all congenital heart defects.2 Since the development and evolution of the Fontan 
procedure long-term survival of these patients has improved, resulting in an increasing 
number of surviving Fontan patients.3 
Despite decline of mortality and morbidity after the Fontan operation over the last 
decades, long-term complications including circulatory failure, thromboembolic events, 
arrhythmias and death are still common.3, 4 Morphological factors, e.g. hypoplastic left 
heart syndrome (HLHS) and functional measurements such as peak oxygen uptake 
(VO2) and ventricular size and function have been found predictors for outcome.
5-9
Cardiovascular magnetic resonance (CMR) imaging provides valuable information 
on anatomy and is the gold standard for measuring ventricular function in these 
patients.10, 11 
Evaluation of ventricular function using exercise or pharmacological stress CMR has 
been advocated as additional tool to reveal impending dysfunction.12, 13 Several studies 
have shown that patients with a Fontan circulation have an abnormal response to 
dobutamine or physical stress.14-19 
However, the prognostic value of stress CMR in Fontan patients is still unclear. Our 
aim was to evaluate the value of dobutamine stress CMR to predict adverse outcome 
in patients with a Fontan circulation.
Methods
Patients and methods
We included patients that underwent a dobutamine stress CMR in the setting of two 
cross-sectional and prospective studies in five tertiary referral centers between 2004 
and 2012. All participants, and if necessary their parents, gave written informed 
consent before inclusion in these studies. The inclusion and exclusion criteria, study 
protocol, methods, adverse event rate and results have been published previously.10, 
17 Patients included in the current analysis have been shown not to differ from other 
eligible patients with regard to age, gender, age at Fontan completion and surgical 
techniques.10, 17
The dobutamine CMR was considered as the baseline measurement. At this time, 
patients underwent CMR imaging at rest and during low-dose dobutamine stress, 
cardiopulmonary exercise testing (CPET) and assessment of N-terminal pro-brain 
natriuretic peptide (NT-proBNP). After the baseline examination patients received 
regular patient specific care in the outpatient clinic. For the purpose of the current 
study the last available medical data were reviewed for cardiac events during follow-
up. 
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CMR acquisition
CMR imaging was performed with a dedicated phased-array cardiac surface coil. All 
images were acquired without breath-hold. Technical details of the sequences and the 
protocols have been previously published.10, 17 
Scans were performed at rest and repeated during continuous infusion of 
dobutamine-hydrochloride (Centrafarm Services, Etten-Leur, the Netherlands) with a 
dosage of 7.5 μg/kg/min. Dobutamine infusion was decreased to 5.0 μg/kg/min (or if 
necessary stopped) when the heartrate increased >50%, when the systolic and/or 
diastolic blood pressure increased >50% or decreased <20%, when rhythm disturbances 
were seen, or with complaints of the patient. Details on our dobutamine stress protocol 
have been published previously.10, 17
CMR analysis
Analysis was performed with the software packages MASS and FLOW (Medis Medical 
Imaging Systems, Leiden, the Netherlands). Contours were manually drawn in end-
diastole and end-systole, papillary muscle and trabeculae were excluded from the 
blood pool. All CMR’s were analysed under supervision of one of the authors (WH) with 
longstanding experience. 
End diastolic volume (EDV) and endsystolic volume (ESV) were obtained and used to 
calculate ejection fraction (EF). Ventricular volumes were defined as the sum of the 
volumes of the systemic ventricle and the hypoplastic chamber. All ventricular volumes 
were indexed (i) for body surface area (BSA).
A normal stress response to low dose dobutamine in healthy individuals consist of 
a decrease in ESVi and a subsequent increase of EF.20 Therefore an abnormal response 
to stress was defined as the inability to decrease ESV during stress and/or the inability 
to increase EF during stress.
Changes in CMR parameters were calculated as follows: parameter change (Δ) = 
parameterstress− parameterrest, functional reserve (FR) is described as the EFstress – EFrest. 
Clinical parameters
Blood samples were taken from a peripheral vein after 30 minutes rest in supine 
position. Plasma and serum were separated within 30 min after collection and stored 
at −80°C. NT-proBNP was measured with the Elecsys electrochemiluminescence 
immunoassay (Roche Diagnostics).
CPET were performed on a bicycle ergometer according to previously described 
protocols.21, 22 From these exercise tests the VO2 peak was assessed and expressed as 
percentage of predicted values. Exercise tests with a peak respiratory exchange rate 
(RER peak) of ≥1.0 were included in the analysis.23
Study endpoint
The study endpoint was described as cardiac death, out of hospital cardiac arrest 
(OHCA), cardiac reintervention, thromboembolic events, protein losing enteropathy 
(PLE), hospitalization for arrhythmias or cardioversion/ablation for arrhythmias.6, 9, 24, 25
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Statistical methods
Continuous variables with a normal distribution were summarized as mean (SD). 
Differences between patients with and without events, between dominant ventricles 
and Fontan technique were analysed by Students t-tests. Variables with a non-normal 
distribution (according to the Shapiro-Wilk test) were presented as median (25-75th 
percentile) and between-group differences were analysed by Mann-Whitney U tests. 
Categorical variables were presented as numbers and percentages, whereas between-
group differences were evaluated by Chi-square test or the Fisher’s exact tests.
Differences between rest and stress CMR measurements were analysed with paired 
Students t-tests. The cumulative endpoint-free survival was estimated by the method 
of Kaplan-Meier curves and between-group differences were evaluated by the log-rank 
test. We applied Cox proportional hazard regression analyses to relate CMR findings 
with endpoint-free survival. A p-value <0.05 was required for the variable to be retained 
in the equation for multivariable cox regression models. Correlations between CMR 
parameters were studied by Pearson’s correlation coefficients (rP).
All analyses were performed using the SPSS statistical software package version 21.0 
(SPSS, Inc., Chicago, IL, USA). Two-sided p-values <0.05 were considered statistically 
significant.
Results 
All patients that had successfully undergone stress CMR for evaluation of a Fontan 
circulation were included. Dobutamine stress CMR was well tolerated in most patients. 
One patient reported a minor headache. In 15 patients dobutamine infusion was 
reduced to 5 μg/kg/min due to an increase of heartrate >50% or because of frequent 
ventricular extra systoles. These patients were included in the analysis. Adverse effects 
recovered spontaneously directly after terminating the dobutamine infusion.10, 17
A total of 92 patients were included in our analysis. These patients underwent stress 
CMR at a median age of 11.5 (9.8 – 15.3) years. Median time after Fontan completion 
was 8.0 (6.9 – 11.3) years, patients characteristics and clinical parameters at baseline 
are shown in Table 1.
At baseline 27 patients had more than mild AV (atrioventricular) valve regurgitation 
assessed by echocardiography (n=87) or CMR (n=5). Thirty-one (33.7%) patients had a 
dominant right ventricle (RV) and 56 (60.9%) patient had a dominant left ventricle (LV), 
in 5 (5.4%) patients the anatomy of the dominant ventricle was undefined. The intra-
atrial tunnel (ILT) technique was used in 45 (48.9%) patients, 42 (45,7%) patients had 
an extracardiac conduit (ECC) and in 5 (5.4%) patients an atriopulmonary connection 
(APC) was used. There was no significant difference in age between patients with an 
ILT or ECC (11.9 (9.7 – 16.6) years vs 11.1 (10.2 – 13.4) years, p=0.28). Patients with 
dominant RV were younger at baseline compared to patients with dominant LV (10.3 
(9.5 – 14.0) vs 11.8 years (10.2 – 15.5) p=0.04). Patients with an APC were older than 
patients with a TCPC, 19.4 (16.4 – 21.2) vs 11.3 (9.8 – 14.8) years, p=0.002. 
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Ventricular response to stress
The results of the CMR are shown in Table 2. For the entire group there was a significant 
decrease in ESVi (39 ± 16 vs 26 ± 13 ml/m2, p<0.001) and in EDVi (85 ± 21 vs 73 ± 21 ml/m2, 
p<0.001) during stress. Indexed stroke volume (SVi) did not change during stress, EF 
increased during dobutamine stress (55 ± 10 vs 65 ± 10%, p<0.001).
In seven patients (7.6%) an abnormal stress response was observed; six patients 
could not increase EF and three patients were not able to decrease ESV during stress. 
Events developed in four of these seven patients, median 1.3 (0.5 – 4.8) years after the 
dobutamine CMR.
There were no significant differences at rest nor in stress response between the 
dominant RV or LV. We also found no relation between RV/LV dominance or AV valve 
regurgitation and stress response. 
Cardiac events
As shown in Table 3, after a median follow-up of 5.8 (4.9 – 10.0) years 23 patients (25%) 
developed a cardiac event. This event developed at a median of 3.1 (1.5 – 5.7) years 
after the dobutamine CMR and at a median time of 12.6 (9.7 – 17.8) years after Fontan 
completion. One patient was listed for heart transplantation. 
Table 1. Patient characteristics at baseline visit
Patients (n=92) Patients with 
eventa (n=23)
Patients without 
eventb (n=69)
P-valuea, b 
Male (n, %) 58 (63.0) 17 (73.9) 41 (59.4) 0.212
Median age at baseline visit 
(years)
11.5 (9.8-15.3) 13.3 (10.2-16.0) 11.3 (9.7-15.0) 0.193
      Median time after Fontan 
completion (years)
     8.0 (6.9-11.3)      8.4 (6.8 - 12.2)      7.8 (6.9 - 10.8) 0.404
Dominant ventricle      
     Right (n, %)      31 (33.7)      8 (34.8)      23 (33.3)
     Left (n, %)      56 (60.9)      13 (56.5)      43 (62.3)
     Undetermined (n, %)      5 (5.4)      2  (8.7)      3 (4.3)
Median age at Fontan (years) 3.0 (2.5-3.9) 3.2 (2.5 - 4.2) 3.0 (2.5 - 3.8) 0.636
TCPC (n, %) 87 (94.6) 20 (87.0) 67 (97.1) 0.063
      ECC (n, %)       42 (45.7)       7 (30.4)       35 (50.7) 0.146
      ILT (n, %)       45 (48.9)       13 (56.5)       32 (46.4) 0.399
APC (n, %) 5 (5.4) 3 (13.0) 2 (2.9) 0.098
Results are given as mean (SD), median (25-75th percentile) or as counts (percentages). 
Abbreviations; APC: atriopulmonary connection, ECC: extracardiac conduit, ILT: intra-atrial lateral tunnel, TCPC: 
total cavopulmonary connection. 
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There was no difference in median age at baseline between the event-group and the 
non-event group. Moderate to severe AV-valve regurgitation was present in seven 
(30.4%) of the event-group vs 20 (29.0%) of the non-event group, p=0.895. There was 
also no significant difference in peak VO2 (34.4 (24.8 – 39.4) vs 34.1 (28.1 – 39.2 ml/min/
kg, p=0.66, n=72), predicted VO2 peak (77.5 (57.7 – 88.3) vs 84.1 (66.7 – 95.0) %, p=0.14, 
n=72) or NT-proBNP (13.7 (8.2 – 47.8) vs 10.7 (6.1-22.1) pmol/l), p=0.18, n=83) at baseline 
for the event vs the non-event group. 
Table 2 shows that the event-group has a higher indexed ventricular mass compared 
to the non-event group. Also the mass volume ratio was statistically higher in the event 
group vs the non-event group. 
Patients who did develop an event had a significantly lower FR during stress compared 
to the non-event-group (6 ± 7 vs 11 ± 6%, p=0.002). in Figure 1 the event-free survival 
for the different quartiles of FR is shown. The event-free survival was better for the 
patients in the highest quartile of FR (Log-rank: 0.024), patients in the highest quartile 
had a FR ≥14%.
Table 2. CMR parameters at baseline for patients with and without events
All patients (n=92) Patients with 
events (n=23)
Patients without 
event (n=69)
P-value 
event 
vs no 
event 
Rest Stress Rest Stress Rest Stress
Median age at 
baseline (years)
11.5 (9.8-15.3) 13.3 (10.2-16.0) 11.3 (9.7-15.0) 0.193
Mass (g/m2) 61 ± 19 73 ± 23 57 ± 16 <0.001
Mass/EDV ratio (g/ml) 0.75 ± 0.26 0.87 ± 0.35 0.71 ± 0.21 0.048
EDV (ml/m2) 85 ± 21 73 ± 21 * 89 ± 26 76 ± 26 * 84 ± 19 72 ± 19 * 0.369
ESV (ml/m2) 39 ± 16 26 ± 13 * 43 ± 21 32 ± 19 * 38 ± 14 25 ± 11 *, †  0.167
SV (ml/m2) 46 ± 12 47 ± 12 47 ± 14 45 ± 14 46 ± 12 47 ± 12 0.898
EF (%) 55 ± 10 65 ± 10 * 54 ± 12 60 ± 13 * 56 ± 9 67 ± 9 *, †   0.586
Δ stress -rest
EDV (ml/m2) - 13 ± 9 - 12 ± 6 - 13 ± 9 0.849
ESV (ml/m2) - 13 ± 7 - 11 ± 8 - 13 ± 7 0.312
SV (ml/m2) 1 ± 6 - 2 ± 6 1 ± 6 0.051
EF (%) 10 ± 7 6 ± 7 11 ± 6 0.002
Results are given as mean (SD) or as median (25-75th percentile). 
* indicates a statistical significant difference between rest vs stress within the subgroup. 
† indicates a statistical significant difference between stress within the event vs no event group.
Abbreviations; EDV: end diastolic volume, ESV: end systolic volume, SV: stroke volume EF: ejection fraction. 
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Predictors for events
Univariable analysis showed that FR (HR: 0.88; 95% CI 0.82 –0.95, p=0.001) and cardiac 
mass (HR: 1.03; 95% CI 1.01 – 1.06, p=0.003) were significantly associated with the risk 
of an event. FR has a C-index of 0.70 and cardiac mass a C-index of 0.62. NT-proBNP 
was found borderline predictive for future cardiac events in univariable analysis (HR: 
1.02; 95% CI 1.00 – 1.04, p=0.052). Other baseline characteristics were not significantly 
associated with the risk of cardiac events, see Table 4.
In multivariable analyses with the following two parameters indexed ventricular mass 
and FR, both FR (HR 0.86; 95% CI 0.79 – 0.93; p<0.001) and indexed ventricular mass 
(HR 1.04; 95% CI 1.02 – 1.07; p=0.001) were predictive for future cardiac events. Both 
predictors combined have a C-index of 0.73. However there was no correlation (r=-
0.069, p=0.510) between ventricular mass and FR.  
If patients with an APC (n=5) are excluded from the analysis, the same parameters 
remain predictive in multivariable analysis (FR (HR 0.87; 95% CI 0.80 – 0.94; p=0.001) 
and indexed ventricular mass (HR 1.03; 95% CI 1.00 – 1.07; p=0.030)).
Table 3. Clinical state at latest follow-up  
Patients (n=92)
Median age at latest follow-up (years) 18.6 (16.1-22.1)
        Median follow op time since dobutamine CMR (years)   5.8 (4.9-10.0) 
Overall cardiac event (n, %)    23 (25.0)
Median time after dobutamine CMR (years)   3.1 (1.5-5.7)
Median time after Fontan completion (years) 12.6 (9.7-17.8)
     Cardiac reoperation (n, %)       7 (7.6)
          Aortic valve replacement (n, %)           2 (2.2)
          AV valve repair and ECC replacement (n, %)           2 (2.2)
          ECC replacement (n, %)           1 (1.1)
          Conversion to bidirectional Glenn (n, %)           1 (1.1)
          Tunnel repair (n, %)           1 (1.1)
     Pacemaker (n, %)      5 (5.4)
     Ablation/cardioversion of arrhythmias (n, %)      4 (4.3)
     Hospitalization for arrhythmias (n, %)      3 (3.3)
     Coiling of collaterals (n, %)      1 (1.1)
     Stenting of the ECC (n, %)      1 (1.1)
     Plastic bronchitis (n, %)      0 (0)
     OHCA (n, %)      1 (1.1)
     Cardiac death (n, %)      1 (1.1)
Results are given as median (25-75th percentile) or as counts (percentages). 
Abbreviations; AV: atrio ventricular, CMR: cardiac magnetic resonance imaging, ECC: extracardiac conduit, OHCA: 
out-of-hospital cardiac arrest.
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Discussion
In this study we have demonstrated that there is a clear relation between ventricular 
response to low-dose dobutamine stress and subsequent outcome at medium term 
follow-up, even in a relatively young Fontan population. Patients with a FR of ≥14% 
(highest quartile) at baseline had significantly fewer events during follow-up. Patients 
in the lowest quartile, with a FR ≤ 5%, had the highest risk of developing an event during 
follow-up. Furthermore, ventricular mass did differ statistically between the event vs 
the non-event group (73 ± 23 vs 57 ± 16 g/m2, p<0.001).
Patients who have had a Fontan operation are among congenital heart disease 
patients with the highest risk for late death, circulatory failure, arrhythmias, 
thromboembolic events, PLE and re-interventions.7, 24, 25 Parameters that can be used 
to predict these outcomes are required. In studies that have assessed these parameters 
composite end-points have been used that include the well-known outcomes, including 
arrhythmias.24, 26 Ventricular dysfunction is an independent predictor of ventricular 
arrhythmias and chronic volume overload related to ventricular dysfunction has been 
linked to atrial flutter/fibrillation.26 In previous studies, risk factors derived from CMR 
have been identified. Death and (being listed for) heart transplantation were associated 
with higher EDVi (>125 ml/m2) as assessed with CMR in adolescents with a Fontan 
circulation.5, 27 In our present study, only one patient died, at five years after the baseline 
CMR; this patient had an EDVi of 147 ml/m2 at baseline. Our findings on ventricular 
Figure 1. Kaplan-Meier curve for event-free survival for functional reserve 
Abbreviations; CMR: cardiac magnetic resonance imaging
Part I  |  Chapter 4
78
mass confirm earlier observations that in Fontan patients transplantation-free survival 
is better with lower indexed ventricular mass compared to the Fontan patients who 
died or received a heart transplantation.5 
Of the non-imaging derived parameters related to the outcome measures in the 
Fontan population, such as death, thromboembolic events, arrhythmias, PLE and 
unplanned cardiovascular hospitalization, peak VO2 and elevated BNP have been found 
a predictors for poor outcome.6, 9, 28-30 In our study we found no significant difference 
in peak VO2, percent of predicted VO2 or in NT-proBNP levels between the event and 
non-event group. For CPET this may be related to the relatively young age at study of 
our subjects, since exercise performance is relatively well preserved in young Fontan 
patients.21
Since none of the other previously identified predictors related to outcome in our 
relatively young patients, who could be considered at relatively low risk, we think stress 
CMR parameters, particularly FR, may be a useful early marker for outcome in Fontan 
patients.
Dobutamine is a synthetic catecholamine with a positive inotropic effect.31 It increases 
myocardial demand for oxygen in a comparable manner as physical exercise. In healthy 
volunteers the normal response to stress consist of a decrease in ESVi and a subsequent 
Table 4. Cox-regression analyses for combined event 
Univariable Multivariable
HR 95% CI P-value HR 95% CI P-value
Age at dobutamine CMR (years) 1.07 0.16–1.18 0.16
Male 1.58 0.62–4.02 0.34
Age at Fontan (years) 1.05 0.81–1.37 0.70
Dominant LV 0.91 0.40–2.11 0.40
Moderate to severe AV-valve 
regurgitation at baseline
1.41 0.56–3.52 0.47
NT-proBNP (pmol/l) 1.02 1.00–-1.04 0.052
Peak VO2 (% of predicted) 0.98 0.96–1.011 0.23
Mass (g/m2) 1.03 1.01–1.01 0.003 1.04 1.02–1.07 0.001
Mass/EDV ratio (g/ml) 3.71 0.86–15.89 0.078
Rest EDV (ml/m2) 1.01 0.99–1.03 0.20
Rest ESV (ml/m2) 1.02 0.99–1.04 0.057
Rest SV (ml/m2) 1.00 0.97–1.04 0.89
Rest EF (%) 0.98 0.94–1.02 0.33
FR (%) 0.88 0.82–0.95 0.001 0.86 0.79–0.93 <0.001
Abbreviations; CI: confidence interval, EDV: end diastolic volume, EF: ejection fraction, ESV: end systolic volume, 
FR: functional reserve, HR: hazard ratio, LV: left ventricle, peak VO2 : maximum oxygen uptake, SV: stroke volume. 
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increase of EF, while EDVi does not change.20, 32 We have reported the good clinical 
tolerance of low dose dobutamine for stress imaging in children with heart disease.33 
In previous studies using dobutamine CMR we have demonstrated that the ventricular 
response to stress in the Fontan circulation is abnormal: patients were able to increase 
EF and decrease ESVi, but an abnormal decrease in EDVi was observed.16, 17 This resulted 
in no significant increase in SV during stress. More recently, invasive studies in Fontan 
patients have confirmed this highly abnormal stress response of the univentricular 
heart after the Fontan operation, using both dobutamine as well as physical stress.14-16
Several abnormalities could contribute to the impaired stress response. The geometry 
of the Fontan baffle and the directly connected vessels (caval veins and pulmonary 
arteries) has been identified as a source of increased energy loss with increase of 
cardiac output.34, 35 Recently, this has been associated with impaired exercise 
performance.36 
Another factor is pulmonary vascular resistance (PVR). Invasive studies have shown 
conflicting results with regard to this factor with increased cardiac output. A decrease 
of PVR has been demonstrated in young adults with 10 μg/kg/min of dobutamine and 
with physical stress.14 In children 8.6 ± 2.3 years of age with HLHS after the Fontan 
operation no difference in PVR with 10 and 20 μg/kg/min of dobutamine was shown.15 
These observations suggest that a lack of decrease of PVR with increase in cardiac 
output may be considered abnormal in young Fontan patients and may be related to 
abnormal pulmonary vascular function in the Fontan circulation.18, 37 As such, this may 
impair preload and contribute to an abnormal stress response of the single ventricle. 
Our results are compatible with impaired ventricular preload during dobutamine 
stress.38-41 However, diastolic dysfunction may also be involved. In an earlier study we 
demonstrated that the ventricular stress response of patients with most signs of 
diastolic dysfunction of the single ventricle was more abnormal than that of patients 
with normal diastolic function.17 Invasive measurements of end-diastolic pressure and 
of active relaxation have indicated that in HLHS patients after the Fontan operation, 
diastolic function is normal and that serial changes are limited.15 Others have shown 
unfavorable changes in the end-diastolic pressure volume relationship, compatible 
with abnormal compliance of the single ventricle.14 Of note, it has been shown that the 
effect of diastolic dysfunction on ventricular filling during dobutamine stress-testing 
is negligible.10, 40, 41 Furthermore, low-dose dobutamine is considered to improve 
diastolic relaxation.42 This means that preload impairment, rather than diastolic 
dysfunction, is more likely the important factor to explain the abnormal stress 
response.40, 41
Other factors to be considered as predictors of adverse outcome are systolic function 
of the single ventricle and ventriculo-arterial (VA) coupling. Systolic function is generally 
well preserved in children and adolescent Fontan patients who have had a staged total 
cavopulmonary approach.17, 43 Invasive studies have confirmed normal contractility in 
the large majority of these patients.14, 15 Abnormal afterload is common in the Fontan 
circulation. Wong et al.15 recently showed that energetic efficiency as assessed by 
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measures of VA coupling is well preserved in the single right ventricle in young Fontan 
patients. In an older and larger group of patients, Saiki et al.44 demonstrated impaired 
VA coupling and reduced ventricular efficiency, resulting in heightened sensitivity to 
heart rate of cardiac output. These are factors to consider in the interpretation of 
functional reserve.
The predictive and diagnostic role of dobutamine stress imaging for the outcome of 
adult patients with ischemic heart disease has been well established.13 The relation 
between stress CMR parameters and hard outcome measures in adult congenital heart 
disease has only been reported by Winter et al.12 In this study, patients with a systemic 
RV with an abnormal response to stress had a higher risk of developing cardiac events 
during 8 years of follow-up. This abnormal stress response, consisting of an inability 
to increase RVEF or to decrease RVESV, was observed in 17 of the 39 patients in their 
study. In our study a similar response was noted in seven patients. The differences in 
percentage abnormal response most likely relates to differences in age and type of 
disease of the respective patient groups. Both studies indicate that in patients with 
known impairment of preload during situations with increased demand for cardiac 
output, dobutamine stress imaging may be helpful in predicting future events. In 
Fontan patients no other prospective studies with stress CMR are available.
Limitations
We studied a relatively small number of Fontan patients. However compared to existing 
literature this amount of Fontan patients receiving dobutamine CMR is large. We had 
not enough statistical power to specify which events were most related to the 
dobutamine stress response. 
Because our CMR scanner has not been suitable for supine leg exercise, the effects 
of exercise on cardiac function had to be simulated with pharmacologic stress. Because 
of time constraints in an already relatively long scanning protocol we were not able to 
perform late gadolinium enhancement in our patients to detect myocardial fibrosis. 
Conclusion
Ventricular response to dobutamine stress is a predictor for outcome related events 
in young patients with a Fontan circulation. Patients with a FR of ≥14% had significantly 
less events during follow-up.
Stress CMR predicts events in Fontan patients
81
4
References
1. Dabal RJ, Kirklin JK, Kukreja M, Brown RN, Cleveland DC, Eddins MC and Lau Y. The modern Fontan 
operation shows no increase in mortality out to 20 years: a new paradigm. J Thorac Cardiovasc Surg. 
2014;148:2517-23 e1.
2. Pfitzer C, Helm PC, Ferentzi H, Rosenthal LM, Bauer UMM, Berger F and Schmitt KRL. Changing prevalence 
of severe congenital heart disease: Results from the National Register for Congenital Heart Defects in 
Germany. Congenit Heart Dis. 2017;12:787-793.
3. Gersony WM. Fontan operation after 3 decades: what we have learned. Circulation. 2008;117:13-5.
4. d’Udekem Y, Iyengar AJ, Galati JC, Forsdick V, Weintraub RG, Wheaton GR, Bullock A, Justo RN, Grigg LE, 
Sholler GF, Hope S, Radford DJ, Gentles TL, Celermajer DS and Winlaw DS. Redefining expectations of 
long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population 
of Australia and New Zealand. Circulation. 2014;130:S32-8.
5. Rathod RH, Prakash A, Kim YY, Germanakis IE, Powell AJ, Gauvreau K and Geva T. Cardiac magnetic 
resonance parameters predict transplantation-free survival in patients with fontan circulation. Circ 
Cardiovasc Imaging. 2014;7:502-9.
6. Ohuchi H, Negishi J, Noritake K, Hayama Y, Sakaguchi H, Miyazaki A, Kagisaki K and Yamada O. Prognostic 
value of exercise variables in 335 patients after the Fontan operation: a 23-year single-center experience 
of cardiopulmonary exercise testing. Congenit Heart Dis. 2015;10:105-16.
7. Alsaied T, Bokma JP, Engel ME, Kuijpers JM, Hanke SP, Zuhlke L, Zhang B and Veldtman GR. Factors 
associated with long-term mortality after Fontan procedures: a systematic review. Heart. 2017;103:104-
110.
8. Khairy P, Fernandes SM, Mayer JE, Jr., Triedman JK, Walsh EP, Lock JE and Landzberg MJ. Long-term survival, 
modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85-92.
9. Fernandes SM, Alexander ME, Graham DA, Khairy P, Clair M, Rodriguez E, Pearson DD, Landzberg MJ 
and Rhodes J. Exercise testing identifies patients at increased risk for morbidity and mortality following 
Fontan surgery. Congenit Heart Dis. 2011;6:294-303.
10. Robbers-Visser D, Jan Ten Harkel D, Kapusta L, Strengers JL, Dalinghaus M, Meijboom FJ, Pattynama PM, 
Bogers AJ and Helbing WA. Usefulness of cardiac magnetic resonance imaging combined with low-dose 
dobutamine stress to detect an abnormal ventricular stress response in children and young adults after 
fontan operation at young age. Am J Cardiol. 2008;101:1657-62.
11. van der Hulst AE, Roest AA, Westenberg JJ, Kroft LJ and de Roos A. Cardiac MRI in postoperative congenital 
heart disease patients. J Magn Reson Imaging. 2012;36:511-28.
12. Winter MM, Scherptong RW, Kumar S, Bouma BJ, Tulevski, II, Tops LF, Roest AA, Vliegen HW, de Roos 
A, Groenink M and Mulder BJ. Ventricular response to stress predicts outcome in adult patients with a 
systemic right ventricle. Am Heart J. 2010;160:870-6.
13. Jahnke C, Nagel E, Gebker R, Kokocinski T, Kelle S, Manka R, Fleck E and Paetsch I. Prognostic value of 
cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion 
imaging. Circulation. 2007;115:1769-76.
14. Schmitt B, Steendijk P, Ovroutski S, Lunze K, Rahmanzadeh P, Maarouf N, Ewert P, Berger F and Kuehne 
T. Pulmonary vascular resistance, collateral flow, and ventricular function in patients with a Fontan 
circulation at rest and during dobutamine stress. Circ Cardiovasc Imaging. 2010;3:623-31.
15. Wong J, Pushparajah K, de Vecchi A, Ruijsink B, Greil GF, Hussain T and Razavi R. Pressure-volume loop-
derived cardiac indices during dobutamine stress: a step towards understanding limitations in cardiac 
output in children with hypoplastic left heart syndrome. Int J Cardiol. 2017;230:439-446.
16. Van De Bruaene A, La Gerche A, Claessen G, De Meester P, Devroe S, Gillijns H, Bogaert J, Claus P, 
Heidbuchel H, Gewillig M and Budts W. Sildenafil improves exercise hemodynamics in Fontan patients. 
Circ Cardiovasc Imaging. 2014;7:265-73.
17. Bossers SS, Kapusta L, Kuipers IM, van Iperen G, Moelker A, Kroft LJ, Romeih S, de Rijke Y, Ten Harkel AD 
and Helbing WA. Ventricular function and cardiac reserve in contemporary Fontan patients. Int J Cardiol. 
2015;196:73-80.
18. Robbers-Visser D, Helderman F, Strengers JL, van Osch-Gevers L, Kapusta L, Pattynama PM, Bogers AJ, 
Krams R and Helbing WA. Pulmonary artery size and function after Fontan operation at a young age. J 
Magn Reson Imaging. 2008;28:1101-7.
19. Pushparajah K, Wong JK, Bellsham-Revell HR, Hussain T, Valverde I, Bell A, Tzifa A, Greil G, Simpson 
JM, Kutty S and Razavi R. Magnetic resonance imaging catheter stress haemodynamics post-Fontan in 
hypoplastic left heart syndrome. Eur Heart J Cardiovasc Imaging. 2016;17:644-51.
20. De Wolf D, Suys B, Verhaaren H, Matthys D and Taeymans Y. Low-dose dobutamine stress 
echocardiography in children and young adults. Am J Cardiol. 1998;81:895-901.
Part I  |  Chapter 4
82
21. Bossers SS, Helbing WA, Duppen N, Kuipers IM, Schokking M, Hazekamp MG, Bogers AJ, Ten Harkel AD 
and Takken T. Exercise capacity in children after total cavopulmonary connection: lateral tunnel versus 
extracardiac conduit technique. J Thorac Cardiovasc Surg. 2014;148:1490-7.
22. Robbers-Visser D, Kapusta L, van Osch-Gevers L, Strengers JL, Boersma E, de Rijke YB, Boomsma F, 
Bogers AJ and Helbing WA. Clinical outcome 5 to 18 years after the Fontan operation performed on 
children younger than 5 years. J Thorac Cardiovasc Surg. 2009;138:89-95.
23. Van Mechelen W and Armstrong N. Paediatric Exercise Science and Medicine (Oxford Medical Publications): 
Oxford University Press; 2008.
24. Pundi KN, Johnson JN, Dearani JA, Pundi KN, Li Z, Hinck CA, Dahl SH, Cannon BC, O’Leary PW, Driscoll DJ 
and Cetta F. 40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients. J Am 
Coll Cardiol. 2015;66:1700-10.
25. Diller GP, Giardini A, Dimopoulos K, Gargiulo G, Muller J, Derrick G, Giannakoulas G, Khambadkone 
S, Lammers AE, Picchio FM, Gatzoulis MA and Hager A. Predictors of morbidity and mortality in 
contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise 
testing in 321 patients. Eur Heart J. 2010;31:3073-83.
26. Gatzoulis MA, Munk MD, Williams WG and Webb GD. Definitive palliation with cavopulmonary or 
aortopulmonary shunts for adults with single ventricle physiology. Heart. 2000;83:51-7.
27. Ghelani SJ, Harrild DM, Gauvreau K, Geva T and Rathod RH. Comparison Between Echocardiography and 
Cardiac Magnetic Resonance Imaging in Predicting Transplant-Free Survival After the Fontan Operation. 
Am J Cardiol. 2015;116:1132-8.
28. Ohuchi H, Yasuda K, Miyazaki A, Iwasa T, Sakaguchi H, Shin O, Mizuno M, Negishi J, Noritake K and 
Yamada O. Comparison of prognostic variables in children and adults with Fontan circulation. Int J 
Cardiol. 2014;173:277-83.
29. Eindhoven JA, van den Bosch AE, Jansen PR, Boersma E and Roos-Hesselink JW. The usefulness of 
brain natriuretic peptide in complex congenital heart disease: a systematic review. J Am Coll Cardiol. 
2012;60:2140-9.
30. Lechner E, Gitter R, Mair R, Pinter M, Schreier-Lechner E, Vondrys D and Tulzer G. Aminoterminal brain 
natriuretic peptide levels in children and adolescents after Fontan operation correlate with congestive 
heart failure. Pediatr Cardiol. 2008;29:901-5.
31. Ruffolo RR, Jr. The pharmacology of dobutamine. Am J Med Sci. 1987;294:244-8.
32. Roest AA, Kunz P, Lamb HJ, Helbing WA, van der Wall EE and de Roos A. Biventricular response to supine 
physical exercise in young adults assessed with ultrafast magnetic resonance imaging. Am J Cardiol. 
2001;87:601-5.
33. Robbers-Visser D, Luijnenburg SE, van den Berg J, Roos-Hesselink JW, Strengers JL, Kapusta L, Moelker 
A and Helbing WA. Safety and observer variability of cardiac magnetic resonance imaging combined 
with low-dose dobutamine stress-testing in patients with complex congenital heart disease. Int J Cardiol. 
2011;147:214-8.
34. Khiabani RH, Whitehead KK, Han D, Restrepo M, Tang E, Bethel J, Paridon SM, Fogel MA and Yoganathan 
AP. Exercise capacity in single-ventricle patients after Fontan correlates with haemodynamic energy loss 
in TCPC. Heart. 2015;101:139-43.
35. Bossers SS, Cibis M, Gijsen FJ, Schokking M, Strengers JL, Verhaart RF, Moelker A, Wentzel JJ and Helbing 
WA. Computational fluid dynamics in Fontan patients to evaluate power loss during simulated exercise. 
Heart. 2014;100:696-701.
36. Tang E, Wei ZA, Whitehead KK, Khiabani RH, Restrepo M, Mirabella L, Bethel J, Paridon SM, Marino BS, 
Fogel MA and Yoganathan AP. Effect of Fontan geometry on exercise haemodynamics and its potential 
implications. Heart. 2017;103:1806-1812.
37. Khambadkone S, Li J, de Leval MR, Cullen S, Deanfield JE and Redington AN. Basal pulmonary vascular 
resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation. 2003;107:3204-8.
38. Kondoh C, Hiroe M, Nakanishi T, Nakazawa M, Nakae S, Imai Y and Takao A. Left ventricular characteristics 
during exercise in patients after Fontan’s operation for tricuspid atresia. Heart Vessels. 1988;4:34-9.
39. Gewillig MH, Lundstrom UR, Bull C, Wyse RK and Deanfield JE. Exercise responses in patients with 
congenital heart disease after Fontan repair: patterns and determinants of performance. J Am Coll 
Cardiol. 1990;15:1424-32.
40. Senzaki H, Masutani S, Ishido H, Taketazu M, Kobayashi T, Sasaki N, Asano H, Katogi T, Kyo S and Yokote 
Y. Cardiac rest and reserve function in patients with Fontan circulation. J Am Coll Cardiol. 2006;47:2528-35.
41. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Sasaki N, Asano H, Kyo S, Yokote Y and Ishizawa A. 
Ventricular afterload and ventricular work in fontan circulation: comparison with normal two-ventricle 
circulation and single-ventricle circulation with blalock-taussig shunts. Circulation. 2002;105:2885-92.
42. Harada K, Tamura M, Ito T, Suzuki T and Takada G. Effects of low-dose dobutamine on left ventricular 
diastolic filling in children. Pediatr Cardiol. 1996;17:220-5.
Stress CMR predicts events in Fontan patients
83
4
43. Anderson PA, Sleeper LA, Mahony L, Colan SD, Atz AM, Breitbart RE, Gersony WM, Gallagher D, Geva T, 
Margossian R, McCrindle BW, Paridon S, Schwartz M, Stylianou M, Williams RV, Clark BJ, 3rd and Pediatric 
Heart Network I. Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network 
multicenter study. J Am Coll Cardiol. 2008;52:85-98.
44. Saiki H, Eidem BW, Ohtani T, Grogan MA and Redfield MM. Ventricular-Arterial Function and Coupling in 
the Adult Fontan Circulation. J Am Heart Assoc. 2016;5.
Tetralogy of Fallot
Part II

Jelle P.G. van der Ven
Eva van den Bosch
Ad J.J.C. Bogers
Willem A. Helbing
Current outcomes and treatment
of Tetralogy of Fallot
F1000 Res. 2019. Doi:10.12688/f1000research.17174.1
Chapter 6
Part II  |  Chapter 6
110
Abstract
Tetralogy of Fallot (ToF) is the most common type of cyanotic congenital heart disease. 
Since the first surgical repair in 1954, treatment has continuously improved. The 
treatment strategies currently used in the treatment of ToF result in excellent long-term 
survival (30 year survival ranges from 68.5% to 90.5%). However, residual problems 
such as right ventricular outflow tract obstruction, pulmonary regurgitation, (ventricular) 
arrhythmia are common and often require re-interventions.
Right ventricular dysfunction can be seen following longstanding pulmonary 
regurgitation and/or stenosis. Performing pulmonary valve replacement or relief of 
pulmonary stenosis before irreversible right ventricular dysfunction occurs is important, 
but determining the optimal timing of pulmonary valve replacement is challenging for 
several reasons.
The biological mechanisms underlying dysfunction of the right ventricle as seen in 
longstanding pulmonary regurgitation are poorly understood.  Different methods of 
assessing the right ventricle are used to predict impending dysfunction. The 
atrioventricular, ventriculo-arterial and interventricular interactions of the right ventricle 
play an important role in right ventricle performance, but are not fully elucidated.
In this review we present a brief overview of the history of ToF, describe the treatment 
strategies currently used, and outline the long-term survival, residual lesions, and re-
interventions following repair. We discuss important remaining challenges and present 
the current state of the art regarding these challenges.
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Introduction 
Tetralogy of Fallot (ToF), the most common type of cyanotic congenital heart disease 
(CHD), has an incidence of 0.34 per 1000 live births.1 The classic tetrad (Figure 1) was 
first described in 1673 by bishop and anatomist Nicolas Steno, but the anatomy was 
more extensively described by the French physician Étienne-Louis Fallot in 1888.2, 3 
Patients with ToF have varying degrees of cyanosis depending on the severity of right 
ventricular outflow tract (RVOT) stenosis and pulmonary artery (PA) anatomy. The 
anatomic abnormalities seen in ToF vary from milder to more severe phenotypes, such 
as ToF with pulmonary atresia and Fallot-type double outlet right ventricle (RV). These 
more severe forms may require different management and treatment strategies. This 
review focuses on the “classic” ToF, with right ventricular outflow (pulmonary) stenosis, 
rather than atresia, and excluding double outlet right ventricle. 
Surgical approaches to repair 
Surgical repair of ToF was first described in 1955 by Lillehei et al.4 The right ventricular 
outflow tract obstruction (RVOTO) was approached by a ventriculotomy into the right 
Modified from Englert et al.174 with permission from the publisher.
1) Pulmonary stenosis. 2) Overriding aorta. 3) Malalignment ventricular septal defect. 4) Right ventricular 
hypertrophy. 
Figure 1. Schematic overview of the defects seen in Tetralogy of Fallot
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ventricular anterior wall and relief included inserting a transannular patch (TAP) if 
required (Figure 2, left). Aggressive RVOTO relief was advocated as initial results had 
demonstrated that residual RVOTO was predictive of early mortality.5 This approach 
resulted in relatively good long-term survival.6 However, residual lesions after repair 
were common and follow-up studies of these first operations showed that these 
residual lesions resulted in late morbidity and mortality.7-10 Pulmonary regurgitation 
(PR) was reported in the majority of patients, more commonly in those with TAPs.11 PR 
initially was thought to be a relatively benign hemodynamic residual lesion but 
subsequently was found to be predictive of decreased exercise performance and 
progressive RV dilation. RV dilation, in turn, was associated with ventricular arrhythmia 
and biventricular dysfunction.12-14 Furthermore, patients were noted to be at higher 
risk of sudden cardiac death.7, 8, 10, 15, 16
Different surgical techniques were developed minimizing the extent of the 
ventriculotomy and trying to preserve competence of the pulmonary valve without 
causing significant residual RVOTO. Via a transatrial or transatrial-transpulmonary 
approach, the need for a ventriculotomy can be reduced (Figure 2, right). The transatrial 
or transatrial-transpulmonary approach is currently employed in most centers, and 
the long-term results are excellent.11, 17-20 In patients with a small pulmonary valve 
annulus, a TAP is still necessary for adequate RVOTO relief. Other techniques to 
preserve or replace pulmonary valve competence include pulmonary valvuloplasty 
with patching limited to the infundibulum,21, 22 implantation of a monocusp valve,23, 24 
a valved RV-to-PA conduit, 25, 26 or a homograft valve.25 A survival benefit of these valve-
sparing or valve-replacing techniques has not yet been demonstrated.27-30 
Figure 2. Transventricular (left) and transatrial-transpulmonary (right) approach to Tetralogy of Fallot (ToF) 
repair
VSD, ventricular septal defect. Adapted from Bushman175 with permission from the publisher. 
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Variations in current treatment strategies 
In general, it is thought that earlier primary repair of ToF can limit prolonged exposure 
to RV pressure loading and reduced oxygen saturations, preserving cardiovascular31 
and brain32 function. However, there is no consensus on the definition of “early” versus 
later repair. Neonatal repair (that is, repair before 1 month of age) is feasible with 
acceptable results but is not widely used and this is because of better short-term 
outcomes of non-neonatal repair.33 Neonatal repair more often requires TAP compared 
with repair beyond the neonatal period, resulting in worse event-free survival.33 In the 
majority of patients, primary repair can be postponed to 3 to 6 months of age with 
excellent outcomes.34, 35
Symptomatic ToF patients may require an intervention in the neonatal period. 
Different strategies can be used if primary repair is judged not to be the best option. 
Historically, a systemic-to-pulmonary shunt — typically a modified Blalock-Taussig 
(mBT) shunt — has been used to increase pulmonary flow, reduce hypoxemia, and 
allow time for PA growth. This allows repair to be performed at an older age and has 
the potential advantage of using no, or less extensive, TAP. However, palliative shunt 
procedures are associated with a 3% to 5% early mortality rate.36, 37 The superiority of 
a staged approach versus primary neonatal repair has not been demonstrated.38, 39
Stenting of the ductus arteriosus (DA) is another strategy to warrant pulmonary blood 
flow after birth by inducing a systemic-to-pulmonary shunt. However, in cyanotic CHD, 
the anatomy of the DA might be complex and unsuited for stenting.40 Procedural 
success is estimated to be 83%.41 Recently published multicenter studies compared 
outcomes following DA stenting and mBT shunting using propensity score–adjusted 
models.41, 42 Clinical status, assessed by saturation, hemoglobin levels, and PA size, was 
more favorable following DA stenting compared with mBT shunting.41, 42 Bentham et 
al. found better survival (hazard ratio 0.25, 95% confidence interval (CI) 0.07–0.85) for 
DA stent compared with mBT,41 whereas Glatz et al. found no difference in survival 
(hazard ratio 0.64, 95% CI 0.28–1.47).42 A trend toward higher re-intervention rate in 
the DA stent group was observed in both studies.41, 42 DA stenting appears to be a 
feasible strategy for selected cases.
Alternatively, palliative balloon dilation of the pulmonary annulus can be used to 
increase oxygen saturation and promote growth of the pulmonary vasculature and as 
bridge to later complete repair in selected patients.43, 44 Whether this strategy ultimately 
reduces TAP use or improves long-term outcomes remains controversial.43, 44
Similarly, RVOT stenting can be used as a palliative strategy or bridge to repair in 
neonatal life.45, 46 Experience with this strategy is still relatively limited but it has been 
demonstrated to be a relatively safe procedure promoting growth of the pulmonary 
arteries as a bridge to repair.46-48 Quandt et al. compared medium-term outcomes of 
RVOT stent with systemic-to-pulmonary shunt and found no difference in survival 
between strategies.47 Intensive care and hospital stay duration and peri-operative 
complications were more favorable for the RVOT stenting group but the re-intervention 
rate was higher for this group.47 The most common re-interventions in this group were 
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re-stenting and re-ballooning. (Re)shunt surgery or early complete repair was less 
common in this group compared with patients who underwent primary mBT. 
Comparisons between neonatal repair and RVOT stenting have shown comparable 
short-term and long-term outcomes.49, 50 During 10 years of follow-up, Wilder et al. 
demonstrated a similar increased rate of catheter-based re-interventions in the RVOT 
stent group compared with neonatal repair.50 More studies are needed to determine 
the best strategy for the patient group requiring early intervention. Management 
strategies likely need to be individualized for optimal outcome.
Overall survival 
Overall survival following ToF repair has significantly improved in recent eras. Figure 
3 outlines survival in several large studies published within the last two decades, and 
follow-up was up to 40 years for older cohorts.11, 51-63 Early mortality has significantly 
decreased in more recent eras. European and American congenital cardiothoracic 
surgery registries have reported a peri-operative mortality below 3% in recent years.64-66 
Peri-operative outcomes are determined largely by the severity of the ToF described 
by, for example, the pre-operative size of the pulmonary valve and pulmonary arteries, 
RV-PA pressure gradient, and oxygen saturation.59, 67-69 Patients with repair including 
TAP have higher peri-operative mortality.64 As most centers consider a TAP only when 
the pulmonary annulus z-score is lower than −2 or −3, this in part reflects more severe 
ToF.19, 70 Furthermore, co-morbidities, such as coronary abnormalities, prematurity, 
small body size–associated lesions, and genetic abnormalities, have been associated 
with increased peri-operative mortality.59, 67-69, 71
Mortality rates at medium-term follow-up have not changed much across the 
different surgical eras (Figure 3).63 Survival at 30 years ranges from 68.5% to 90.5%.52, 
55, 56, 60-63 Long-term (20 to 30 years) survival from large cohorts of patients operated on 
with more recent surgical modifications of ToF repair (for example, valve-sparing and 
valve-replacing techniques) is still lacking. Important factors determining long-term 
outcome are residual RVOTO and severity of PR.52
Survival into adulthood is currently expected following ToF repair, leading to a 
growing population of adults with corrected ToF who require lifelong specialized 
medical care.72-75 Re-interventions are common in these patients. Cuypers et al. found 
that 44% of patients underwent at least one surgical or catheter re-intervention after 
35 years of follow-up.61 D’Udekem et al. found that 24 ± 5% of patients underwent re-
operation after 30 years of follow-up.62 Following transatrial transpulmonary repair, 
lower rates of re-interventions have been reported. Luijten et al.11 found a 80% freedom 
of re-intervention and death after 10 years and D’Udekem et al.62 found 75% freedom 
of re-operation after 25 years.11, 62 A small case-control study found a lower pulmonary 
valve replacement (PVR) rate following transatrial repair compared with transventricular 
repair. The use of a TAP is associated with a higher re-intervention rate,11, 52 as is severity 
of ToF at repair.54, 63 Specific indications for re-interventions will be discussed later in 
this article.
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Residual problems and re-interventions 
Residual right ventricle outflow tract obstruction 
Residual RVOTO is common following repair and results in residual or progressive 
concentric hypertrophy of the RV. Data obtained from the INDICATOR study suggest 
that RV hypertrophy, due to increased mass-to-volume ratio, is a more important long-
term risk factor for ventricular tachycardia (VT) and death than severity of RV dilation 
(RV end-diastolic volume index).76 Current guidelines provide clear indications for re-
intervention for residual RVOTO (Table 1).73-75 Balloon valvuloplasty or PVR can be 
performed for valvular pulmonary stenosis (PS). PA branch stenosis can be safely 
relieved by balloon dilation, stenting, or PA reconstruction.77 In several large studies, 
1% to 7% of patients have undergone PA dilation or stenting at long-term follow-up 
(median of 5.8 to 36 years).59, 61, 62, 78, 79 Surgical relief of the RVOT and PA plasties were 
performed in 1% to 5% of patients at long-term follow-up.59, 61, 78, 79
Pulmonary regurgitation 
PR is very common at medium- to long-term follow-up. Five to ten years after repair, 
40% to 85% of patients have moderate to severe PR.51, 71, 80-82 PR induces RV volume 
overload of the RV with often progressive RV dilation, which may include the 
development of tricuspid regurgitation (TR) and RV dysfunction. It is often accompanied 
Each colored line represents a single study, and dots represent Kaplan–Meier survival estimates at different 
time points.11, 51-63 Ninety-five percent confidence intervals, where published, are shown in vertical lines. Lines 
are colored according to surgical era.
Figure 3. Survival following Tetralogy of Fallot (ToF) repair
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by prolongation of the QRS complex, and RV dyssynchrony could contribute to the 
progression of dysfunction.83-85 There generally is a long period in a compensated state, 
during which RV function is maintained. In some patients, these compensatory 
mechanisms fail, leading to progressive RV dysfunction.83, 84 The mechanisms of RV 
adaptation and remodeling, as well as the molecular events contributing to the 
transition from a compensated to a decompensated state, are still poorly understood. 
Timely restoration of pulmonary valve competence is considered to halt the progressive 
adverse RV remodeling resulting in RV dysfunction seen in chronic PR. 
Table 1. Indications for pulmonary valve replacement in current guidelines
European Society of 
Cardiology (2010)75
American College of 
Cardiology/American Heart 
Association (2008)73
Canadian Cardiovascular 
Society (2009)74
Class I Symptomatic patients  
with severe PR and/or 
PS (RV systolic pressure >60 
mm Hg, TR velocity >3.5 m/s)
Severe PR and 
Symptoms or decreased 
exercise tolerance
Class IIa Severe PR or PS (or both)
and either:
Severe PR and either: Free PR and either:
RV size Moderate to severe RV 
enlargement
EDVi 170 mL/m2
Progression 
of RV size
Progressive RV dilation Progressive RV dilation
RV function Progressive RV dysfunction Moderate to severe  
RV dysfunction
Moderate to severe  
RV dysfunction
TR Progressive TR,  
at least moderate
Moderate to severe TR Important TR
PS PS RV systolic pressure 
greater than 80 mm Hg,  
TR velocity 4.3 m/s
Peak instantaneous 
echocardiography gradient 
greater than 50 mm Hg
or
RV/LV pressure ratio greater 
than 0.7
or
Residual RVOT obstruction 
(valvular or subvalvular) with 
progressive and/or severe 
dilatation of the RV with 
dysfunction
RV pressure at least 2/3 
systemic pressure
Exercise 
capacity
Decrease in objective 
exercise capacity
Symptoms such as 
deteriorating exercise 
performance
Arrhythmia Sustained atrial or  
ventricular arrhythmia
Symptomatic or sustained 
atrial and/or ventricular 
arrhythmias
Atrial or ventricular 
arrhythmia
Abbreviations: EDVi, end-diastolic volume index; LV, left ventricle; PR, pulmonary regurgitation; PS, pulmonary 
stenosis; RV, right ventricle; RVOT, right ventricle outflow tract; TR, tricuspid regurgitation.
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Thirty-five years after ToF repair, PVR will have been performed in about 40% of 
patients.61, 63, 86 Staged repair and TAP are risk factors for late PVR.11, 52, 61, 78, whereas 
mild residual PS seems to reduce risk.87 As more patients with ToF survive into 
adulthood, PVRs are increasingly being performed.88
PVR is effective in decreasing RV volumes, reducing TR, decreasing QRS duration, 
increasing left ventricle (LV) ejection fraction (EF), and improving functional status.89, 90 
It should be noted that no improvement in survival following PVR compared with 
medical management has been demonstrated to date.91, 92
Homograft or bioprosthetic valves are currently the preferred valves for PVR.93 The 
current 10-year re-PVR–free survival of ToF patients undergoing homograft PVR ranges 
from 74% to 89%.93, 94
Tissue-engineered valves with a non-synthetic and non-immunogenic surface have 
the potential to provide lifelong valve replacement.95 In situ tissue engineering 
techniques, in which a decellularized “starter scaffold” of polymers can be used to 
provide shape and structure to the valve, are of particular interest. This scaffold is 
infiltrated by endogenous cells to provide a regenerating functional valve. As the 
scaffold would be non-immunogenic, this could provide a relatively cheap “off the shelf” 
valve. Current studies evaluating tissue-engineered valves in animals and humans 
show promising early results.96
Several transcatheter PVR strategies have been developed and are increasingly used 
in a clinical (trial) setting.97 However, clinical experience compared with (surgical) 
homograft PVR is limited.97 Procedural success of transcatheter PVR is generally good 
(>95%).98 The hazard rate for re-intervention following transcatheter PVR ranges from 
0.4% to 5.9% per patient-year.98 However, high rates of infective endocarditis during 
follow-up have been described.99 Recent results from the MELODY Registry estimate 
the infective endocarditis risk to be 2.3% per patient-year.100 In comparison, the infective 
endocarditis risk in surgical PVR has been estimated to be 0.3% per patient-year.101 
Transcatheter PVR has been shown to increase exercise capacity and quality of life 6 
months after the procedure.102, 103 Direct comparisons with surgical PVR are still lacking.
Arrhythmia 
Ventricular tachycardia 
VT is a common arrhythmia in the repaired ToF population. Cuypers et al. reported a 
5% cumulative incidence of sustained VT after a median of 35 years after ToF repair61 
and these figures are similar to those of most reports.56, 104 However, cumulative 
incidences of up to 15% have been reported in some adult populations.105 Predictors 
of sustained VT include higher age, number of prior cardiac surgeries, presence of a 
TAP, LV diastolic dysfunction, and QRS width.61, 104-106 Most guidelines recommend 
implantable cardioverter defibrillators (ICDs) for patients who have had sustained VT 
or cardiac arrest.74, 75 ICDs are also employed for primary prevention, although 
selecting high-risk patients who would benefit from ICD implantation remains 
challenging.74, 75 Pacemaker and ICD prevalences in adult ToF populations both range 
from 5% to 10%.61, 105, 107
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Electrophysiological studies can help to determine the underlying substrate, and 
radiofrequency ablation can be performed. Ablation of monomorphic VT substrates 
has excellent short-term outcomes with recurrent VT in 18% of patients after a mean 
follow-up of 34 months.108 Another study found a similar recurrence rate (19%) 10 years 
after ablation.109
Supraventricular tachycardia 
The prevalence or cumulative incidence of supraventricular tachycardia (SVT) in adult 
patients ranges from 4% to 20%.105-107, 110 In the first 10 to 15 years following ToF repair, 
SVT is relatively uncommon but the incidence rises steadily after this period.105 Intra-
atrial re-entrant tachycardia, typically involving the right atrium, is the most common 
type of SVT in patients with ToF.105 Two large studies found that SVT was an independent 
predictor of death or VT.76 Few studies have assessed the efficacy of ablation of atrial 
arrhythmias in corrected ToF, and long-term follow-up is lacking.111-113
Aortopathy 
Dilation of the aorta is seen in 12% to 24% of adult patients with ToF.114-116 In patients 
with aortic dilation, aortic root size seems to progressively increase over a period of 
years. Aortic dissection following ToF appears to be a rare complication.117 A population-
based study in Texas demonstrated no increased risk for thoracic aortic dissection for 
patients with ToF compared with the general population.117 However, progressive aortic 
root dilation can lead to malcoaptation of the aortic valve and aortic regurgitation. 
Furthermore, the elasticity of the dilated aortic root was shown to be reduced in 
patients with ToF, possibly hampering circulatory function.118 The importance of 
aortopathy in circulatory function and mortality remains incompletely understood.
Knowledge gaps 
Right ventricular adaptation and remodeling 
The mechanisms of RV adaptation and remodeling in response to chronic RV volume 
overload, resulting from PR, are poorly understood.119 In young pig models, chronic PR 
affects biventricular systolic function, RV myocardial contractility, and LV diastolic 
performance.120 Histopathology of several animal models displays early hypertrophy 
of the chronically volume-loaded RV and, in a later stage, myocardial fibrosis.119 The 
molecular responses to increased volume or pressure loading of the RV are different 
from those in the LV.119, 121-123 In a pig model of repaired ToF with induced PR, PS, and 
an RVOT scar, RV hypertrophy and dilation were found after 23 weeks. The myocardium 
was characterized by increased collagen deposition, leading to decreased impulse 
conduction velocity and dispersion.124 Similar findings were found in the LV, despite 
preserved LV function at this stage. This demonstrates biventricular adverse effects 
are present early in the adverse remodeling process.125 
Basic research into RV remodeling has focused mainly on the response to increased 
pressure loading rather than the predominantly volume-loaded RV as seen in PR.122, 123 
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Volume loading and pressure loading increase myocardial metabolic demand. 
This metabolic stress induces an increased amount of reactive oxygen species. 
Compensatory anti-oxidant production in the RV is impaired compared with the LV.123 
This might imply that the RV is more vulnerable to oxidative stress, as seen in abnormal 
loading conditions.
In volume-loaded RV mouse models, a clinical course similar to RV dysfunction with 
volume-loaded RV in humans is observed. RV function is maintained during a 
compensated phase, followed by RV dysfunction.126 Gene expression patterns of the 
cardiomyocyte in the compensated state differ from those of healthy controls. Several 
molecular pathways, such as transforming growth factor beta (TGF-β) signaling, p53 
signaling, and cytoskeleton-related pathways are downregulated in the early 
compensated state but show late upregulation as the RV progressively remodels.126 
However, the exact cellular and molecular mechanisms of transition from a 
compensated to a decompensated state of the volume-loaded RV have not been fully 
elucidated.123, 127 
Assessing the right ventricle in patients with Tetralogy of Fallot 
Our limited understanding of the pathophysiology of RV failure hampers our ability to 
adequately detect failure in the early stages in clinical practice. Imaging techniques are 
used to assess the RV and follow patients serially, aiming to detect early changes in 
biventricular size and performance. Cardiovascular magnetic resonance (CMR) imaging 
is routinely used to reliably quantify RV volumes and function, wall mass, and PR.128 
Adverse clinical events have been related to larger RV volumes, PR severity, biventricular 
EF, and mass-to-volume ratio.76, 129, 130 Increased RV volumes, most commonly end-
diastolic volume index (EDVi), have been considered a sign of prolonged high PR burden 
and thus a predictor of RV dysfunction. However, exercise capacity can be preserved 
even in severely dilated ventricles, demonstrating that compensatory mechanisms can 
still be adequate to maintain performance of large RVs.131 In the INDICATOR cohort, 
increased RV wall mass-to-volume ratio, among other factors, was found to be an 
independent predictor of VT and all-cause mortality, whereas RV EDV and end-systolic 
volume were not predictive of the end-points.76 RV hypertrophy could be a more 
sensitive marker of pending dysfunction than EDV, although this might be particularly 
true for patients with residual PS.
Regional myocardial performance and mechanical synchrony can be assessed by 
strain imaging studies. Global circumferential or longitudinal strain has been used to 
assess RV function. Under normal circumstances, the RV ejects mainly by longitudinal 
shortening while, with increased RV pressure loading, circumferential contraction is 
increased.132 The predictive value of global longitudinal or circumferential strain in ToF 
is still uncertain: Orwat et al. found that RV global longitudinal strain assessed by CMR 
was a superior independent predictor for death, cardiac arrest, or VT compared with 
RV volumes.133 RV global circumferential strain was not predictive of outcome in that 
study.133 Diller et al. found a similar relation for LV global longitudinal strain assessed 
by echocardiography.134
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Mechanical dyssynchrony has been demonstrated to relate to prolonged or 
fragmented (QRS complex containing additional spikes without bundle branch block) 
QRS complexes.135 The contributions of this mechano-electrical interaction to RV 
function remain uncertain, as studies assessing mechanical dyssynchrony report 
conflicting results.133, 134, 136-139 RV circumferential dyssynchrony was shown to negatively 
predict exercise capacity in one study.138 This association has not been confirmed in 
other studies.139, 140 Cardiac resynchronization therapy is increasingly used in ToF. A 
recent study found that 12 out of 15 adult patients with ToF had an improved NYHA 
(New York Heart Association) class or LV function after 2.6 years (median) of cardiac 
resynchronization therapy.141 Procedural success was high and adverse events were 
rare.
Right ventricular interactions in Tetralogy of Fallot 
Atrio-ventricular interactions. Diastolic function after ToF repair is a determinant of the 
amount of PR. In some patients, end-diastolic forward flow (EDFF) in the main PA during 
right atrial contraction can be observed.142 This is considered a sign of “restrictive RV 
physiology” as the non-compliant RV acts as a conduit during atrial contraction as RV 
diastolic pressure exceeds PA diastolic pressure.143, 144 Restrictive physiology could limit 
the amount of PR as elevated diastolic RV pressure reduces the amount of PR. A recent 
study found no relationship between the presence of EDFF and other markers of 
diastolic dysfunction (that is, RV hypertrophy, atrial dilatation, reduced stroke volume, 
or reduced PR).145 Different mechanisms, such as pulmonary arterial capacitance and 
atrial function,146 may play significant roles in the occurrence of EDFF. Luijnenburg et 
al. found that bi-atrial function, but not diastolic ventricular function, differed between 
patients with EDFF and those without it.146 In that study, abnormal atrial function was 
related to worse exercise capacity and higher N-terminal pro brain natriuretic peptide 
(NT-proBNP). Kutty et al. found that right atrial longitudinal strain predicted RV 
performance but not exercise capacity.147
The effect of EDFF on circulatory function is controversial. Studies found conflicting 
results regarding the relationship between EDFF and the amount of PR,142, 143, 145 exercise 
capacity,143-146 and EDV.143-146 The presence of EDFF might have a different etiology and 
clinical importance early versus late after repair or in severely dilated versus non-dilated 
ventricles.
Ventriculo-arterial interactions. Adequate atrio-ventricular coupling and ventriculo-
arterial (VA) coupling are required for an energetically efficient transfer of blood 
through the right heart. VA coupling has not been studied extensively in ToF. Latus et 
al. assessed VA coupling as the relationship between pulmonary arterial elastance and 
ventricular end-systolic elastance in adult patients with ToF by using CMR and catheter-
derived measurements both in resting conditions and during dobutamine stress.148 VA 
coupling was impaired during resting conditions. EF and load-independent parameters 
of RV contractility increased during dobutamine stress. Pulmonary arterial elastance 
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increased accordingly and the impaired VA coupling that resulted during dobutamine 
stress was similar to that under resting conditions. 
Interventricular interactions. Interactions between the RV and LV have been extensively 
described. The LV and RV have common myocardial fibers, the interventricular septum, 
the anatomic space confined by the pericardium, and a common neurohumoral 
system.149 Not unexpectedly, the effects of chronic PR are not limited to the RV, although 
the mechanisms of this ventriculo–ventriculo interaction in chronic PR remain poorly 
understood. A linear correlation between LV and RV EF has been described.149, 150 Severe 
RV dilation causes abnormal diastolic septal positioning, influencing LV filling.151 The 
role of the LV in outcomes in ToF is increasingly appreciated, as LV function has been 
associated with increased mortality and increased risk of VT.134, 152 In the INDICATOR 
registry, LV EF was one of three independent predictors of mortality and VT.153 Geva et 
al. found that LV EF, independent of RV parameters, predicted poor functional status.150 
Remarkably, parameters of LV function are not considered in current guidelines for 
the timing of PVR (Table 1).
Drug therapy for right ventricular failure 
Pharmacotherapy is important in the treatment of LV failure and improves outcomes. 
However, the effects of the use of heart failure medication for RV failure have been 
disappointing.154-156 In patients after ToF repair, RAAS (renin–angiotensin–aldosterone 
system) inhibitors do not appear to influence RV EF or exercise capacity.157 In a 
randomized controlled trial of 33 patients with ToF, beta blockers showed no beneficial 
effects after 6 months of treatment and an increase in NT-proBNP was noted.158 
Increasing our understanding of the pathophysiology of RV failure might elucidate new 
targets for medical treatment unique to the RV.
Current guidelines on the timing of pulmonary valve replacement 
Restoring pulmonary valve function before irreversible RV dysfunction occurs could 
be important to prevent RV failure. However, the durability of currently used pulmonary 
prosthetic valves is limited. Therefore, the timing of PVR always is a compromise: It 
should be timed early enough to prevent irreversible adverse remodeling but late 
enough to limit the number of re-interventions. Because of the difficulties in assessing 
RV function, predicting decline in RV function is difficult, and the optimal timing of PVR 
is controversial. Guidelines by the European Society of Cardiology, the Canadian 
Cardiovascular Society (CCS), and the American College of Cardiology/American Heart 
Association provide some recommendations on indications for performing PVR.73-75 
These indications are summarized in Table 1.
Indications differ between guidelines and have several limitations. Most guidelines 
do not provide specific cutoff points since these are statistical constructs that do not 
work for individual patients. The 2009 CCS guideline provides an absolute cutoff value 
for EDVi but does not take into account the considerable differences in normal (indexed) 
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RV volumes between genders and age.159 End-systolic volume index and RV mass-to-
volume ratio have been proposed as superior predictors compared with EDV.76, 160 
Progressive RV dilation is considered an indication for PVR, but there is no consensus 
on what too much progression is.161-164 Longitudinal changes in RV size and function 
following ToF repair have been reported in several studies.165-172 RV volumes increase 
non-linearly and seem to stabilize in adolescence. These factors need to be taken into 
account when assessing progressive RV dilation.
Furthermore, the recommendations in current guidelines are often based on long-
term outcomes of studies in patients who have been operated at a much older age 
than has been the practice in the past 20 years. This warrants caution when 
extrapolating these results to current adolescent or younger patients.
Careful interpretation of current guidelines seems to be justified. Individual patient 
parameters and views should always be taken into consideration. In clinical practice, 
an approach using information from different sources, including history, physical 
examination, electrocardiogram, imaging techniques, exercise testing, and blood 
biomarkers, may be most useful.173
Conclusions 
ToF can be repaired with low short-term and long-term mortality. This has caused a 
demographic shift such that many patients survive well into adulthood. Long-term 
follow-up of older cohorts has shown the detrimental effects of PR in the long-term. 
However, residual lesions cause significant morbidity. Surgical modifications to preserve 
pulmonary valve function, such as the transatrial (and transpulmonary) approaches 
and restricted use of TAPs, have been widely adopted. Despite improvements in 
morbidity, follow-up duration for these techniques is probably too limited to 
demonstrate a survival benefit.
Our limited understanding of RV adaptation and the pathophysiology of RV heart 
failure hampers the ability to detect failure in early stages in clinical practice and to 
predict future decline of RV function. While a large proportion of adult ToF survivors 
require one or multiple PVRs in their lifetimes, selecting optimal candidates and optimal 
timing for PVR remains challenging. Increasing our understanding of RV failure seems 
key to answer these difficult questions. This might provide treatment options to attain 
optimal long-term health outcomes for patients with ToF.
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Abstract
Objectives
The surgical approach to repair of Tetralogy of Fallot (ToF) has shifted over the years. 
We aimed to report the long-term follow-up after ToF repair with the transatrial–
transpulmonary approach and to determine predictors of long-term outcomes. 
Methods
Retrospective analysis of patients operated on in two tertiary referral centres. Primary 
outcome measures were: death, pulmonary valve replacement (PVR), reintervention 
for other reasons, internal cardiodefibrillator and/or pacemaker placement. Kaplan– 
Meier assessment of overall and event-free survival as well as uni- and multivariate 
analyses of risk factors for outcomes were performed.
Results
Four hundred and fifty-three patients were included. Median age at operation was: 0.6 
years (range 0–19.6) and median age at the last follow-up was 14.3 years (range 0.1–
42.1). Median age at repair decreased from 1.2 years (range 0.6–5.8) (1970–80) to 0.3 
years (range 0–4.7) (2000–12). A transannular patch (TP) was used in 65% of all patients. 
The use of a TP showed a decline from 89% in the initial years of the cohort to 64% in 
2000–12. Early mortality was 1.1% (5 patients) for the entire cohort and late mortality 
2.4% (11 patients). Overall survival for the entire cohort was 97.3% (95% CI 95.7–98.8) 
and 91.8% (95% CI 85.9–97.7) at 10 and 25 years, respectively. For patients with a TP 
(n= 294) vs non-TP (n= 159), this was 97.2% (95% CI 95.2–99.2) vs 97.5% (95% CI 95.1–
99.9) at 10-year and 91.0% (95% CI 83.9–98.1) vs 96.3% (95% CI 93.0–99.6) at 25-year 
follow-up (P= 0.958). Fifty-two patients underwent PVR, and in 5 a pacemaker was 
inserted. Event-free survival for TP versus non-TP patients was 80.2% (95 CI% 75.5–84.9) 
vs 81.7% (95% CI 75.2–88.2) at 10-year and 27.9% (95% CI 17.7–38.1) vs 78.5% (95% CI 
71.4–85.6) at 25-year follow-up (P= 0.016). In multivariate analysis, both the use of a 
TP (HR 1.705, 95% CI 1.023–2.842) and the year of surgical repair of Tetralogy of Fallot 
(HR 1.039, 95% CI 1.006–1.073) were associated with a higher probability of an event.
 
Conclusions 
ToF patients corrected with the transatrial–transpulmonary approach have good long-
term survival. PVR is a frequent event at longer follow-up, and other events are limited. 
The use of a TP is a predictor for poorer event-free outcomes, increasing the risk of 
the composite endpoint 1.7 times.
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Introduction
Surgical correction of Tetralogy of Fallot (ToF) is reported to date back as early as 1954. 
Since then major developments have resulted in excellent present-day survival in ToF 
patients, which is, however, still reduced compared to the overall population.1
Over the years the surgical approach to ToF has shifted from a repair via a right 
ventriculotomy, commonly combined with a patch in the right ventriculair outflow tract 
(RVOT), often after initial palliative shunting, to a transatrial-transpulmonary approach 
often as primary repair.1 The aim of the latter approach was to minimize the 
unfavourable side effects associated with a ventriculotomy, such as transmural 
myocardial scarring and coronary artery damage, which were thought to contribute 
to long-term impairment of right ventricular function and the risk for ventricular 
arrhythmias.2 
Long-term complications like decreased exercise intolerance, (right) heart failure, 
arrhythmias and sudden death are well-known to occur after repair of ToF.2 Pulmonary 
valve replacement (PVR) and, to a lesser extent, implantable cardiodefibrillator (ICD) 
placement are common procedures long-term after repair of ToF.
Predictors for negative long-term outcome after ToF repair have been studied 
extensively and include the amount of residual pulmonary regurgitation (PR), right 
and left ventricular size and function, myocardial tissue composition, right ventricular 
outflow function and electrical inhomogeneity.2-6 Despite extensive literature on the 
results of ToF repair, relatively limited information is available specifically on the 
long-term outcomes of the transatrial-transpulmonary approach. Many studies on 
the subject of long-term outcome of ToF repair have not focussed on the outcomes 
of this approach, have used different criteria to define the population with ToF that 
was included, or have been hampered by small patient numbers or short duration 
of follow-up.7, 8
The aims of this study were to report the long-term follow up after ToF repair with 
the transatrial-transpulmonary approach in a relatively large cohort and to determine 
predictors of long-term adverse outcome.
Patients and methods
Patients
A retrospective analysis was made of all patients that underwent ToF repair with a 
transatrial-transpulmonary approach in two tertiary referral centres in the Netherlands, 
with special attention to whether a transannular patch (TP) was used or not (non-TP). 
Data of all patients born after January 1st 1970 and who had undergone ToF repair 
were analysed. ToF was defined as ventricular septal defect with anterior deviation of 
the outflow septum, without major anomalies, requiring desobstruction of right 
ventricular outflow obstruction and closure of ventricular septal defect. Patients with 
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other diagnoses including pulmonary atresia (PA), double outlet right ventricle (DORV), 
atrioventricular septal defect (AVSD) and absent pulmonary valve syndrome (APVS) 
were excluded. Other exclusion criteria were patients whose surgical reports were not 
available, patients with insufficient follow-up data and patients who did not have a 
transatrial-transpulmonary ToF repair. 
In general, in all the years of the study, the transatrial-transpulmonary strategy 
essentially consisted of right atriotomy as first step in the approach of the VSD and the 
RVOT. As second step the main pulmonary artery was opened with a longitudinal 
incision as an approach to the pulmonary valve and the subvalvular area. Only after 
endoventricular desobstruction of the RVOT and when considered necessary by the 
attending surgeon, this incision was continued along the length of the infundibulum 
and reconstructed with a TP to create an adequate diamater of the RVOT. Patients in 
whom primarily a ventriculotomy was performed were excluded from our study. 
Patients were included if treated in the Erasmus Medical Centre (EMC), Rotterdam 
or the Radboud University Medical Centre Nijmegen (RadboudUMC), Nijmegen, the 
Netherlands.The study complies with the regulations of institutional review boards 
with regard to retrospective data collection.
Methods
Data collection 
The medical and surgical records of all patients were reviewed. Demographic 
characteristics are given in Table 1. Characteristics of the ToF repair including operative 
techniques and preoperative parameters were collected (Table 2). Postoperative 
complications were scored.
Primary outcomes were defined as death, PVR, late reoperations other than PVR, 
balloon dilatations for pulmonary stenosis (PS) and the placement of an ICD or 
pacemaker. Patient status was checked in the municipal basic administration in the 
Netherlands. Patients lost to follow-up were censored at the last known follow-up date 
according to hospital records and / or the municipal basic administration. We recorded 
and analysed the last outpatient visits for all patients in the period from 1 January 2010 
until 30 June 2012. Collected parameters were: length, weight, use of medication, QRS-
duration and QTc-time (corrected QT-time) on ECG, severity of PR, PS and RV dilatation 
on echocardiography and VO2 max, maximal work load and maximal heart rate at 
graded step-wise bicycle cardiopulmonary exercise testing. The presence of residual 
PS was recorded if a mean echocardiographic gradient of ≥16 mmHg was present. The 
severity of pulmonary and tricuspid regurgitation (TR) was assessed semi-quantitatively 
on echocardiography.9 MRI data obtained in relation to the latest outpatient visit were 
recorded. MRI volumetric data was indexed to body surface area. 
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Complications after ToF repair were defined as infection, arrhythmia, early reoperation 
(within 30 days of complete repair) , fluid retention and prolonged use of inotropic drugs 
(>48hr) 
Data analysis
Statistical analyses were performed with IBM SPSS Statistics 20 (SPSS, Inc., USA). We 
tested with a significance level of 0.05.
Data were summarized for all patients using frequencies and percentages for 
categorical variables and either mean ± standard deviation (SD) or median with range 
for numerical variables.
A student’s t-test was used to compare means between independent groups. In case 
a value did not have a normal distribution, we calculated the medians and used a (non-
parametric) Mann-Whitney test to compare these medians between the groups. We 
used a χ2 test to compare categorical variables with a normal distribution between 
independent subgroups. When a categorical value was not distributed normally, Fisher 
exact test was used to compare these variables between groups. Chi-squared 
approximation was not considered suitable when the expected values in any of the 
cells of a table are below 5. 
The probability of long-term survival and event-free survival was estimated by Kaplan-
Meier curves. A log-rank test was used to compare these curves between different 
groups.
Table 1. Patient characteristics (demographic) 
Number of patients (n=453) 
Male (n, %) 286 (63.1)
Mean duration of pregnancy (weeks) (n=290) 38.54±2.70
Mean birth weight (kg) (n=266) 2.98±0.75
Median time to diagnosis (days) (n=333) 36.00 (0-3504)
Other cardiac anomalities (n, %) 436 (96.2)
        ASD (n, %)         359 (82.3)
        PDA (n, %)         89 (20.4)
        Unicuspid pulmonary valve (n, %)         29 (6.7)
        Bicuspid pulmonary valve (n, %)         228 (52.3)
        Right aortic arch (n, %)         70 (16.1)
        Aberrant coronary origin (n, %)         22 (5.0)
Previous palliative shunts (n, %) 58 (12.8)
Mean PS gradient before repair (mmHg) 74±25 (n=224)
Data are either mean ±SD or median with range. 
Abbreviations; ASD: atrial septal defect, PDA: patent ductus arteriosus, PS: pulmonary stenosis.
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With a Cox proportional hazard analysis (forward step-wise regression method) we 
analysed whether parameters had an influence on the probability of an event. The 
seven best parameters in univariate analysis were included in the multivariate analysis. 
We composed a composite endpoint, which was defined as death, PVR, other (late: 
after 30 days after complete repair) reoperations, balloon dilatations for PS or 
pacemaker insertion.
Results
Patient characteristics
We identified 465 patients who met the inclusion criteria, as shown in Figure 1; 288 
patients from Centre 1 and 165 patients from Centre 2 were included. Twelve patients 
were excluded because they were lost to follow-up. Eleven patients had their ToF repair 
in the Netherlands but lived abroad and were lost to follow-up. In 1 patient, the follow-
up was insufficient.
Table 1 summarizes patient characteristics of the 453 patients; 63.1 % was male. In 
96.2% of the patients associated cardiac anomalies were found: secundum type atrial 
septal defect in 82.3%, patent ductus arteriosus in 20.4%, uni- and bicuspid pulmonary 
valve in respectively 6.7% and 52.3%. A coronary artery had an aberrant origin in 5% 
of the patients an 16.1% had an right aortic arch. 
Prior to TOF repair 12.8% of the patients received a palliative shunt, as shown in 
Table 1. This percentage was significantly higher in the patients who later received a 
TP compared with those who did not (15% (n= 45) versus 8 % (n= 13) (p=0.030). Mean 
PS gradient before complete repair was higher in the TP group compared to the non-
TP group (80±24 (n= 134) vs 66±25 (n= 90) mm Hg (p< 0.001). The median age at repair 
Figure 1. Flow-chart of patient enrolment
Abbreviation; ToF: Tetralogy of Fallot.
Part II  |  Chapter 7
140
of ToF was 0.6 (0-19.6) years, as shown in Table 2. Of the 453 patients, a TP was used 
in 215 (47.5%) patients, and both a TP and valvotomy were done in 79 (17.4%). In further 
analysis these 294 patients were termed the TP group. In 98 (21.6%) patients, only 
pulmonary valvotomy was performed, and in 61 (13.5%) patients no valvotomy and no 
TP were required. These patients were included as the not-TP group (n= 159). 
A total of 20 patients received an early reoperation within 30 days of ToF repair, as 
shown in Table 2. Eleven patients needed rethoracotomy due to rebleeding, 7 due to 
a residual VSD and 2 because of residual RVOT obstruction.
A trend towards decreasing median age at ToF repair over time was noted: in the 
cohort 1970-1980 median age at repair was 1.8 (0.6–5.8) years, compared with 0.3 
(0–4.7) years in the cohort 2000-12. Valvulotomy increased during the years from 0.0% 
in the cohort 1970-1980 to 48.5% in the cohort 1990-2000, with a slight decrease in the 
cohort 2000-12 to 36.3%. The use of a TP shows a reverse trend: it decreased from 
88.9% in the first cohort to 59.4% in the cohort 1990-2000, with a slight increase in the 
last cohort to 63.8%. 
A total of 77 patients (17.0%) were diagnosed with a genetic syndrome or association. 
In 28 patients this concerned trisomy 21, in 25 patients 22q11 deletion, in 7 patients 
vertebral anomalies, anal atresia, cardiac defects, tracheoesophageal fistula and/or 
esophageal atresia, renal & radial anomalies and limb defects (VACTERL) association 
and in 17 patients a range of individual gene abnormalities, syndromes or associations.
Survival and event-free survival
Sixteen patients died during follow up. This represents 3.5% of the study population. 
Early mortality (within 30 days of ToF repair) was 1.1% (5 patients), late mortality was 
2.4% (11 patients). The median age at time of death was 1.8 (0.1–32.8) years. Eight 
patients died from cardiac causes, 6 from non-cardiac causes and in 2 patients the 
cause of death was unknown. Down-syndrome was diagnosed in 3 of the deceased 
patients, 2 deceased patients had the VACTERL-association. 
The cumulative overall survival was 97.3% (95% CI 95.7–98.8) at 10 years and 91.8% 
(95% CI 85.9–97.7) at 25 years after ToF repair. Figure 2 shows the cumulative overall 
survival for patients with and those without a TP. Survival for the TP group was 97.2% 
(95% CI 95.2–99.2) at 10 years and 91.0% (95% CI 83.9–98.1) at 25 years after ToF repair, 
compared with 97.5% (95% CI 95.1-99.9) at 10 years and 96.3% (95% CI 93.0–99.6) at 
25 years in the non-TP group (p=0.958). 
The cumulative overall event-free survival was 80.7% (95% CI 76.9–84.6) at 10 years 
and 37.0% (95% CI 27.2–46.8) at 25 years after ToF repair. In Figure 3 the event-free 
survival is shown for the patients with and those without a TP. For the TP-group the 
cumulative total event-free survival is 80.2% (95% CI 75.5–84.9) at 10 years and 27.6% 
(95% CI 17.7–38.1) at 25 years; for the non-TP group it is 81.7% ( 95% CI: 75.2–88.2) at 
10 years and 78.5% (95% CI 71.4–85.6) at 25 years after ToF repair. The differences in 
event-free survival were statistically significantly different (p=0.016).
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Long-term outcomes
In Table 3, the long-term outcomes of all patients are shown. The patients are divided 
into two groups: TP (n= 294) and non-TP (n= 159). The median age at the end of the 
follow-up period for the entire cohort is 14.4 (0.1–42.1) years. There was no significant 
difference between the median age at the end of follow-up between the two subgroups.
A total of 52 patients underwent a first PVR; this was 11.5% of the study population. 
The first PVR was performed at a median of 20.2 (1.9–34.8) years after the ToF repair. 
In the TP group, 51 (17.3%) patients received a PVR, and in the non-TP group only 1 
patient (0.6%) did (p< 0.001). 
As shown in Table 3, a total of 72 (15.9%) patients needed a late reoperation other 
than PVR, 17.0% in the TP group and 13.8% in the non-TP goup (p= not significant). 
Reoperations performed were infundibulectom (desobstruction of the RVOT) combined 
with reconstruction of the pulmonary artery in 3.3% of all patients. Isolated 
infundibulectomy (RVOT desobstruction) was performed in 4.9% of all patients and 
isolated reconstruction of the pulmonary was performed in 1.8% of all patients.
Clinical state at latest evaluation
In Table 4, information regarding the last outpatient visit between 2010 and 2012 is 
given. Three hundred and sixty patients were seen in that setting in this period, 49 of 
whom had had a PVR.
Abbreviation; ToFr: Tetralogy of Fallot repair.
Figure 2. Kaplan Meyer curve for overall survival 
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Patients in the PVR group were significantly older than those in the non-PVR group: 
27.7 (10.9–42.1) compared with 11.7 (0.3– 36.1) years (p< 0.001). The median age at 
follow-up post-ToF repair was also significantly higher in the PVR group.
Electrocardiography was performed in 341 patients and QRS duration was assessed 
in 324 patients. A significant difference (p< 0.001) was found in mean QRS duration 
between the two groups. In the PVR group, the mean QRS duration was 136 ± 25 ms, 
compared with 119 ± 25 ms in the non-PVR group. The mean QRS duration in all 
patients was 121 ± 26 after a mean follow-up of 12 years, and 5 patients had a QRS 
duration of more than 180 ms.
In 298 patients, an echocardiogram was performed. Seventeen percent of patients 
had no RV dilatation; mild dilatation was found in 32% of patients, moderate dilatation 
in 48% and severe dilatation in 2%. Echocardiography did not show statistically 
significant differences for RV size between the TP and non-TP groups. 
A more than minimal residual PS gradient was found in 70% of the patients. Patients 
in the PVR group had significantly more PS than those in the non-PVR group: 90.0% 
compared with 66.2% (p=0.009).
In 246 patients, TR was noted at echocardiography. No TR was found in 21.5% of the 
patients, mild TR in 67.4% and moderate TR in 10.6%. In 0.4% of the patients, severe 
TR was found. Two patients with moderate TR underwent a PVR and the patient with
severe TR had a pacemaker due to a third-degree heart block.
Abbreviation; ToFr: Tetralogy of Fallot repair.
Figure 3. Kaplan-Meyer curve for event-free survival. 
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Predictors for negative outcome
Table 5 presents the results of Cox proportional hazard analysis of the most important 
parameters for the combined event. Univariate analysis showed that the use of a TP 
during ToF repair was associated with a higher probability of an event (HR 1.631, 95% 
CI 1.077–2.471). Also, postoperative complications after ToF repair (HR 1.506, 95% CI 
1.035–2.191), year of TOFr (HR 1.034, 95% CI 1.007–1.061) and age at TOFr (HR 0.987, 
95% CI 0.976–0.997) were associated with a higher risk. The parameters Hb level before 
ToF repair, male gender and the presence of a genetic disorder did not show a 
significant association in univariate analysis.
In multivariate analysis, both the use of a TP (HR 1.705, 95% CI 1.023–2.842) and year 
of TOFr (HR 1.039, 95% CI 1.006–1.073) were associated with a higher probability of an 
event.
In hazard analysis for the event death, both uni- and multivariate analyses did not 
show significant associations. 
Discussion 
This study shows that overall, ToF patients corrected with the transatrial–
transpulmonary approach have excellent survival rates. Over several decades, the 
operative mortality (5 of 453 patients) was 1.1%, and 25-year overall survival rate was 
92%, more specifically 91% in the TP group and 96% in the non-TP group. In the time-
span we studied, there was a clear trend towards repair at younger age and a decrease 
in the use of transannular patching of the RVOT, confirming other reports on this 
subject.
Whereas 10- to 15-year survival has been documented frequently in various cohorts 
of ToF, relatively few studies have reported on 25-year survival after ToF repair. In 
Table 5. Cox-regression combined event
Univariate Multivariate
HR 95% CI HR 95% CI
Transannular patch 1.631* 1.077-2.471 1.705* 1.023-2.842
Complications after TOFr 1.506* 1.035-2.191 - -
Year of TOFr 1.034* 1.007-1.061 1.039* 1.006-1.073
Hb level before TOFr 1.013 0.930-1.103 - -
Age at TOFr (months) 0.987* 0.976-0.997 - -
Gender 0.873 0.611-1.247 - -
Genetic disorder 0.800 0.480-1.334 - -
*Statistically significant factor with P-value < 0.05.
Abbreviation; ToFr: Tetralogy of Fallot repair.
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2008, a group from Toronto reported a 25-year survival of ≈90% for ToF without PA, 
DORV, AVSD or branch PS, in patients born before 1984.10 Recently, 25-year overall 
survival in a large Korean cohort was reported to be 93%, with statistically better 
survival for transatrial and non-transannular approaches.11 The improvements in 
survival, in part, relate to improved early mortality.10 While long-term deterioration 
of clinical state and the need for reinterventions are commonly recognized, it is less 
clear whether the mortality risk increases with time.10 Considering the low rate of 
late mortality in our patients, this could not be assessed from our data. Of note, only 
3.5% of the patients died, many of whom had associated genetic abnormalities. Most 
of these patients were relatively young at time of death. The number of patients who 
died late in follow-up in our cohort is very low. The explanation probably lies in the 
fact that with the surgical approach as described, these patients are in good clinical 
condition after ToF repair and apparently have a good prognosis with regard to 
survival for the observed period.6, 12
Timely reintervention is another factor to consider. In fact, there is a clear increase 
of reinterventions with time, particularly after 15-year follow-up. There was a clear 
difference in event-free survival for the TP versus the non-TP group. Multivariate 
analysis demonstrated that the use of a TP in the setting of transatrial– transpulmonary 
approach was associated with a 1.7 times higher risk of the composite endpoint of 
death, PVR, reoperation for other reasons, balloon dilatation for PS or pacemaker 
placement in our patients. This confirms findings from earlier reports in combined 
cohorts.2 Since the use of a TP depends on the anatomy and haemodynamics at initial 
repair and often cannot be avoided, this emphasizes the importance of comparison 
of results among clearly defined and highly comparable populations.5, 10, 13 
Event-free survival differs significantly from overall survival in most series. The 
majority of reinterventions are related to the long-term effects of PR and particularly 
consist of PVR. At a median follow-up of 15 years, 17% of our patients who had 
transannular patching of their RVOT at the initial repair had PVR; this compares 
favourably with similar reports in the literature.10, 11 Patients without a TP had better 
event-free survival. These types of observations resulted in attempts to avoid 
transannular patching and avoid damage1-24 to the pulmonary valve and/or 
infundibulum.1, 8 
Recently, Bove et al.8 demonstrated in an experimental setting that of the available 
alternatives, extensive transannular patching results in the most severely dilated and 
functionally impaired right ventricles. Whether the alternative TP-avoiding strategies 
will result in improved (event-free) survival of patients is to be seen; in earlier studies, 
this could not be demonstrated.5, 8 The trade-off of restrictive strategies aimed to avoid 
residual PR may be an increased reoperation rate for residual stenosis. Preliminary 
data from a large registry study may point towards an increased risk of arrhythmias 
and sudden death in patients with residual RV outflow obstruction and RV hypertrophy.17
The long-term problems related to chronic PR are well known and include right 
ventricular dilatation, impaired right and left ventricular function and increased risk of 
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arrhythmias. Risk factors for late problems related to PR have been identified and 
include the amount of residual PR, right and left ventricular size and function, 
myocardial tissue composition, right ventricular infundibular and outflow tract function, 
right atrial function and electrical inhomogeneity.2-5, 22 Many of these risk factors cannot 
be fully avoided, despite individualized operative strategies aimed at preservation of 
RVOT function.
A remarkable finding of our study is the lack of improvement in exercise performance, 
pro-arrhythmic ECG parameters, ventricular size and an increase in RVOT stenosis in 
patients after PVR. Although this data must be interpreted with caution considering 
the limited number of observations for some parameters, this questions the timing 
and effects of PVR. Considerable debate exists with regard to indications for PVR. 
Current guidelines include factors from history, ECG signs of increased electrical 
inhomogeneity and haemodynamic factors related to residual RVOT problems.17 These 
factors include older age at repair and ECG parameters, particularly QRS duration. 
Recommendations with regard to RV size provide a wide range of end-diastolic 
dimensions, from ±140 to ±180 ml/m2 body surface area.15, 16 In this size range of the 
RV, normalization of systolic RV function after restoration of pulmonary valve 
competency and resection of the dilated RV outflow has been demonstrated. Whether 
this results in improved long-term survival has not yet been established.18 Recent data 
suggest that patients with intermediate RV dilatation (132 ± 9 ml/m2) and severe PR 
(40 ± 3%) are at low risk of significant progression of RV size in the short term, suggesting 
that some delay in PVR may be acceptable in this group.23 PVR may also induce some 
degree of RVOT stenosis, as was noted in our patient group. This could be caused by 
the use of a relatively small homograft or by deterioration of the homograft.24
The lack of change in important pro-arrhythmic parameters, such as QRS duration 
and QTc time, reflects earlier observations.18 In a study that has been criticized for 
problems related to adequate matching of the groups involved, Harrild et al.18 could 
not demonstrate a beneficial effect of PVR with regard to post-PVR occurrence of 
ventricular tachycardia or death. The implications of these observations are that current 
long-term treatment strategies may require modification.17
A common indication for reintervention after ToF repair is prevention or treatment 
of haemodynamically important arrhythmias. The burden of arrhythmias is considerable 
in these patients, particularly in the adult age range. Atrial arrhythmias occur frequently, 
in up to one-third of the patients.20 Pacemaker implantation, for bradycardia and 
tachycardia/bradycardia syndromes, is required in up to 8%.20 Haemodynamic factors 
and prior surgeries are among the most important risk factors. In our population, 
pacemaker implantation was relatively infrequent and was required only in the TP 
group.
More than moderate TR may be another indication for reintervention. The occurrence 
of more than minimal TR in our series was limited and comparable/compares 
favourably with other recent reports. Important TR may relate to intrinsic valve 
abnormalities, traction on the tricuspid annulus or damage to tricuspid structures 
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during repair or to RV dilatation in the setting of impaired RV function.19 In recent series, 
late TR did not differ between transatrial and transventricular approaches to ToF repair.
Since the 1970s, less than 10% of ToF repairs in our institutions have been performed 
with the transventricular approach, which has hampered a direct comparison between 
results of transatrial and transventricular repairs. Recent single- and multicentre data 
suggest that both techniques can be used successfully. Ventriculotomy has been 
thought to contribute to long-term impairment of right ventricular function and the 
risk of ventricular arrhythmias. Whether the transatrial–transpulmonary approach has 
actually resulted in long-term benefits for the patients is still a subject of debate. The 
transatrial–tranpulmonary approach does not use a ventriculotomy in the body of the 
RV and a limited, if any, incision of the RV outflow tract. Comparison of results is often 
difficult, since different approaches in time, different anatomical variants and different 
age groups have been included in different studies. Furthermore, the long-term effects 
of the approach to VSD closure and of RV outflow desobstruction are hard to distinguish. 
Lindberg et al.5 in a single-centre study of 570 patients did not find any difference in 
long-term outcomes of transatrial versus transventricular repair. Any transannular 
incision increased the risk of reinteventions, but did not impact on long-time survival.5, 
11 In the series of Alexiou et al.14 a significantly higher reintervention rate at 10- and 
20-year follow-up was noted in the atrial versus the transventricular approach, 
particularly for RV outflow obstruction, for reasons that were not clear to the authors. 
This has not been a common observation.5, 6 Data from the Society of Thoracic Surgeons 
Database and of the European Association for Cardio-Thoracic Surgery Congenital 
Database have shown that both approaches continue to be used widely, with excellent 
early results and ventriculotomy and TP as the most prevalent type of operation.3, 4 A 
temporal trend towards the transatrial approach has been reported in the most recent 
studies.3, 21
Study limitations
A limitation of this study is the retrospective design, resulting in a considerable number 
of missing values. Another limitation was the small number of patients with an event. 
Furthermore, a direct comparison of different surgical approaches could not be made. 
Conclusions
ToF patients corrected with the transatrial–transpulmonary approach have good long-
term survival. Clinical condition after ToF repair is good; PVR is a frequent event at 
longer follow-up, other events are limited in number. The use of a TP at ToF repair is 
a predictor for poorer event-free outcome; it almost doubles the risk of the composite 
endpoint of death, reoperation, balloon dilatation, pacemaker placement or PVR. 
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Abstract
Objectives
Our goal was to report the long-term serial follow-up after transatrial–transpulmonary 
repair of (TOF) and to describe the influence of the timing of the repair on outcome.
Methods
We included all patients with TOF who had undergone transatrial-transpulmonary 
repair between 1970 and 2012. Records were reviewed for patient demographics, 
operative details and events during the follow-up period (death, pulmonary valve 
replacement, cardiac reinterventions and hospitalization/intervention for arrhythmias). 
In patients with elective early primary repair of TOF after 1990, a subanalysis of the 
optimal timing of TOF repair was performed.
Results
A total of 453 patients were included (63% male patients; 65% had transannular patch); 
261 patients underwent primary elective repair after 1990. The median age at TOF 
repair was 0.7 years (25th-75th percentile 0.3–1.3) and decreased from 1.7 to 0.4 years 
from before 1990 to after 2000, respectively (p<0.001). The median follow-up duration 
after TOF repair was 16.8 years (9.6–24.7). Events developed in 182 (40%) patients. In 
multivariable analysis, early repair of TOF (<6 months) (hazard ratio [HR] 3.06; p<0.001) 
and complications after TOF repair (HR 2.18; p=0.006) were found to be predictive for 
an event.
In a subanalysis of the primary repair of TOF after 1990, the patients (n= 125) with 
elective early repair (<6 months) experienced significantly worse event-free survival 
compared to patients who had elective repair later (n=136). In multivariable analysis, 
early repair (HR 3.00; p=0.001) and postoperative complications (HR 2.12; p=0.010) 
were associated with events in electively repaired patients with TOF.
Conclusions
Transatrial-transpulmonary repair of TOF before the age of 6 months may be associated 
with more events during the long-term follow-up period. 
Optimal timing of primary TOF repair
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Introduction
Since the first repair of Tetralogy of Fallot (TOF) in 1954, the surgical approach and the 
timing of the operation have changed. Initially, a right ventricular (RV) incision with a 
patch across the RV outflow tract (RVOT) was performed. In the current era, the primary 
transatrial-transpulmonary approach with the intention to minimize the use of a 
transannular patch (TP) is commonly used.1-3 The goal of this transatrial-transpulmonary 
approach is to preserve the integrity of the pulmonary annulus and to avoid a 
ventriculotomy. This approach potentially reduces myocardial scarring and ventricular 
dilatation.1, 2 These changes in surgical techniques together with improvements in 
cardiopulmonary bypass techniques and perioperative management have been 
associated with increased survival rates.1, 2
The age at which TOF is repaired has decreased over time.2-5 However, there is no 
consensus regarding the optimal timing of the primary repair of TOF.2, 4, 6, 7 Early primary 
repair of TOF is advocated by some because it minimizes the time at risk for cyanotic 
spells, hypoxia and RV pressure overload.6, 8 The potential disadvantages of early repair 
of TOF are a longer stay in the intensive care unit, increased risk of reinterventions and 
more frequent use of a TP.7, 9-12
We previously published results of a relatively large TOF cohort operated on by the 
transatrial-transpulmonary approach.2 
Considering the ongoing discussion on the timing of primary repair of TOF 2, 13, the 
current updated serial analysis of this identical cohort had 2 objectives: first, to 
investigate the current freedom from events and second, to investigate the potential 
influence of the timing of primary TOF repair on long-term outcomes. 
Methods
Patients
All included patients had undergone transatrial-transpulmonary repair of TOF before 
June 2012 and were born after January 1, 1970.2 We excluded patients with pulmonary 
atresia, absent pulmonary valve syndrome, double outlet RV and atrioventricular septal 
defect, with missing surgical reports or in whom a primarily trans-ventricular approach 
was used. The local ethics committees approved this retrospective study and waived 
informed consent.
Events
The medical records of all patients were reviewed through December 2017. Cardiac 
events during the follow-up period were recorded until the patient’s latest visit to the 
outpatient clinic. All patients were followed according to regular follow-up protocols. 
The latest information for these follow-up visits was obtained for >85% of patients 
within 4 years before data acquisition. For mortality rate analysis, each patient’s status 
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was checked in municipal administrative records. Early complications after TOF repair 
were defined as complications within 30 days or during the hospital stay.14 After TOF 
repair, the following early postoperative complications were recorded: infection, 
arrhythmia, chylothorax, post-pericardiotomy syndrome, fluid retention, prolonged 
use of inotropic drugs (>48 h), early reoperation and early death. Long-term events 
were defined as all-cause mortality, pulmonary valve replacement (PVR), cardiac 
reoperations, catheter-based reinterventions and arrhythmias that required 
intervention and/or hospitalization. Patients lost to follow-up were censored at the last 
known follow-up date.
Elective repair of Tetralogy of Fallot 
A subgroup analysis was performed regarding the optimal timing of primary TOF repair 
in electively repaired patients. TOF repair before the age of 6 months was considered 
early; repair when the patient was older than 6 months was considered late. For this 
analysis, patients with a palliative shunt, a duct-dependent circulation and a balloon 
pulmonary valvuloplasty or RV outflow stent prior to TOF repair were excluded. Also, 
patients who had a non-elective operation, defined as a TOF repair within 72 h of 
worsening cyanosis or cyanotic spells, were excluded.
Prior to the year 2000, the 2 centres in this study had the same surgical practice 
regarding the timing of TOF repair, and the age at TOF repair did not differ between 
the centres. After the year 2000, one of the centres opted for earlier primary TOF repair 
around the age of 3 months. This practice resulted in a difference in median age at 
TOF repair in the cohort after 2000. In the Netherlands, referral to a specific centre is 
based mainly on where the patient lives. 
Statistical analyses
Continuous variables with a normal distribution were summarized as the mean 
(standard deviation). Variables with a non-normal distribution were presented as the 
median (25th-75th percentiles). Differences between groups were analysed using the 
Student t-test or the Mann-Whitney U-test. Categorical variables were presented as 
numbers and percentages and were evaluated by the χ2 test.
The incidence of the events over time was evaluated according to the Kaplan-Meier 
method; differences between groups were evaluated using the log-rank test. The Cox 
proportional hazard analysis was used to determine whether factors had an influence 
on the probability of the event. We found no deviations of the proportional hazards 
assumption by inspecting the plots of log minus log survival functions. Potential factors 
associated with events—selected from the literature—were explored in univariable 
Cox regression models. All factors from the univariable analyses were included in the 
multivariable backward model in which a p-value of <0.157 was required for the factor 
to be retained in the model. All analyses were performed using SPSS version 25.0 (IBM 
Corp. Armonk, NY USA). Two-sided p-values <0.05 were considered statistically 
significant.
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Results
We included 453 patients. The median age at TOF repair was 0.7 (0.3–1.3) years.2 A TP 
was used in 294 (65%) patients (Table 1). The total analysis comprised 7505 patient-
years (5118 TP; 2387 non-TP). The maximum follow-up after TOF repair was 40.6 years, 
with a median follow-up of 16.2 (9.2–22.8) years. 
Mortality rate
The overall mortality rate was 4% (14 TP; 5 non-TP); the early mortality rate was 2%; 
late deaths occurred in 10 patients. For the entire cohort, the overall survival rate was 
97% at 10 years (standard error [SE] 1%); 96% at 20 years [SE 1%]; 95% at 25 years [SE 
1%] and 93% at 30 years [SE 2%], with no significant differences in survival between 
patients who had a TP and those who did not (Figure 1). 
Eleven patients died of cardiac causes; 6 patients, of non-cardiac causes; and in 2 
patients, the cause of death was unknown. Since our previous analysis, 3 patients died, 
1 of cardiac cause.2
Events during the follow-up period
After TOF repair, 270 events developed in 182 (40%) patients; 55 (12%) patients 
developed 2 or more events. The event-free survival rate was 74% at 10 years (SE 2%), 
62% at 20 years (SE 3%) and 34% at 30 years (SE 4%). Non-TP patients experienced a 
better event-free survival rate (p<0.001) (Figure 1). However, events developed earlier 
in the non-TP group at a median of 2.9 (0.5–7.6) versus 6.9 (2.1–19.9) years after TOF 
repair (p=0.02) (Table 1).
Abbreviations; TOF: Tetralogy of Fallot; TP: transannular patch.
Figure 1. (A) Overall survival; (B) event-free survival after TOF repair. 
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A total of 88 (19%) patients received a PVR: 29% in the TP group versus 1% in the 
non-TP group (p<0.001). The PVR-free survival rate was 96% at 10 years (SE 1%), 83% 
at 20 years (SE 2%) and 48% at 30 years (SE 5%) after TOF repair. Since our previous 
analysis, 36 patients received a first PVR. 
Excluding PVR, other late reoperations were performed in 58 (13%) patients, 6 more 
since the previous analysis. The main indication for late reoperations was residual 
RVOT obstruction and trunk or branch pulmonary stenosis (PS) in 47 patients. Other 
reoperations were for a ventricular septal defect (n= 4), a ventricular septal defect and 
RVOT obstruction or PS (n= 5) and other causes (n= 2). 
A total of 23 percutaneous interventions for valvular PS and 33 for branch PS were 
performed in 38 (8%) patients. Eighteen (4%) patients needed percutaneous 
interventions for valvular PS; 18, for branch PS (4%); and 2 patients needed both. In 3 
patients a stent was implanted in the RVOT prior to PVR and an aorta-pulmonary 
collateral was closed in 1 patient. 
Late after TOF repair, 5 patients received a pacemaker and 1 patient, an implantable 
cardioverter defibrillator due to heart failure. Two patients needed a catheter ablation 
for ventricular arrhythmias; 2 patients needed a catheter ablation for atrial flutter; and 
1 patient needed an ablation for Wolf-Parkinson-White syndrome. One patient was 
hospitalized due to a self-limiting arrhythmia.
Early versus late primary repair of Tetralogy of Fallot
Figure 2 and Table 2 show the decrease in age at TOF repair. Before 1990, the median 
age at TOF repair was 19.5 (9.1–48.4) months compared to 6.5 (3.5–11.5) months after 
1990 (p<0.001). Likewise, patients in the 1990-1999 cohort were significantly older at 
TOF repair compared to those in the 2000-2012 cohort: 9.9 (5.3–15.7) versus 4.2 (3.0–
10.1) months (p<0.001). Patients in the youngest cohort at TOF repair (2000-2012) 
experienced the worst event-free survival rate (Figure 3). There is a strong, significant 
correlation between weight and age at TOF repair (r=0.924; p<0.001).
To explore the potential influence of timing of TOF repair on outcomes, we performed 
a subanalysis of patients who underwent primary elective TOF repair after 1990 (n=261). 
The patient characteristics and outcomes of the primary elective TOF repair group are 
shown in Table 3. A TP occurred significantly more often in the early repair group 
compared to the late repair group: 64.0% versus 51.5% (p=0.046).
Prior to TOF repair, no differences in oxygen saturation were observed between the 
total early repair and late repair groups. The median echocardiographic RVOT velocity, 
indicating the gradient, was slightly higher in the early repair group compared to the late 
repair group: 4.6 (4.0–5.0) versus 4.3 (4.0–4.7) m/s (p=0.047). A shorter interval between 
the echocardiogram before surgery and the TOF repair was observed in the early repair 
group compared to the late repair group: 33 (17–48) versus 67 (35–110) days (p<0.001).
Despite a significantly shorter median follow-up period in the early repair group, 
significantly more events developed in the early repair group (37% vs 20%; p=0.003). 
A total of 30 patients received a PVR: 8.8% in the early repair group versus 13.9% in 
the late repair group (p=0.24). The overall PVR-free survival rate in the primary elective 
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TOF repair group was 97% at 10 years (SE 1%), 85% at 20 years (SE 3%) and 66% at 25 
years (SE 6%). The reported difference in events was mainly driven by late reoperations 
other than PVR (n=27), 22 (17.6%) in the early repair group versus 5 (3.7%) in the late 
repair group (p<0.001). The main reason for late reoperation other than PVR was 
residual RVOT obstruction and trunk or branch PS in 24 patients. In 1 patient, a residual 
VSD was closed and the trunk PS was relieved; in 1 patient a VSD was closed and in 1 
patient the patent ductus arteriosus was closed. Figure 4 shows that patients in the 
late repair group had a significantly better event-free survival rate (p<0.001).
Abbreviations; TOF: Tetralogy of Fallot; TP: transannular patch.
Figure 2. Median age at TOF repair over time. 
Table 2. Characteristics of repair of Tetralogy of Fallot over time
TOF repair 
before 19901
TOF repair 
1990-20002
TOF repair 
>20003
P-value1-2* P-value2-3*
Number of patients (n, %) 81 (17.9) 165 (36.4) 207 (45.7)
Median age at TOF repair (months) 19.5 (9.1–48.4) 9.9 (5.3–15.7) 4.2 (3.0–10.1) <0.001 <0.001
Previous balloon dilatation (n, %) 0 (0.0) 1 (0.6) 5 (2.4) 1.00 0.23
Previous palliative shunt (n, %) 9 (11.1) 23 (13.9) 24 (11.6) 0.54 0.50
Transannular patch (n, %) 64 (79.0) 98 (59.4) 132 (63.8) 0.002 0.39
Early reoperation (n, %) 9 (11.1) 6 (3.6) 5 (2.4) 0.021 0.55
Early death (n, %) 2 (1.2) 2 (2.5) 5 (2.4) 0.600 0.47
*A p-value of <0.025 can be considered statistically significant after the Bonferroni correction.
Results are given as mean (standard deviation), as median (25th-75th percentile) or as counts (percentages).
Abbreviation; TOF: Tetralogy of Fallot.
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Predictors for events
In Table 4, the Cox proportional hazard analysis is shown for all patients (n= 453). In 
univariable analysis, TP, postoperative complications, early TOF repair and year of TOF 
repair were found to be predictive for events. Multivariable analysis showed that 
patients were significantly more likely to experience an event if they had an early TOF 
repair (HR 3.06, CI 1.67–5.61) or a postoperative complication (HR 2.18, 95% CI 1.25–
3.83). 
Table 4 shows the Cox proportional hazard analysis for the patients who underwent 
primary elective TOF repair after 1990 (n=261). Multivariable analysis showed that 
patients were significantly more likely to experience an event if they had an early TOF 
repair (HR 3.06, 95% CI 1.67–5.61) or postoperative complications (HR 2.18, 95% CI 
1.25–3.83).
In the primary elective repair group, female patients experienced a worse event-free 
survival rate (p=0.010). No gender differences were observed in the median age at TOF 
repair, degree of RVOT obstruction (RVOTO) before TOF repair or the use of a TP. There 
was also no significant difference in weight at TOF repair in male versus female patients. 
In the overall patient group, no difference in the event-free survival rate between 
gender was observed. 
Abbreviation; TOF: Tetralogy of Fallot.
Figure 3. Event-free survival for the different surgical decades. 
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Table 3. Patient, surgical and outcome characteristics for primary elective repair of Tetralogy of Fallot after 
1990. 
Early TOF repair 
(n=125)
Late TOF repair 
(n=136)
P-value
Patient and surgical characteristics
TOF repair after 2000 (n,%) 94 (75.2) 54 (39.7) <0.001
Male (n, %) 76 (60.8) 90 (66.2) 0.37
Birth weight (kg) 3.2 (2.6–3.7) (n=80) 2.9 (2.5–3.5) (n=67) 0.094
22q11 deletion (n,%) 14 (11.2) 8 (5.9) 0.18
Trisomy 21 (n,%) 4 (3.2) 11 (8.1) 0.075
Age TOF repair (years) 0.29 (0.23–0.39) 0.95 (0.68–1.43) <0.001
RVOT gradient before TOF repair (m/s) 4.6 (4.0–5.0) (n=116) 4.3 (4.0–4.7) (n=105) 0.047
    Time between repair and presurgical
    echocardiogram (days)
    33 (17–48) (n=16)     67 (35–110) (n=105) <0.001
Oxygen saturation at TOF repair (%) 95 (85–99) (n=73) 91 (85–98) (n=54) 0.80
Weight at TOF repair (kg) 5.3 (4.6–6.2) (n=121) 8.6 (7.4–9.6) (n=133) <0.001
Aortic cross-clamp time (min) 66 (47–90) (n=65) 90 (61–115) (n=109) <0.001
TP (n,%) 80 (64.0) 70 (51.5) 0.046
Valvulotomy (n,%) 33 (26.4) 70 (51.5) <0.001
ICU stay (days) 3.0 (2.0–4.0) (n=20) 3.0 (2.0–3.0) (n=117) 0.85
Postoperative complications (n,%) 28 (22.4) 19 (14.0) 0.11
Early reoperation (n,%) 4 (3.2) 2 (1.5) 0.30
Early death (n,%) 4 (3.2) 1 (0.7) 1.00
Gradient RVOT after TOF repair (m/s) 2.7 (2.0–3.3) (n=99) 2.5 (2.2–3.2) (n=99) 0.71
    Time between TOF repair and post- 
     surgical echocardiogram (days)
    7 (6–8) (n=99)      7 (6.5–9) (n=99) 0.058
Outcomes during follow-up
Age at end of follow-up (years) 12.5 (7.1–17.2) 18.8 (11.8–23.8) <0.001
   Time after TOF repair (years)     12.1 (6.8–16.8)       18.0 (10.6–22.4) <0.001
Patients with events (n,%) 46 (36.8) 28 (20.6) 0.004
   Time after TOF repair (years)       2.7 (0.8–10.0)       9.6 (2.5–16.0) 0.022
Deaths (n,%) 5 (4.0) 1 (0.7) 0.107
PVR (n,%) 11 (8.8) 19 (13.9) 0.24
    Time after TOF repair (years)       15.8 (12.4–19.5)       14.6 (7.7–22.0) 0.97
Other late reoperations (n,%) 22 (17.6) 5 (3.7) <0.001
   Time after TOF repair (years)       2.8 (1.3–7.1)       3.1 (1.2–5.8) 0.98
HC intervention for PS (n,%) 12 (9.6) 7 (5.1) 0.23
Pacemaker (n,%) 1 (0.8) 0 0.48
ICD (n,%) 0 (0) 0 (0) -
Results are given as mean (standard deviation), as median (25th-75th percentile) or as counts (percentages).
Abbreviations; TOF: Tetralogy of Fallot; RVOT: right ventricular outflow tract; TP: transannular patch; ICU: 
intensive care unit; PVR: pulmonary valve replacement; HC: heart catheterization; PS: pulmonary stenosis, ICD: 
implantable cardioverter defibrillator.
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Discussion 
This study is one of the largest describing several decades of serial follow-up in 
transatrial-transpulmonary repair in patients with TOF. Our main findings are that 
survival is good, but long-term morbidity may increase in patients who have an early 
repair. Furthermore, long-term morbidity after transatrial-transpulmonary TOF repair 
remains high. Compared to our previous analysis of the same cohort (2015), longitudinal 
follow-up showed an increase of 0.7% (n=3) in the mortality rate and 7.9% (n=36) of 
PVR over a 3.5-year period. 
Timing of repair of Tetralogy of Fallot 
The debate regarding the optimal timing of primary TOF repair is ongoing, and the 
data on this topic with sufficient follow-up duration are relatively scarce.4, 6, 7, 15
Our study stands out because of the relatively long follow-up period.12, 16-18 In 
agreement with much of the literature, we observed a significant decrease in the 
median age at TOF repair over time.2-5 Remarkably, patients in our 2000-2012 cohort 
with the lowest age at TOF repair (4.2 months) experienced the worst event-free 
survival. 
We analysed the whole group (n= 453) and the electively repaired patients after 1990 
(n= 261) separately. For this analysis we excluded patients with previous palliation or 
Abbreviation; TOF: Tetralogy of Fallot.
Figure 4. Event-free survival for early versus late primary elective TOF repair after 1990. 
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with nonelective surgery, because they probably reflect the more severe spectrum of 
TOF. In the subanalyses of elective primary TOF repair, patients with early repair 
received more TPs and experienced significantly worse event-free survival rates 
compared to patients with late primary TOF repair. We assessed relevant preoperative 
clinical parameters that might have affected this outcome. The degree of RVOTO was 
slightly higher in the early repair group. This result might indicate a somewhat more 
severe phenotype in the early repair group. On the other hand, considering the longer 
time between assessment of the RVOTO and TOF repair in the late repair group, it is 
possible that there was a larger increase of the RVOTO after assessment in the late 
repair group. Postoperative data indicated similar relief of RVOTO in both groups (RVOT 
velocities 2.7 [2.0–3.3] vs 2.5 [2.2–3.2] m/s; p=0.71). However, during follow-up, late 
reoperations, usually for residual RVOTO, were significantly more prevalent in the early 
repair group. Cunningham18 also observed that, despite similar residual RVOTO of <20 
Table 4. Predictors for the composite end point for all patients and for patients with an elective primary 
Tetralogy of Fallot repair after 1990
Univariable Multivariable
Hazard 
ratio
95% CI P-value Hazard 
ratio
95% CI p-value
All patients (n=453)
Female 1.22 0.90 to 1.64 0.20 -
Centre 1.27 0.91 to 1.79 0.16 -
22q11 deletion 0.82 0.40 to 1.67 0.59 -
Year of TOF repair 1.02 1.00 to 1.05 0.026 -
TOF repair <6 months 1.87 1.37 to 2.54 <0.001 3.06 1.67 to 5.61 <0.001
RVOT obstruction at TOF repair (m/s) 1.31 0.98 to 1.73 0.065 -
TP 2.18 1.52 to 3.13 <0.001 -
Complications after TOF repair 3.03 2.21 to 4.15 0.017 2.18 1.25 to 3.83 0.006
Elective primary repair patients (n=261)
Female 1.81 1.15 to 2.87 0.011 -
Centre 1.55 0.94 to 2.56 0.086 -
22q11 deletion 1.39 0.66 to 2.89 0.39 -
Year of TOF repair 1.08 1.03 to 1.13 0.001 -
TOF repair <6 months 2.85 1.76 to 4.64 <0.001 3.00 1.61 to 5.60 0.001
RVOT obstruction at TOF repair (m/s) 1.26 0.90 to 1.76 0.19 -
TP 1.86 1.12 to 3.10 0.017 -
Complications after TOF repair 3.30 2.01 to 5.40 <0.001 2.12 1.20 to 3.78 0.010
Results are given as mean (standard deviation), as median (25th-75th percentile) or as counts (percentages).
Abbreviations; CI: confidence interval; RVOT: right ventricular outflow tract; TOF: Tetralogy of Fallot; TP: 
transannular patch.
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mm Hg after TOF repair, reinterventions were more common when the TOF repair was 
performed before 55 days of age. Possibly there is a difference in growth of the (branch) 
pulmonary arter(y)(ies) between patients operated on early or later in life18 or a patient-
size difference in the size of the TP, resulting in more PR/PS and the subsequent need 
for reinterventions. 
Some researchers observed that repair before the age of 28 days is associated with 
more TPs, longer hospital stay and increased mortality rate.7, 17, 19, 20 Studies in patients 
beyond the neonatal age found that an older age at complete TOF repair is associated 
with shorter hospital stays and lower mortality rates.16, 17, 20-22 Dorobantu 16 observed, 
in a large (n=1662) study with a median follow-up of 4.7 years, that at 12 years the 
mortality rate was higher when repair was performed before the age of 60 days. 
However, these studies often have limited follow-up duration. In our electively repaired 
cohort, the median follow-up after TOF repair was 13.9 years. 
It is hard to determine whether our findings relate to more severe anatomical defects 
and therefore the need for the earlier TOF repair. However, the combined findings 
from the literature may indicate that it might be better to postpone primary elective 
TOF repair in asymptomatic patients with TOF until at least 6 months of age. Recently, 
interest has increased in transcatheter RVOT palliation prior to primary repair, 
potentially postponing repair in symptomatic patients with TOF.16, 17, 20 
Survival 
Recent observations point towards increased survival after TOF repair performed in 
past decades, which is mainly driven by the decrease in early mortality rates.2, 5, 11, 23 We 
observed an overall survival rate of 96% at 20 years and of 93% at 30 years. Relatively 
few studies have reported the 25- to 30-year survival rates of contemporary surgical 
approaches. D’Udekem.11 described a 97% 25-year survival rate in a large cohort 
operated on after 1980, with only 16 patients followed up 25 years after TOF repair. 
Park 5 described, in a cohort operated on after 1986, a 25-year survival rate of 93%. In 
our study, the overall survival rate was higher, which may relate in part to differences 
in the composition of the diagnoses of the populations.5
Morbidity
Morbidity remains high after TOF repair, with worse survival in patients who have a 
TP. The use of a TP damages the integrity of the pulmonary valve and the RVOT, causing 
PR.13, 23 Long-term exposure to moderate to severe pulmonary regurgitation (PR) causes 
RV dilatation, impaired ventricular function and arrhythmias that often require 
reinterventions.1, 13, 23 Over time, attempts were made by surgeons to avoid or minimize 
the use of a TP, and new valve-sparing techniques were developed.3 In patients with 
narrow RVOTs, a TP might be necessary and cannot be avoided, but TP use also differs 
among surgeons.24 
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Gender 
In patients who had elective primary repair after 1990, we observed a significantly 
better event-free survival in male compared to female patients. The reason for this is 
not entirely clear. We did not observe this difference in the overall cohort. Gender 
differences in PS or valve sizes have not been reported. In older patients with TOF, 
male gender was associated with ventricular tachyarrhythmias, a larger cardiac mass, 
biventricular volumes and peak VO2, but a lower ejection fraction.
25, 26 These factors 
may affect long-term morbidity and survival rates.13 
Study limitations
Due to the retrospective nature of this study, we had missing values. Our study 
represents the experience of 2 centres. After the year 2000 there was a difference in 
age of TOF repair between the 2 centres, which could have influenced our results. We 
also did not perform a competing risk analysis.
Likewise our study shows the experience after TOF repair over multiple decades. 
During this time, the availability of diagnostic methods, indications for and timing of 
(re) interventions has changed, which could have influenced our results and could 
therefore be a bias. 
Conclusions
The transatrial-transpulmonary repair of TOF before the age of 6 months is associated 
with more events during long-term follow-up, mainly due to an increase in interventions 
for RVOT obstruction. We noted a trend towards a decrease of age at TOF repair. These 
findings suggest that, if clinically feasible, it may be better to delay primary TOF repair 
as long as possible. Further prospective studies are needed to determine the optimal 
timing for primary repair of TOF. 
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Abstract 
Aims
The aim of this study was to evaluate the possible value of dobutamine stress cardiac 
magnetic resonance imaging (CMR) to predict adverse outcome in Tetralogy of Fallot 
(TOF) patients.
 
Methods and results
In previous prospective multicentre studies, TOF patients underwent low-dose 
dobutamine stress CMR (7.5 µg/kg/min). Subsequently, during regular-care patient 
follow-up, patients were assessed for reaching the composite endpoint (cardiac death, 
arrhythmia-related hospitalization or cardioversion/ablation, VO2 max ≤65% of 
predicted). A normal stress response was defined as a decrease in end- systolic volume 
(ESV) and increase in ejection fraction. The relative parameter change during stress 
was calculated as relative parameter change= [(parameterstress− parameterrest)/
parameterrest] *100. The predictive value of dobutamine stress CMR for the composite 
endpoint was determined using time time-to-event analyses (Kaplan-Meier) and Cox 
proportional hazard analysis. 
We studied 100 patients (67 (67%) male, median age at baseline CMR 17.8 years (IQR 
13.5–34.0), age at TOF repair 0.9 years (0.6–2.1)). After a median follow-up of 8.6 years 
(6.7–14.1), 10 patients reached the composite endpoint. An abnormal stress response 
(30% vs 4.4%, p=0.021) was more frequently observed in composite endpoint patients. 
Also in endpoint patients, the relative decrease in right ventricular ESV decreased less 
during stress compared to the patients without an endpoint (-17±15 vs -26±13 %, 
p=0.045). Multivariable analyses identified an abnormal stress response (HR 10.4; 95% 
CI 2.5–43.7; p=0.001) as predictor for the composite endpoint.
Conclusions
An abnormal ventricular response to dobutamine stress is associated with adverse 
outcome in patients with repaired TOF. 
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Introduction
Survival after surgical repair of Tetralogy of Fallot (TOF) in infancy is good, long-term 
survival of 95% at 10-year and >90% at 25 year has been reported.1-3 However, TOF 
patients frequently develop long-term problems such as pulmonary regurgitation (PR), 
right ventricular (RV) dilatation, ventricular dysfunction, arrhythmias and even 
mortality.1, 2, 4, 5 
In TOF patients, peak VO2, NT-proBNP levels and QRS duration have been related to 
ventricular volumes, function and outcome.6-10 RV end diastolic volume (EDV), LV end 
systolic volume (ESV), LV ejection fraction (EF) and myocardial deformation parameters 
are associated with sudden cardiac death, severe arrhythmias and heart failure.8, 11-13 
Nonetheless, additional parameters are needed for better risk stratification.5 This 
search for additional outcome determinants is hampered by long symptom-free 
intervals and therefore surrogate outcome markers are often used.14
A potential additional parameter is a dobutamine stress CMR. This technique 
combines the gold standard for volumetric cardiac parameters with functional 
information during (dobutamine) stress.14 Compared with healthy volunteers, TOF 
patients often have an abnormal decrease in RVEDV, an impaired decrease in RVESV 
and an impaired increase RVEF following the use of dobutamine stress.15-18 Luijnenburg 
et al.17 showed that this poorer RVEF stress response is associated with a larger decrease 
in peak VO2 at 5 year follow-up. Ventricular response to exercise or dobutamine stress 
CMR might help identifying patients at risk for developing an event.19, 20 
Our aim was to evaluate the possible additional value of stress CMR, compared to 
the existing parameters, to predict adverse outcome in TOF patients.
Methods
Patients
We included TOF patients that underwent successful dobutamine stress CMR in four 
prospective studies in tertiary referral centers between 2002 and 2012.17, 21-23 The 
institutional review boards approved the studies. All participants, and if necessary their 
parents, gave written informed consent before inclusion. The inclusion and exclusion 
criteria, study protocol, methods, adverse event rate and results have been published 
previously.17, 21-23
Patients underwent the baseline CMR study at rest and during low-dose dobutamine 
stress. NT-proBNP was measured with the Elecsys electrochemiluminescence 
immunoassay (Roche Diagnostics) and cardiopulmonary exercise testing (CPET) was 
performed according to previously described standardized protocols within one year 
from the dobutamine CMR.17, 21-23 From that CPET the baseline peak VO2 was assessed 
and expressed as percentage of predicted values. Exercise tests with a peak respiratory 
exchange rate of ≥1.0 were included in the analysis.
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Composite study endpoint
After the study examination patients received regular patient specific care in the 
outpatient clinic. Since information on how to interpret stress CMR in TOF patients was 
not available at that time, stress CMR parameters were not used for clinical decision 
making. 
 Before data acquisition we defined our study endpoint as a composite of cardiac 
death, hospitalization for arrhythmias or cardioversion/ablation for arrhythmias and 
reaching a CPET VO2 max below 65% of predicted (due to cardiac reasons) during 
follow-up after the study CPET.9, 10 The medical records of all patients were reviewed 
up until January 2019.
CMR acquisition and analysis
All participants underwent CMR on the locally available scanners with dedicated 
phased-array cardiac surface coils. All images were obtained during breath-hold. CMR 
imaging was performed at rest and repeated during continuous infusion of low-dose 
(7.5 μg/kg/min) dobutamine hydrochloride (Centrafarm Services, Etten-Leur, the 
Netherlands). The dobutamine infusion was decreased (or stopped if necessary) when 
the heartrate increased >50%, if the systolic and/or diastolic blood pressure increased 
>50% or decreased >20%, if serious arrhythmias occurred, or if a patient did not tolerate 
the dobutamine effect. Technical details on our rest and dobutamine stress protocol 
have been published previously.17, 21-23
Analysis was performed with the software packages MASS and FLOW (Medis Medical 
Imaging Systems, Leiden, the Netherlands). Contours were manually drawn, under 
supervision of an experienced observer (WAH), in end-diastole and end-systole. 
Papillary muscle and large trabeculae were excluded from the blood pool. Biventricular 
EDV and ESV were obtained and used to calculate the EF. All ventricular volumes were 
indexed (i) for body surface area.
A normal stress response to low-dose dobutamine in healthy individuals consist of 
a decrease in ESV and a subsequent increase in EF.15 Therefore an abnormal response 
to stress was defined as the inability to decrease ESV during stress and/or the inability 
to increase EF. Relative changes in CMR parameters were calculated as follows: relative 
parameter change= [(parameterstress− parameterrest)/parameterrest] *100. 
Statistical methods
Continuous variables with a normal distribution were summarized as mean (standard 
deviation (SD)). Differences between groups were analysed by Student’s t-tests. 
Variables with a non-normal distribution were presented as median (interquartile 
range), and between-group differences were analysed by Mann-Whitney U tests. 
Categorical variables were presented as numbers and percentages, whereas between-
group differences were evaluated by Chi-square tests or the Fisher’s exact test. 
Differences between rest and stress CMR measurements were analysed with paired 
Student’s t-tests.
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The correlation between relative change in RVESV and NTproBNP was evaluated with 
the Spearman’s rank correlation. The cumulative endpoint-free survival was estimated 
with Kaplan-Meier curves and differences between patients with and without the 
cumulative endpoint were evaluated by the log-rank test. We applied Cox proportional 
hazard regression analyses to relate CMR parameters, age at CMR, NTproBNP levels 
and QRS-duration with endpoint-free survival. In a multivariable cox regression model 
we included NTproBNP and a CMR stress parameter We performed two separate 
multivariate analyses with two parameters instead of a multivariate model with more 
parameters due to the limited cumulative endpoints and therefore limited statistical 
power. All analyses were performed using the SPSS statistical software package version 
24.0 (IBM Corp. in Armonk, NY, USA), two-sided p-values <0.05 were considered 
statistically significant. 
Results
In total, 104 patients underwent dobutamine stress CMR. Of these 104, four patients 
were not included in the final analysis because the dobutamine infusion had to be 
terminated or decreased because of adverse effects such as ventricular bigeminy and 
>50% increase of heartrate. These adverse effects recovered spontaneously directly 
after termination of the dobutamine infusion.17, 21-23
Dobutamine stress CMR was well tolerated and successfully completed in 100 
patients, these were included in this analysis. The median age at dobutamine CMR was 
17.8 (13.5–34.0) years, median time between the TOF repair and dobutamine CMR was 
16.7 (12.6–33.2) years. Patients characteristics are shown in Table 1. At dobutamine 
CMR 15 (15%) patients had undergone a first pulmonary valve replacement (PVR) and 
seven (7%) patients had a residual pulmonary stenosis with a peak gradient >30 mmHg 
(but <60 mmHg) measured by ultrasound. 
After the stress CMR the median follow-up was 8.6 (6.7–14.1) years. At the latest 
follow-up, 10 patients (10%) had reached the composite endpoint, median 6.2 (3.1–13.3) 
years after stress CMR (Table 2). All patients were alive at their latest follow-up.
Ventricular response to stress
The results of the CMR studies are shown in Table 3. For the entire group, during 
dobutamine stress there was a significant decrease in LVESV (33±9 vs 22±8 ml/m2, 
p<0.001) and RVESV (67±26 vs 51±23 ml/m2, p<0.001). Both LVEF (59±7 vs 72±7%, 
p<0.001) and RVEF (49±7 vs 61±8%, p<0.001) increased significantly during stress. In 
seven patients (7%) an abnormal stress response (i. e. inability to decrease ESV and/
or increase EF during stress) was observed; three patients could not increase EF, two 
patients could not decrease ESV during stress and in two patients no change in these 
parameters was noted.
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Study endpoints
There was no difference in median age at dobutamine CMR between the patients who 
did and did not reach the composite endpoint. NT-proBNP levels, predicted-peak VO2 
and rest CMR parameters did not differ between both groups (Table 1, Table 3). 
Patients with an abnormal stress response had a poorer endpoint-free survival 
(Figure 1, p<0.001). A significantly lower relative decrease in RVESV during stress was 
observed in endpoint patients compared to patients who did not reach the study 
endpoint (-17±15 vs-26±13 %, p=0.045). 
In figure 2 the endpoint-free survival for the patients with the largest (≥-25%) and 
lowest (<-25%) relative decrease in RVESV during stress is shown. Patients with a larger 
relative decrease during stress experienced a better endpoint-free survival (p=0.044). 
Determinants of the composite endpoint
Univariable analysis showed that patients were significantly more likely to experience 
the composite endpoint when they had an abnormal stress response (HR: 10.5; 95% 
CI 248-44.78), higher NTproBNP levels (HR: 1.03; 95% CI 1.00-1.05), or a higher relative 
Table 1. Patient characteristics at dobutamine CMR
Total
(n=100)
Composite
endpoint
(n=10)
No composite 
endpoint
(n=90)
P-
value*
Male (n, %) 67 (67.0) 7 (70.0) 60 (66.7) 0.83
22q11 Syndrome (n, %) 3 (3.0) 1 (10.0) 2 (2.2) 0.27
Age at CMR (years) 17.8 (13.5–34.0) 15.2 (10.4–34.6) 18.2 (14.0–34.6) 0.35
Time after TOFr (years) 16.7 (12.6–33.2) 15.6 (13.2–17.5) 17.0 (12.1–33.6) 0.30
Length (cm) 166.8 ± 15.7 166.5 ± 22.4 166.9 ± 14.9 0.96
Weight (kg) 61.5 ± 18.7 61.8 ± 23.7 61.5 ± 18.2 0.97
BSA (m2) 61.5 ± 18.7 1.7 ± 0.44 1.68 ± 0.32 0.99
Palliative shunt (n, %) 18 (18.0) 1 (10.0) 17 (18.9) 0.69
Age at TOFr (years) 0.9 (0.6–2.1) 0.6 (0.2–1.6) 1.0 (0.6–2.1) 0.076
Transannular patch (n, %) 80 (80.0) 8 (80.0) 72 (80.0) 1.00
PVR at baseline (n, %) 15 (15.0) 3 (30.0) 12 (13.3) 0.17
Pulmonary stenosis at 
baseline# (n, %)
7 (7.0) 1 (1.0) 6 (6.0) 0.53
QRS duration (ms) 129±24 (n=98) 134±23 (n=10) 129±25 (n=85) 0.50
NT-proBNP (μmol/l) 12.9 (6.8–21.2) (n=96) 16.4 (10.7–41.2) (n=10) 12.4 (6.6–20.3) (n=86) 0.13
Peak VO2 (ml/min/kg) 35.7±9.5 (n=92) 35.6±9.6 (n=7) 37.6±8.2 (n=85) 0.60
Peak VO2 (% predicted) 89.9±19.3 (n=92) 89.8±19.3 (n=7) 92.1±21.1 (n=85) 0.76
*: P-value between patients with and without a composite endpoint.
#: >30 mmHg (but <60 mmHg) measured by ultrasound
Results are given as mean (SD), as median (IQR) or as counts (percentages). 
Abbreviations; TOFr: Tetralogy of Fallot repair, CMR: Cardiovascular magnetic resonance imaging, PVR: 
pulmonary valve replacement, VO2: oxygen uptake.
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decrease in RVESV during stress (HR: 1.06; 95% CI 1.01–1.12), see Table 4. There was 
no-statistical significant correlation between NTproBNP levels and relative change in 
RVESV during stress, r=0.06, p=0.54. 
In a multivariable model with both NTproBNP and relative change in RVESV, both 
parameters remained predictive for the composite endpoint. In a multivariable model 
with NTproBNP and abnormal stress response, NTproBNP lost its predictive value for 
the composite endpoint however abnormal stress response remained a strong 
independent predictor for the composite endpoint, see Table 5. 
Discussion
In this study we demonstrated, despite a relatively low number of endpoints, a clear 
relation between ventricular response to low-dose dobutamine stress CMR and a 
composite endpoint in TOF patients mid-term after TOF-repair. An abnormal response 
to dobutamine stress and a diminished relative decrease in RVESV during stress were 
associated with adverse outcome. 
Patients with TOF are at increased risk of mortality and morbidity.1, 2, 4, 5 Many of the 
studies that have looked at predictors in TOF patients have been performed in in older 
patients cohorts with an older age at initial repair.4, 7-9, 12, 13, 24 What our current study 
adds, in a cohort of adolescents and young adults (median age 17.8 years), is that stress 
CMR is more predictive for poor outcome after 8.6 years follow-up than conventional 
CMR imaging parameters. Also the median age at TOF-repair in our cohort was 0.9 
years, which is highly comparable to the clinical practice for the past two decades.25, 26
In other studies, several predictors for outcome have been described.4, 8, 9, 12, 24, 27
Table 2. Clinical state at latest follow-up
Patients (n=100)
Median age at latest follow-up (years) 29.4 (24.3–39.7)
     Median time after dobutamine CMR (years)      8.6 (6.7–14.1)
Composite endpoint (n, %) 10 (10.0)
     Median time after dobutamine CMR (years)      6.2 (3.1–13.3)
     Median time after TOFr (years)      26.0 (17.1–37.2)
Ablation/cardioversion of arrhythmias (n, %) 5 (5.0)
     Atrial arrhythmia (n, %)      3 (3.0)
     Ventricular arrhythmia (n, %)      2 (2.0)
ICD after VT (n, %) 1 (1.0)
VO2 max ≤65% of predicted (n, %) 4 (4.0)
Results are given as median (IQR) or as counts (percentages). 
Abbreviations; CMR: cardiac magnetic resonance imaging, TOFr: Tetralogy of Fallot repair, ICD: implantable 
cardioverter defibrillator, VT: Ventricular tachycardia, VO2: oxygen uptake.
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Abbreviations: CMR; cardiac magnetic resonance imaging.
Figure 1. Endpoint-free survival for normal vs abnormal dobutamine stress response 
Abbreviations: RVESV: right ventricular end systolic volume, CMR; cardiac magnetic resonance imaging. 
Figure 2. Endpoint-free survival for the relative decrease of RVESV during stress
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Clinical and non-imaging parameters
Of the non-imaging derived parameter, NT-proBNP, QRS-duration and peak VO2 are 
related to outcome in TOF.4, 8, 9 In an adult congenital heart disease (CHD) cohort, a 
NT-proBNP level of >33 μmol/L identified patients with increased risk for poor 
outcome.28 Also in adult TOF patients elevated NT-proBNP levels are related to adverse 
clinical outcome.8 Although the median NT-proBNP levels in our study were relatively 
low (12.9 μmol/L). We observed that higher NTproBNP levels were associated with the 
composite endpoint in univariable analysis and in a multivariable model with relative 
change in RVESV. In a multivariable model with abnormal stress response NTproBNP 
lost its predictive value for the composite endpoint, however a strong trend (p=0.055) 
remained. 
QRS duration ≥180 ms in adults and ≥170 ms in children are known predictors for 
ventricular tachycardia and sudden death.4, 29 In our relatively young TOF cohort, we 
observed no differences in QRS duration between the patients with and without a 
composite endpoint. Only three patients had a QRS duration >170 ms. 
Peak VO2 is an established prognostic marker in CHD patients and TOF patients and 
guidelines recommend cardio-pulmonary exercise testing during routine follow-up of 
TOF patients.9, 10, 26, 27, 30 Diller et al.10 reported in 2005 that older (31.8 years) TOF patients 
with a peak VO2 of ≤15.5 ml/kg/min have an increased risk of hospitalization and death 
during follow-up. Giardini et al.31 observed that a lower peak VO2 is associated with 
death and hospitalization during follow-up. In another larger and relatively young (25.5 
years) TOF cohort, a peak VO2 ≤65% of predicted was associated with an increased risk 
for death, sustained ventricular tachycardia and cardiac related hospitalizations.9 
As mentioned, research in CHD patients is complicated by the relatively low incidence 
of hard endpoints, resulting in the use of surrogate endpoints.14 Based on the relations 
between exercise performance, particularly VO2 max and subsequent outcome, peak 
VO2 ≤65% was included in the composite endpoint used in our study. 
RV size and function
Alongside clinical parameters, RV size is a key factor in outcome in TOF and the decision 
for PVR. If PVR is performed on time, i.e. before irreversible remodeling has occurred, 
it might help to normalize volumes and improve function. However, survival benefit 
of PVR using the current criteria has not been demonstrated.5, 14, 32, 33 International 
guidelines indicate that several factors such as the presence of symptoms, degree of 
PR, RVEDV, RVESV and objective exercise performance can be used to determine if PVR 
is justified.14, 26, 30 However, often no quantitative limits are given and the criteria differ 
between guidelines.26, 30 Also, RV size parameters fail to take into consideration the 
underlying RV mechanics, such as contractility, diastolic function, energy loss, ventriculo-
arterial coupling (VA coupling) or ventricular function during stress.21, 34-36 Contractility 
can be maintained in severe RV dilatation.35 Diastolic RV function is impaired in many 
TOF patients and relates to clinical state, but has not been shown to predict poor 
outcome.37 Latus et al.35 showed that RV-Pulmonary arterial (PA) coupling is impaired 
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in TOF patients at rest and did not improve with dobutamine stress. In patients without 
a transannular patch, RV-PA coupling did improve with dobutamine stress.35 Whether 
these findings relate to our and observations of others of impaired reduction of RVESV 
with dobutamine stress,18 is not certain at present. 
It is important to identify parameters for early RV dysfunction that have prognostic 
impact. The cardiac response to dobutamine stress could be an additional parameter 
in this decision process, combining volumetric and functional parameters with a state 
of stress, unmasking abnormalities only visible during stress.21 
Stress CMR
Previous studies using low-dose dobutamine stress CMR, demonstrated that TOF 
patients are able to decrease ESV and increase EF during stress. Some studies also 
describe an abnormal decrease in RVEDV.16-18, 21 In a 5-year follow-up study of TOF 
patients, our group previously showed that patients with a small relative increase in 
RVEF during dobutamine stress were more likely to have a large decrease in peak VO2 
Table 4. Univariable cox-regression analyses for the composite endpoint 
Univariable analysis
HR 95% CI P-value
Age at CMR (years) 1.01 0.95–1.07 0.74
NT-proBNP (μmol/l) 1.03 1.00–1.05 0.030
QRS duration (ms) 1.01 0.99–1.04 0.41
Rest CMR
LVEDV (ml/m2) 1.02 0.97–1.08 0.43
LVESV (ml/m2) 0.86 0.93–1.09 0.86
LVEF (%) 1.01 0.92–1.11 0.82
RVEDV (ml/m2) 0.99 0.97–1.01 0.22
RVESV (ml/m2) 0.98 0.95–1.01 0.094
RVEF (%) 1.04 0.95–1.04 0.83
RV mass volume ratio  (g/ml) (0.1) 1.40 0.32-6.02 0.65
Relative change during stress
LVESV (%) 1.04 0.99–1.09 0.086
LVEF (%) 0.98 0.92–1.04 0.42
RVEDV (%) 1.07 1.01–1.15 0.036
RVESV (%) 1.06 1.01–1.12 0.016
RVEF (%) 0.94 0.89–0.99 0.043
Abnormal stress response 10.5 2.48–44.78 0.001
Abbreviations; CMR: cardiac magnetic resonance imaging, LV: left ventricle, RV: right ventricle, EDV: end diastolic 
volume, ESV: end systolic volume, SV: stroke volume, EF: ejection fraction. 
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five years later.17 However the relationship between stress response and cardiac events 
has not been described yet in TOF patients. 
In systemic RV patients with a biventricular circulation, a previous study identified 
that an abnormal stress response (present in 17 of the 39 patients) was predictive for 
cardiac events during follow-up.20 We observed an abnormal stress response in only 
seven patients, most likely explained by the differences in age and type of CHD. 
However, these seven patients experienced more often an adverse outcome during 
follow-up and had a worse endpoint-free survival.
 In young Fontan patients, without other known parameters predictive for cardiac 
events, the relationship between single ventricle functional reserve (EFstress-EFrest) and 
events has recently been described by our group.19 In our current TOF study, the 
relative decrease of RVESV during stress was also associated with the composite 
endpoint. All these studies mentioned above indicate that dobutamine stress imaging 
may be helpful in risk stratification and predicting future events. 
Limitations 
Although the absolute number of TOF patients receiving a dobutamine CMR is the 
largest reported cohort so far, the number of hard endpoints during follow-up was 
limited, which is a known limitation in CHD research.14 We therefore used a composite 
endpoint of cardiac death, arrhythmias and diminished exercise tolerance to assess 
the possible association between the stress CMR and subsequent adverse outcome. 
Relatively few patients reached this composite endpoint, which is a limitation of our 
study. However, despite the small number of endpoints obtained, we observed a clear 
relationship between the ventricular stress response and subsequent outcomes during 
follow-up. Information on how to interpret stress CMR in TOF patients was not available 
at the time of stress CMR and therefore stress CMR parameters were not used for 
clinical decision making.
Table 5. Multivariable cox-regression analyses for the composite endpoint
multivariable analysis
HR 95% CI P-value
Multivariable model 1
NT-proBNP (μmol/l) 1.0 1.0–1.1 0.055
Abnormal stress response 10.4 2.5–43.7 0.001
Multivariable model 2
NT-proBNP (μmol/l) 1.0 1.0–1.1 0.009
Relative change in RVESV (%) 1.1 1.0–1.1 0.004
Abbreviations; CMR: cardiac magnetic resonance imaging, LV: left ventricle, RV: right ventricle, EDV: end diastolic 
volume, ESV: end systolic volume, SV: stroke volume, EF: ejection fraction. 
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Secondly, it is not certain whether dobutamine stress CMR gives the same results as 
exercise stress CMR. Because our CMR scanner is not suitable for supine leg exercise, 
the effects of exercise on cardiac function had to be simulated with pharmacological 
stress. Thirdly, LGE or T1 mapping could not be performed because of time constraints 
during the extensive scan protocol. Both factors are associated with outcome in TOF 
patients.38, 39
Conclusion
An abnormal ventricular response to dobutamine stress is associated with adverse 
outcome in young TOF patients. 
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General Discussion
Due to great advances in treatment, the survival rate of patients with severe congenital 
heart defects (ConHD) such as a Tetralogy of Fallot (TOF) or univentricular hearts have 
increased dramatically in the last 50 years.1-3 As a result, the number of adults with 
ConHD is now larger than the number of children with ConHD.4 
Patients with univentricular heart defects and patients with TOF are amongst those 
with the highest risk of complications later on during follow-up. Although many studies 
have looked at the occurrence-risk of these complications, there remains a clinical 
need for additional markers to detect early signs of cardiac and circulatory dysfunction. 
The aim of this thesis was to describe the medium to long-term outcomes of 
univentricular heart defect patients, treated with the Fontan operation, and repaired 
TOF patients and to explore clinical parameters, imaging characteristics and laboratory 
markers which are related to the maintenance of cardiac homeostasis or the 
development of adverse outcome.
Endpoints in congenital heart disease research
The search for markers with prognostic value in ConHD is ongoing. Several of the 
established prognostic parameters have mainly been assessed in older ConHD cohorts 
from earlier surgical eras.5-7 Therefore the results cannot be simply extrapolated to 
younger patients operated at a younger age and/or with different treatment strategies. 
Due to the change in surgical techniques, timing of interventions and improvement of 
perioperative care the overall survival of ConHD patients has improved.8-11 It is expected 
that these improvements in management will influence the morbidity rates at mid- to 
long-term follow-up.9, 12-14 15 For these reasons it is important to perform research in 
younger populations of ConHD patients and to assess their follow-up and determinants 
of outcome. 
Research in ConHD, especially in the contemporary cohorts, is complicated in a way 
by the successful therapeutic strategies developed in the last decades, resulting in a 
low incidence of ‘hard outcomes’ such as cardiac death and documented arrhythmias.16 
This is why additional outcome measurements and composite endpoints often are 
used. These alternative outcome parameters include cardiac reinterventions and 
objective clinical parameters such as exercise capacity, imaging parameters and ECG-
derived information, e.g. QRS-duration.17-19 
In this thesis we studied cohorts of contemporary Fontan and repaired TOF patients 
with a relatively low incidence of hard outcomes. In several chapters (chapter 3, 4, 5, 
7, 8, 9 & 10) we used a composite endpoint of cardiac death, arrhythmias, cardiac 
reinterventions, cardiac hospitalization and a cut-off point in exercise capacity, namely 
a peak oxygen uptake (VO2) ≤65% of predicted. We used this cut-off point in exercise 
capacity because a peak VO2 is a well-known prognostic marker and repeated cardio 
pulmonary exercise test is recommended by the guidelines.7, 16, 17, 20, 21 Several studies 
have established an association between lower peak VO2 or predicted peak VO2 and 
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hospitalization, sustained ventricular tachycardia and death during subsequent follow-
up.7, 17, 22 A recent study in relatively young (25 years) TOF patients observed that a peak 
VO2 ≤65% of predicted was related to an increased risk for cardiac hospitalization and 
death.17
Imaging the heart
Cardiac imaging with cardiovascular magnetic resonance imaging (CMR) is an important 
tool in the follow-up of both Fontan and TOF patients. CMR provides detailed 
information on anatomy and cardiac and valvular function. In our multicenter 
prospective COBRA3 study, TOF and Fontan patients underwent CMR for detailed 
cardiac assessment. The main advantage of CMR in the follow up of patients with 
ConHD is that it provides both quantitative information on large vessel and transvalvular 
flow as well as information on ventricular size and function in geometrically complex 
ventricles such as the right ventricle (RV) and single ventricle.23, 24 
In Fontan patients several CMR derived parameters have been associated with clinical 
outcome.25 A single ventricle end diastolic volume (EDV) >125 mL/BSA1.3 was associated 
with an increased risk of death of or cardiac transplantation (listing) during 4 year 
follow-up.25 In this study by Rathod et al.25 a CMR derived ejection fraction (EF) <40% 
and a higher cardiac mass were significantly more common in patients who would die 
or receive a cardiac transplant during the follow-up.25 In the prospective CMR studies 
in our Fontan patients (chapter 4 and 5) we did not observe an association between 
CMR derived EDV or EF and subsequent outcome. This might be explained by the 
younger age of our cohort and the use of other cardiac endpoints. In our study cardiac 
interventions and arrhythmias were also included in the cardiac endpoint, whereas 
Rathod et al.25 used endpoints such as death and cardiac transplantation in their 
analysis. In chapter 4 we did observe that Fontan patients who would reach an event 
during subsequent follow-up had a higher cardiac mass.26 Late gadolinium enhancement 
(LGE) CMR is a method to assess myocardial fibrosis and has been linked to non-
sustained ventricular tachycardia (VT).27 Recently a diminished CMR-derived global 
longitudinal strain was found predictive for adverse events including death, cardiac 
reinterventions, unscheduled hospitalization, heart failure and arrhythmias.28 In this 
thesis we did not research LGE CMR or strain analysis.
In TOF patients CMR is the golden standard to monitor pulmonary valve competence 
and RV and left ventricular (LV) volumes and function.16, 24, 29 A regular CMR during 
follow-up is recommended by the guidelines.16, 24, 29 Serial CMR measurements in TOF 
patients show progression of RV volumes and pulmonary regurgitation (PR) over time.30 
Progressive RV dysfunction and dilatation are indications for a pulmonary valve 
replacement (PVR).29 In addition to the role of CMR in determining the optimal timing 
for PVR in TOF patients, several CMR parameters have been associated with death, 
cardiac arrest and major arrhythmias during follow-up.31, 32 These parameters include 
conventional ventricular function measurements such as diminished LVEF and RVEF 
but also reduced RV longitudinal strain and reduced LV circumferential strain measured 
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by CMR-based feature tracking.31, 32 Recently Geva et al.33 observed that an increased 
RV mass volume ratio is associated with death and sustained VT in TOF patients who 
underwent a PVR and had residual pulmonary stenosis.33 In our cohort we did not 
observe an association between RV mass/volume ratio and subsequent outcome 
(chapter 9), which might be explained by the younger age of our patients and limited 
incidence of outcomes such as VT and cardiac death.
Dobutamine stress CMR
In chapter 4 and 9 we have focused on the potential prognostic value of a dobutamine 
stress CMR in Fontan and TOF patients. In chapter 4 we observed that in a young 
Fontan cohort the ventricular response to dobutamine stress was predictive for adverse 
events during follow-up. Fontan patients with a diminished functional reserve (FR) 
(EFstress-EFrest) experienced a worse event-free survival.
26 Similarly to Fontan patients, in 
TOF patients we observed in chapter 9 an association between the ventricular response 
to dobutamine stress CMR and outcome. An abnormal stress response (e.g. inability 
to increase EF or decrease end systolic volume (ESV)) was associated with an increased 
risk of the composite endpoint during 8 year follow-up, as was the relative change in 
RVESV during stress. 
In ConHD patients an association between the response to dobutamine stress and 
adverse outcome previously has only been described in patients with a systemic RV in 
a biventricular circulation.34 In these patients an abnormal stress response was 
predictive for adverse outcome during 8 years of follow-up.34 In TOF patients a smaller 
relative increase in RVEF during stress has been associated with a large decrease in 
peak VO2 during subsequent five year follow-up.
35 To our knowledge we are the first 
to describe an association between the ventricular response to dobutamine stress and 
adverse events in Fontan and TOF patients. Both patients groups were asymptomatic 
at the time of dobutamine CMR and none of the other size and function imaging 
parameters we tested for this purpose were associated with outcomes. Our findings 
therefore highlight the potential importance of using stress imaging techniques to 
detect sub-clinical ventricular dysfunction in ConHD patients. 
Blood biomarkers
In chapter 5 and 10 we have described an exploratory approach to assess blood 
biomarkers involved in maintaining cardiac function and outcome in Fontan and TOF 
patients. Blood biomarkers could represent pathways that are involved in maintaining 
cardiac function and the development of heart failure. 
Relatively little is known about het processes leading to myocardial changes to adapt 
to chronic abnormal loading conditions in ConHD.36, 37 It is thought that processes 
involving inflammation and cardiac fibrosis are essential in the deterioration of cardiac 
function.36 Furthermore, pathways and biomarkers involved in heart failure may be 
different in ConHD children compared to adults with heart failure, including adults 
with ConHD.36, 38, 39 In the COBRA3 project, which forms the backbone of this thesis, we 
have focused on the following blood markers:
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NT-proBNP
In the last decades neurohormones such as brain natriuretic peptide (BNP) and 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) have received much attention 
as a marker for cardiac disease.40 The ventricular myocyte releases NT-proBNP as a 
response to stretch and in acquired heart failure patients NT-proBNP levels have an 
important role the clinical follow-up.41, 42 
In TOF and Fontan patients (NT-pro)BNP levels are related to the clinical condition.43-46 
Although NT-proBNP levels are often within normal range in Fontan patients,47 Fontan 
patients with heart failure, patients in which older Fontan techniques were used and 
in patients with a morphological RV higher NT-proBNP levels are found.43, 48-50 Other 
studies observed correlations between (NT-pro)BNP levels and exercise capacity, EDV, 
cardiac mass or atrioventricular valve regurgitation in Fontan patients.40, 45, 51 In chapter 
5 we described that elevated NT-proBNP levels were associated with adverse outcome, 
indicating its potential value in the routine follow-up in young and contemporary Fontan 
patients. In recent international guidelines the monitoring of (NT-pro)BNP levels in 
Fontan patients is not mentioned.16, 21 Our results indicate the value of NT-proBNP 
levels in the follow-up of young Fontan patients.47
In TOF patients numerous studies have shown correlations between NT-proBNP and 
impaired LV function, degree of pulmonary regurgitation, RVEDV size and exercise 
capacity.40, 44, 52-55 Elevated NT-proBNP, unadjusted for age, has also been associated 
with adverse clinical outcome in adult TOF patients.44, 52 In chapter 9 and 10 we 
prospectively evaluated the value of NT-proBNP in relatively young TOF patients. Similar 
to other studies44, 52 we observed that NT-proBNP levels were associated with adverse 
events during follow-up. However, in our analysis in chapter 10, NT-proBNP lost its 
predictive value when adjusted for age. Our results in combination with the existing 
literature indicate that NT-proBNP may have a role in monitoring of cardiac function 
and deterioration in TOF patients.40, 56 However the exact prognostic value of NT-proBNP 
still needs to be determined.56
Inflammatory markers 
Inflammation and a pro-inflammatory state have been associated with heart failure in 
patients with acquired heart disease.57-59 Besides the role of the inflammatory pathways 
in chronic heart failure, inflammation is an important factor in the remodeling process 
after myocardial infarction.57, 59 In this thesis we examined blood biomarkers which 
represent an inflammatory response and their potential role in ConHD. Suppression 
of tumorigenicity 2 (ST2) is a marker for inflammation and remodeling, fibrosis and 
apoptosis in the myocardium and is upregulated in response to myocardial stress.60-62 
Fatty acid-binding protein 4 (FABP-4) expression plays a role in the activation of several 
inflammatory pathways in adipocytes and macrophages and is associated with diabetes, 
atherosclerosis and metabolic syndrome.63-65 Cardiomyocytes also produce FABP-4, in 
mice overexpression of FABP-4 by the cardiomyocyte is associated with pressure 
induced cardiac hypertrophy.64
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In humans FABP-4 has mainly been studied in acquired heart disease and elevated 
FAPB-4 levels have been associated with adverse outcome and lower peak VO2.
63 66 In 
chapter 5 and 10, we observed an association between higher FABP-4 levels and 
diminished peak VO2 in both the Fontan and TOF patients. FABP-4 may therefore have 
a potential role in the follow-up in ConHD patients, however more studies have to be 
performed to assess its prognostic value. ST2 has been studied in cohorts of ConHD 
patients and has been associated with all-cause mortality in large adult ConHD 
cohorts.60, 62 In chapter 5 we observed that in young Fontan patients higher ST2 levels 
at baseline were associated with severe events during follow-up. We did not observe 
an association between ST2 levels and adverse outcome in our TOF patients.
Fibrosis markers
Myocardial fibrosis is relatively common in Fontan and TOF patients and has been 
associated with morbidity.27, 67-69 Disturbances in the equilibrium between the 
production of collagen by fibroblasts and the degradation of the extracellular matrix 
can result in myocardial fibrosis.68 The mechanisms of developing myocardial fibrosis 
can be acute (due to an operation e. g. cardiac injury) or chronic (caused by abnormal 
hemodynamics) in origin.67 In ConHD patients both mechanisms are likely to be 
important. Myocardial fibrosis has been linked to ventricular arrhythmias and cardiac 
death and assessing myocardial fibrosis through non-invasive imaging and/or blood 
biomarkers could help with risk stratification in the individual patient.27, 67-69 In chapter 
5 and 10 we discuss several potential blood biomarkers that have been linked to 
collagen deposition and fibrosis.
Insulin-like growth factor-binding protein 7 (IGFBP-7) has been linked to collagen 
deposition. We observed that IGFBP-7 was associated with adverse outcome in TOF 
patients. In our Fontan patients we observed an association between increased levels 
of IGFBP-7 and diminished peak VO2. Another promising biomarker linked to collagen 
deposition is DLK-1. In mouse models, DLK-1 knock-out mice have increased collagen 
deposition in the myocardium.70 In our Fontan patients we observed that patients with 
lower levels of DLK-1 display a better severe event-free survival and a higher FR.
Imaging techniques, particularly CMR, can be used to characterize fibrosis in the 
myocardium. CMR provides this opportunity using LGE and/or T1 mapping.71-73 Because 
of limitations in scanning time we did not use these techniques in our studies. Therefore 
we could not confirm the association of both IGFBP-7 and DLK-1 and actual fibrosis in 
the myocardium. This could be the subject of further research. 
Outcomes after the Fontan operation
In chapter 2 we reviewed the medium to long term outcomes and the current ‘state 
of the art’ Fontan strategy. There are several preoperative factors that have been 
identified to have impact on mortality and prognosis. These factors include male 
gender, hypoplastic left heart syndrome (HLHS), atrioventricular (AV) valve regurgitation, 
heterotaxy syndrome and elevated pulmonary artery pressure.74-76 In addition, 
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postoperatively higher EDV, worse peak VO2 and diminished global longitudinal strain 
have been associated with adverse outcome.7, 25, 74, 75, 77-79 Also the choice of surgical 
technique has potential implications for the long-term outcomes of patients.
Intra-atrial lateral tunnel or extra cardiac conduit 
The two surgical total cavopulmonary connection (TCPC) techniques currently in use 
are the intra-atrial lateral tunnel (ILT) and the extra cardiac conduit (ECC) technique.76 
In chapter 3 we retrospectively studied the long-term outcomes of these two TCPC 
techniques. Although the long-term outcomes after TCPC have been studied extensively, 
a shift in surgical preference from the ILT to the ECC technique in many centers 
complicates the comparison.80 In our multicentre study one centre continued to use 
the ILT technique, giving us the opportunity to compare a population of ILT and ECC 
patients from the same surgical era with a comparable follow-up duration. 
We observed late survival rates of 94% at 10-year and 92% at 15 years after TCPC, 
without differences in late survival between the two TCPC techniques. Patients with 
an ILT experienced a worse arrhythmia free survival, which has also been observed in 
other studies.80, 81 ECC patients received significantly more catheter and surgical based 
reinterventions, mainly due to replacements of 16-mm conduits.82 However, over time 
small alterations were made in the ILT and ECC technique. The atrial baffle ILT evolved 
into the prosthetic ILT and 16 mm conduits were no longer used for the ECC.83, 84 We 
compared the long-term results of these newer ILT and ECC techniques and observed 
no differences in long-term arrhythmia-free and reintervention-free survival.12
 In theory there are several potential differences between the ILT and ECC technique. 
ECC patients seem more prone to develop thromboembolic events, while ILT patients 
seem more at risk for arrhythmias.80, 81, 85 Another potential benefit of the ECC is the 
option to perform the TCPC completion with shorter CPB times, or even off-pump.81, 
86-88 This could potentially impact ventricular function during long term follow-up. In 
previous studies several small differences in clinical parameters have been observed 
between ILT and ECC patients.45, 89 Assessed by echocardiography ECC patients had 
poorer diastolic function, lower TDI-based TEI-index and a shorter isovolumic relaxation 
time.45 Assessed by CMR, ECC patients had a significantly higher EF at rest, although 
this was not observed in a larger cohort.45, 89 During dobutamine stress ECC patients 
were able to increase ventricular stroke volume in contrast to ILT patients. Also cardiac 
index en EF during stress were higher and afterload was significantly lower in ECC 
patients.45 Some studies have found less favourable peak oxygen uptake in ILT 
patients.90, 91
Taken together our observations and the results of other studies do not suggest a 
clear benefit for one of the two techniques. The choice of TCPC technique to be used 
depends on local surgical prevalence. 
Fontan failure
In patients with ConHD the incidence of heart failure is 1.2 per 1000 patients-years.92 
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Hospitalization for heart failure has a worse prognosis with a reported 1 year mortality 
of 24%.92 The Fontan circulation creates a situation with elevated systemic venous 
pressure and decreased systemic output.3, 76 Impairments in the Fontan circulation can 
be localized in the systemic venous system, the Fontan pathway, the pulmonary 
vascular system, the single ventricle and the aorta.76 Like in other ConHD patients, the 
incidence of heart failure in Fontan patients increases with age.92 Patients operated on 
with more contemporary Fontan techniques experience lower heart failure rates 
compared the older Fontan technique patients, although this comparison is in part 
hampered by differences in duration of follow-up.76, 93 
The treatment of heart failure in Fontan patients is based on improving myocardial 
function and relieving and treating possible underlying causes of heart failure.94 A heart 
transplantation is the last available option and the use of cardiac transplantation in 
Fontan patients varies across centers worldwide.8, 9, 76 After transplantation 5 year 
survival ranges from 60% to 67% and is less in Fontan patients compared to other 
ConHD.95-97 
Early recognition of patients at risk for adverse events and Fontan failure is necessary. 
In this thesis we have explored several of these potential markers such as dobutamine 
stress CMR and biomarkers. See previous parts of this chapter.
Outcomes after Tetralogy of Fallot repair
We reviewed the outcomes and treatment of TOF in chapter 6. After TOF-repair overall 
survival has significantly improved over the last decades, mainly due to the decrease 
in early mortality.11, 14, 98, 99 Morbidity, often related to pulmonary regurgitation (PR) is 
common after TOF-repair. PR leads to a volume overloaded RV which in turn can lead 
to RV dilatation, ventricular dysfunction and arrhythmias.6, 14, 100, 101
Pulmonary valve replacement
To restore the function of the pulmonary valve TOF patients often undergo a PVR. In 
chapter 8 we observed a PVR-free survival of 96% at 10-year, 83% at 20-year and 48% 
at 30 year after TOF-repair. Patients with a transannular patch (TP) or a staged TOF-
repair receive more frequently a PVR.13, 14, 102, 103 It is thought that if a PVR is performed 
on time the volumes and function of the RV normalize and improve also the functional 
status of the patient.16, 101, 104-106 A homograft or a bio prosthetic valve are the most 
commonly used valves. However these valves have a limited lifespan.107 
Indications for performing PVR have been given in guidelines and are based on the 
presence of symptoms, degree of PR, RVEDV, RVESV and exercise capacity.16, 21 However, 
survival benefit of PVR using the current criteria has not yet been demonstrated.16, 101, 104, 105
Transatrial transpulmonary TOF-repair 
The surgical approach of TOF-repair has changed considerably over time. In the initial 
years of surgery for TOF, repair consisted of a large RV incision and a TP across the RV 
outflow tract (RVOT). This technique later evolved into the primary transatrial 
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transpulmonary approach which reduced the use of a TP and ventriculotomy.1, 14, 100, 103 
The transatrial transpulmonary approach thereby potentially reduces myocardial 
scaring and residual PR.14, 100 In chapter 7 and chapter 8 we describe the long-term 
follow-up of a retrospective cohort of 453 TOF patients operated on with the transatrial 
transpulmonary technique. We observed an overall survival of 96% at 20 years and 
93% at 30 years after TOF-repair. Studies describing the long-term follow-up of 
contemporary surgical TOF-repair are relatively scarce and reported 25-year overall 
survival has ranged between 93-97%.98, 99 In our study the event-free survival was 62% 
at 20 years and 34% at 30 years and was worse for TP patients. Park et al.99 reported 
a 46.6% 20-year freedom from reinterventions and reoperations. This is lower than in 
our cohort, which is most likely explained by the presence of both transventricular and 
trans-atrial repaired TOF patients in their cohort. In a sole trans-atrial cohort, D’udekem 
et al.98 observed a 75% 25-year freedom of reoperations, they did not report data on 
other reinterventions or events.
After TOF repair the incidence of supraventricular tachycardia (SVT) increases with 
increasing follow-up duration.108, 109 In adult TOF patients the incidence of arrhythmias 
is quite high. In a cohort of patients median 35 years after TOF repair 22% had 
experienced SVT and 9% experienced ventricular tachycardia.109 In another large cohort 
of older TOF patients (mean age 36.8 years), 43.3% of the patients had a sustained 
arrhythmia or had received an intervention for arrhythmias.108 In these older TOF 
patients reported risk-factors for arrhythmias are older age at TOF-correction, longer 
QRS duration and an extended ventriculotomy.17 It seems that TOF patients operated 
on in the current era with more contemporary and valve sparing techniques display a 
lower risk of arrhythmias during follow-up.110 
Timing of TOF-repair
Besides the changes in surgical techniques over time, the age at which the TOF-repair 
is performed have changed in the last decades.14, 99, 103, 111 In chapter 7 we show a 
decrease in median age from 1.17 years in the patients operated on between 1970-
1980 to 0.33 years in the patients operated on between 2000-2012.14 Nowadays there 
is no agreement on the optimal timing of primary TOF repair.14, 111-113 Some centers 
advocate early TOF-repair because it minimizes the time at risk for hypoxia, cyanotic 
spells and RV pressure overload.112, 114 However there are disadvantages of early repair, 
including a longer intensive care unit stay and a higher prevalence of TP’s and 
reinterventions.98, 102, 113, 115, 116 In chapter 8 we performed a multicenter retrospective 
analyses in patients who underwent elective primary TOF-repair. We observed that 
patients who underwent elective TOF-repair before the age of 6 months received more 
TP’s and experienced a significantly worse event-free survival compared to the patients 
operated on after 6 months of age. 
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Conclusions 
In this thesis we assessed clinical parameters, imaging characteristics and laboratory 
markers and their relationship to clinical outcome in TOF and Fontan patients.
We observed a relatively good long-term survivals after contemporary TCPC 
completion and TOF-repair. However the morbidity remains relatively high. We 
observed that events after TOF repair were more prevalent in TOF patient who 
underwent elective primary TOF-repair before 6 months of age compared to those 
who were older than 6 months of age. In Fontan patients, similar long-term survival 
rates were observed after staged ILT and ECC. However, late after staged TCPC 
arrhythmias were more prevalent in ILT patients and re-interventions were more 
prevalent in ECC patients. These differences in events during follow-up disappeared 
in patients operated on with more contemporary TCPC techniques.
Using dobutamine stress CMR we found that the ventricular reserve as tested with 
this method related to adverse events during long-term follow-up of both TOF and 
Fontan patients. Furthermore, in our relatively young patient groups, the response to 
stress CMR was a better predictor for later adverse events than previously reported 
risk factors. This suggest this response might be a marker for early dysfunction and 
therefore could be an additional tool in the risk stratification of young TOF and Fontan 
patients. Next to imaging parameters we also explored several blood biomarkers in 
our prospective studies. Adverse events in Fontan patients were associated with 
elevated NT-proBNP and ST2 levels and lower DLK-1 levels. In TOF patients we observed 
an association between elevated IGFBP-7 levels and adverse outcome. In both Fontan 
and TOF patients we observed that higher DLK-1 levels, a marker potentially involved 
in fibrosis pathways, were associated with a favorable ventricular response to 
dobutamine stress CMR. In Fontan patients higher DLK-1 levels were associated with 
a better severe event-free survival.
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SUMMARY 
In chapter 1, the introduction of this thesis, we provide an overview of the prevalence 
of congenital heart disease (ConHD) and specifically of univentricular heart defects 
and Tetralogy of Fallot (TOF). We discuss commonly used modalities to assess clinical 
condition in ConHD patients, such as echocardiography, cardiovascular magnetic 
resonance imaging (CMR), cardiopulmonary exercise test (CPET) and blood marker 
assessment. Furthermore this chapter describes the aims and outline of this thesis. 
Part I: Fontan circulation
In chapter 2 we investigate the current literature on univentricular heart defects. We 
discuss the state of the art Fontan strategy, common complications and interventions 
after the Fontan operations and factors associated with long-term survival and 
morbidity. We also discuss the remaining challenges we face in the Fontan field. 
In chapter 3 we investigate the serial follow-up and the long-term outcomes after the 
staged total cavopulmonary connection (TCPC). We compare the two TCPC techniques, 
the intra-atrial lateral tunnel and the extracardiac conduit (ECC). In this study we include 
208 TCPC patients (103 ILT, 105 ECC) with a median follow-up duration of 13.2 years 
after TCPC. After 15 years of follow-up the overall survival was comparable; 81% for 
ILT and 89% for ECC. Patients with an ILT experience more often arrhythmias during 
follow-up, patients with an ECC experience more surgical and catheter-based 
reinterventions. Over time the ILT and ECC modifications changed and in the patients 
operated on with these current modifications we did not observe a significant difference 
in arrhythmias-free survival and reintervention-free survival during follow-up. 
In chapter 4 we research the additional value of a dobutamine stress CMR in 
contemporary Fontan patients. In prospective studies 92 patients receive a dobutamine 
stress CMR at a median age of 11.5 (9.8 – 15.3) years. After a median follow-up of 5.8 
(4.9 – 10.0) years 23 patients (25%) developed a cardiac event. Patients who develop 
an event have a significantly lower functional reserve (Ejection Fraction (EF)stress – EFrest) 
compared to the patients who did not develop an event. Likewise the event-free survival 
was better for the patients with the highest functional reserve. 
In chapter 5 we study 133 Fontan patients who receive a dobutamine stress CMR, a 
cardiopulmonary exercise test (CPET) and blood sampling. The median age at time of 
study was 13.2 (10.4 – 15.9) years. After a median follow-up of 6.2 (4.9 – 6.9) years, 36 
(27.1%) patients experienced an event of whom 13 (9.8%) had a severe event. We 
observe that elevated levels of NT-proBNP, GDF-15 and vWF are associated with worse 
outcome during follow-up. Elevated levels of DLK-1 correlate with a higher functional 
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reserve during dobutamine stress CMR (a good prognostic sign, see chapter 4). Similary, 
patients with higher DLK-1 levels experience less severe events during follow-up. 
Part II: Tetralogy of Fallot
In chapter 6 we research the literature on TOF and we describe the currently used 
treatment strategy. We elaborate on the long-term survival and residual problems such 
as pulmonary regurgitation, remaining right ventricle (RV) obstruction, RV dysfunction 
and arrhythmias. Important imaging modalities in TOF patients such as CMR and 
echocardiography are also discussed as are the remaining challenges in TOF.
In chapter 7 we investigate the long-term outcomes in 453 TOF patients corrected 
with the transatrial-transpulmonary approach. A transannular patch (TP) was used in 
65% of the patients. We observe a good long-term survival with an early mortality of 
1.1% and a 25-year survival of 92%. No differences in overall survival between patients 
with and without a TP were observed. A pulmonary valve replacement was common 
during follow-up and occurred more frequent in the TP-group. The use of a TP was a 
predictor for poorer outcome after TOF repair.
In chapter 8 we investigate the same cohort as described in chapter 7 with an 
additional 5 years of follow-up. We investigate the serial follow-up long-term after 
transatrial-transpulmonary TOF-repair. The overall survival was 96% at 20 years and 
93% at 30 years after TOF-repair. Morbidity however was common, the event-free 
survival was 62% at 20 years and 34% at 30 years after TOF-repair. In this chapter we 
also describe the influence of the timing of the elective primary TOF-repair on long-
term outcome. Patients who underwent elective early repair (<6 months) experienced 
more events during follow-up.
In chapter 9 we investigate the additional value of a dobutamine stress CMR in TOF 
patients. In previous prospective multicenter studies 100 patients receive a low-dose 
dobutamine stress CMR. The median age at time of study was 7.8 years (13.5 – 34.0) 
years. After a median follow-up of 8.6 (6.7 – 14.1) years 10 patients reached the 
composite endpoint. An abnormal stress response (inability to increase EF or decrease 
end systolic volume (ESV)) was more frequently observed in the patients who reached 
the composite endpoint (30% vs 4.4%). The ventricular response to dobutamine stress 
predicted clinical outcome in these TOF patients.
In chapter 10 we assess blood biomarkers in a relatively young TOF cohort with a 
median age of 19.2 (14.6–25.7) years. A total of 137 patients receive a dobutamine 
stress CMR, blood sampling and a CPET. After a median follow-up of 8.7 (6.3–10.7) 
years, (14.6%) 20 patients reached the composite endpoint. We observe that elevated 
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levels of IGFBP-7 and MMP-2 were associated were associated with adverse outcome 
during follow-up. Similar to in Fontan patients, we observe that higher levels of DLK-1 
were associated with a good response to a dobutamine stress CMR.
Part III: General Discussion
In chapter 11 we discuss all the studies in this thesis and the context of our findings. 
We observe a relatively good long-term survival in our TOF and Fontan patients, 
however the long-term morbidity remains high. In this thesis we assess several clinical 
parameters, imaging characteristics and blood biomarkers and their relationship to 
clinical outcome in TOF and Fontan patients. These parameters can help in the risk-
stratification of our TOF and Fontan patients.
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SAMENVATTING
In hoofdstuk 1, de introductie van dit proefschrift, geven we een overzicht van de 
prevalentie van congenitale hartziekte (ConHD) en specifiek van univentriculaire 
hartafwijkingen en Tetralogy of Fallot (TOF). We bespreken veelgebruikte technieken 
om de klinische toestand bij ConHD patiënten te beoordelen, zoals echocardiografie, 
cardiovasculaire MRI (CMR), cardiopulmonale inspanningstest (CPET) en bloed 
biomarkers. In dit hoofdstuk worden ook de doelen van dit proefschrift beschreven. 
Deel I: Fontan circulatie
In hoofdstuk 2 onderzoeken we de huidige literatuur over univentriculaire 
hartafwijkingen. We bespreken de huidige Fontan-strategie, veel voorkomende 
complicaties en interventies na de Fontan-operaties en factoren die samenhangen met 
overleving en morbiditeit op de lange termijn. We bespreken ook de resterende 
uitdagingen waarmee we worden geconfronteerd op het gebied van de Fontan 
circulatie.
In hoofdstuk 3 onderzoeken we de seriële follow-up en de lange termijn resultaten 
na de gestageerde totale cavopulmonale connectie (TCPC). We vergelijken de twee 
TCPC technieken, de intra-atriale laterale tunnel (ILT) en de extracardiac conduit (ECC). 
In deze studie beschrijven we 208 TCPC-patiënten (103 ILT en 105 ECC) met een 
mediane follow-up duur na TCPC van 13.2 jaar. Na 15 jaar volgen van deze patiënten 
(follow-up) was de totale overleving vergelijkbaar tussen de twee technieken. Patiënten 
met een ILT kregen vaker een aritmie tijdens de follow-up, patiënten met een ECC 
ondergingen meer reïnterventies zoals  hartkatheterisaties en hartoperaties. 
Gedurende de jaren veranderden de ILT- en ECC-techniek. In de patiënten die met 
deze huidige modificaties werden geopereerd zagen we geen verschil in aritmie-vrije 
overleving en reïnterventie-vrije overleving gedurende de follow-up.
In hoofdstuk 4 onderzoeken we de toegevoegde waarde van een dobutamine stress 
CMR in jonge Fontan patiënten. 92 patiënten krijgen een dobutamine CMR, de mediane 
leeftijd van de patiënten was 11.5 jaar ten tijde van de CMR. Na een gemiddelde follow-
up van 5.8 jaar ontwikkelden 23 patiënten (25%) een cardiaal event. Patiënten die 
tijdens de follow-up een cardiaal event ontwikkelen hebben een significant lagere 
functionele reserve (ejectie fractie (EF)stress – EFrest) in vergelijking met de patiënten die 
geen cardiaal event ontwikkelen gedurende de follow-up. 
In hoofdstuk 5 onderzoeken we 133 Fontan-patiënten die een dobutamine stress 
CMR, een CPET en bloedafname krijgen. De mediane leeftijd ten tijde van het onderzoek 
is 13.2 jaar. Na een follow-up van 6.2 jaar hebben 36 (27.1%) patiënten een cardiaal 
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event ontwikkeld waarvan 13 (9.8%) een ernstig cardiaal event. We zien dat verhoogde 
levels van NT-proBNP, GDF-15 en vWF geassocieerd zijn met een slechtere uitkomst 
gedurende de follow-up. Verhoogde levels van DLK-1 zijn ook geassocieerd met een 
betere functionele reserve tijdens de dobutamine CMR (een goed prognostisch teken, 
zie hoofdstuk 4). Ook hebben patiënten met hogere DLK-1 levels minder ernstige 
cardiale events gedurende de follow-up.
Deel II: Tetralogie van Fallot
In hoofdstuk 6 onderzoeken we de literatuur over en beschrijven we de huidige 
behandelingsstrategie bij patiënten met een TOF. We bespreken de lange termijn 
overleving en resterende morbiditeit zoals pulmonaal insufficiëntie, resterende rechter 
ventrikel (RV) obstructie, RV-dysfunctie en ritme problemen. Belangrijke 
beeldvormingsonderzoeken bij TOF-patiënten zoals CMR en echocardiografie worden 
ook besproken, evenals de resterende uitdagingen bij TOF patiënten. 
In hoofdstuk 7 beschrijven we de lange termijn uitkomsten van 3 TOF patiënten die 
een transatriale transpulmonale TOF operatie krijgen. Een transannulaire patch (TP) 
wordt gebruikt in 65% van de patiënten. We observeren een relatief goede lange 
termijn overleving met een vroege mortaliteit van 1.1% en een 25-jaars overleving van 
92%. We zien geen significant verschil in overleving tussen de patiënten met en zonder 
een TP. Relatief veel patiënten krijgen een pulmonaalklep vervanging gedurende de 
follow-up, dit komt vaker voor in de TP-groep. Het gebruik van een TP is een voorspeller 
voor slechtere uitkomsten na de TOF operatie.
In hoofdstuk 8 onderzoeken we hetzelfde cohort als in hoofdstuk 7 alleen  met 5 jaar 
extra follow-up. We beschrijven de seriële follow-up van deze patiënten op lange 
termijn na de transatriale-transpulmonale TOF operatie. De totale overleving is relatief 
goed: 96% overleving na 20 jaar en 93% overleving 30 jaar na de TOF operatie. Echter 
een relatief lage mortaliteit staat niet gelijk aan een lage morbiditeit, de event-vrije 
overleving is 62% na 20 jaar en 34% 30 jaar na de TOF operatie. Daarnaast onderzoeken 
we de invloed van de timing van een electieve TOF operatie op de lange termijn 
uitkomsten. Patiënten die een electieve vroege TOF operatie kregen (<6 maanden) 
ontwikkelen meer cardiale events gedurende de follow-up.
In hoofdstuk 9 onderzoeken we in TOF patiënten de toegevoegde waarde van een 
dobutamine CMR. In eerdere studies krijgen 100 TOF patiënten een dobutamine stress 
CMR. De mediane leeftijd ten tijde van het onderzoek is 7.8 jaar en na een gemiddelde 
follow-up van 8.6 jaar bereiken 10 patiënten een klinisch eindpunt. Een abnormale 
ventriculaire stress reactie (het onvermogen om EF te verhogen of eind systolisch 
volume (ESV) te verlagen) wordt vaker waargenomen bij de patiënten die het klinische 
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eindpunt bereiken (30% versus 4.4%). De ventriculaire respons op dobutamine stress 
lijkt klinische uitkomsten te voorspellen bij deze TOF patiënten.
In hoofdstuk 10 onderzoeken we 137 relatief jonge TOF patiënten die een bloedafname, 
CPET en stress CMR krijgen. Na een mediane follow-up van 8.7 jaar bereiken (14.6%) 
20 patiënten het klinische eindpunt. We zien dat hogere levels van IGFBP-7 en MMP-2 
zijn geassocieerd met een slechtere uitkomst tijdens de follow-up, gecorrigeerd voor 
de leeftijd op het moment van de bloedafname. Net als bij de Fontan patiënten zien 
we dat hogere niveaus van DLK-1 geassocieerd zijn met een betere ventriculaire reactie 
op dobutamine stress. 
Deel III: Algemene discussie
In hoofdstuk 11 bespreken we alle studies in dit proefschrift en de bredere context 
van onze bevindingen. We zien een relatief goede overleving in onze Fontan en TOF 
patiënten, echter de morbiditeit blijft hoog. In dit proefschrift onderzoeken we de 
relatie tussen klinische parameters, beeldvormingsonderzoeken en bloed uitslagen 
met de klinische uitkomsten in TOF en Fontan patiënten. Deze bevindingen kunnen 
helpen in de klinische zorg van TOF en Fontan patiënten. 
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LIST OF ABBREVIATIONS
AOV aortic valve
APC atrio-pulmonary connection
APVS absent pulmonary valve syndrome
ASD atrial septal defect
AV atrio ventricular
AVSD atrioventricular septal defect
AVV atrioventricular valve
BDG bidirectional Glenn anastomosis
BMI body mass index
BNP brain natriuretic peptide
BSA body surface area
BT Blalock-Taussig
CCS Canadian cardiovascular society 
CHD congenital heart defect
CI confidence interval
CMR cardio magnetic resonance imaging 
CoA aortic coarctation 
COBRA3  Congenital heart defects: Bridging the gap between Growth, Maturation, 
Regeneration, Adaptation, late Attrition and Ageing
ConHD congenital heart defect
CPB cardiopulmonary bypass 
CPET cardiopulmonary exercise test
DA ductus arteriosus
DILV double inlet left ventricle
DLK-1 protein delta homolog 1
DORV double outlet right ventricle
ECC extra-cardiac conduit
EDV end diastolic volume 
EDFF end-diastolic forward flow 
EF ejection fraction
EMC Erasmus medical centre
ESV end systolic volume
FABP-4 fatty acid binding protein 4
FR functional reserve
Gal-3 galectin-3
GDF-15 growth differentiation factor 15
HLHS hypoplastic left heart syndrome
HR hazard ratio
ICD implantable cardioverter-defibrillator
ICU intensive care unit
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IGFBPs insulin-like growth factor binding proteins 
IGFBP-1 insulin-like growth factor binding protein 1
IGFBP-7 insulin-like growth factor binding protein 7
ILT  intra-atrial lateral tunnel
IQR interquartile range
LGE late gadolinium enhancement
LPA left pulmonary artery
LV left ventricle
LVEDV left ventricular end diastolic volume
LVEF left ventricular ejection fraction
LVESV left ventricular end systolic volume
LVSV left ventricular stroke volume
mBT modified Blalock-Taussig 
MMP-2 matrix metalloproteinase 
MRI magnetic resonance imaging
NOACs Novel oral anticoagulants
NPX normalized protein expression
NT-proBNP N-terminal prohormone brain natriuretic peptide
NYHA New York Heart Association Classification
OHCA out of hospital cardiac arrest
PA pulmonary artery
PCPC partial cavo-pulmonary connection 
PDA persistant ductus arteriosus 
PEA proximity extension assay
PLE protein-losing enteropathy
PM pacemaker 
PR  pulmonary regurgitation
PS pulmonary stenosis
PVR pulmonary vascular resistance
PVR pulmonary valve replacement
RPA right pulmonary artery
RER respiratory exchange ratio 
RUMC Radboud university medical centre Nijmegen 
RV right ventricle
RVEDV right ventricular end diastolic volume
RVEF right ventricular ejection fraction
RVESV right ventricular end systolic volume
RVOT right ventricular outflow tract
RVOT right ventricular outflow tract obstruction
RVSV right ventricular stroke volume
SD standard deviation
sST2 soluble form of suppression of tumorigenicity 2
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ST2 suppression of tumorigenicity 2 
STE speckle tracking echocardiography 
SV single ventricle
SV stroke volume
SVT supraventricular tachycardia
TAP transannular patch
TCPC total cavo-pulmonary connections
TE thromboembolism
TEs thromboembolic events
TGFβ transforming growth factor beta
TOF Tetralogy of Fallot
TOFr Tetralogy of Fallot repair
TP transannular patch
TR tricuspid regurgitation
VA ventriculo-arterial
VACTERL  vertebral anomalies, anal atresia, cardiac defects, tracheoesophageal 
fistula and/or esophageal atresia, renal & radial anomalies and limb 
defects
VCO2 carbon dioxide production 
VKA vitamin K antagonists
VO2 oxygen uptake
VSD ventricular septal defect
VT ventricular tachycardia
vWF von Willebrand Factor
4D four dimensinoal
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